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Abstract 
Introduction 
Since the 1980’s quality of life (QOL) indicators have been used to assess health outcomes. 
Extensive bodies of work now exist on the QOL of particular groups with chronic conditions 
and in the general population. The case for using QOL is worth reiterating.  In most instances 
medical treatments are justified on the basis that they reduce the symptom burden or the 
duration or severity of an underlying condition.  An improvement in the QOL provides the 
justification for treatment.  Arguably QOL improvements provide the main measure of the 
effects of medical care.  The QOL of drug users, however, has been largely neglected. Those 
studies that do exist are limited to treatment populations, who do not represent the majority of 
people who use drugs.  Drug using behaviours, including the consumption of alcohol, tobacco 
smoking, cannabis use, the non-medical use of medications and (to a lesser extent) injecting 
opioids by people who inject drugs (PWID), are common especially amongst adolescents and 
young adults. Assessing the QOL of drug users should be central to psycho-social approaches 
to understanding drug use patterns and to subsequently addressing patterns of harmful use.  
 
Current perspectives of drug use focus on either its harms or pleasurable aspects. The latter 
approach suggests that, despite the potential for adverse consequences, drug users negotiate 
the risks of use to maximise the benefits, whether this be for pleasure or for an improved state 
of subjective well-being. However whether drug users achieve these positive outcomes is 
uncertain. Assessing the QOL of drug users provides an overarching perspective of the 
consequences of drug use, that is, its potential for both harm and pleasure.  
 
To be able to address the potential harms and benefits associated with drug use, it is first 
necessary to describe the QOL of users and to determine whether drug use is associated with 
changes in the users’ QOL.  There is a need to understand the potential temporal sequence 
between QOL and drug use, and whether drug type or drug taking frequency influences QOL 
assessments (and the reverse).  
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Research Questions 
The purpose of this thesis, therefore, was to examine the QOL of drug users.  To this end this 
thesis addressed the following questions: 
1. What is the QOL of drug users? 
2. Does the QOL of drug users vary by drug type and frequency of use? 
3. What could be the temporal sequence between drug use and QOL? 
4. Does drug use enhance or diminish users’ QOL? 
 
Methods 
This thesis was based on secondary data analysis.  Data collected by the Mater University 
Study of Pregnancy and outcomes (MUSP) was the most commonly used data.  MUSP is a 
longitudinal cohort of mothers and their children.  Mothers were recruited at their first 
antenatal visit.  Offspring data from the 5, 14 and 21 year follow-ups were used in this thesis. 
Behaviours of interest were alcohol consumption, tobacco smoking, cannabis use and 
medication (medical and non-medical) use.  Data from the Australian Needle and Syringe 
Program Survey was also used to examine the QOL of people who inject drugs (PWID).  The 
outcome of interest in all of these studies was QOL.  These investigations have taken the 
form of manuscripts and peer-reviewed published papers.  
 
Results 
People who reported a lower QOL were more likely to initiate the use of both licit and illicit 
substances.  Following drug use the QOL of users remains low and appears to be lower than 
prior to the initiation of drug use.  PWID have a low QOL in comparison with people with 
other chronic conditions.  The results suggest that poor QOL predicts earlier onset of drug 
use. Poor QOL was associated with earlier initiation into cannabis use and also seemed to 
precede any medication use by young adults. Further, poor QOL seems to have been 
cumulative amongst regular drug users. 
 
Conclusions 
Beyond the immediate pleasures of intoxication there are few, if any, benefits from drug use.  
People with a poor QOL prior to commencement of use disproportionately use drugs. Drug 
users disproportionately report diminished QOL compared with people who do not use drugs, 
especially for persons who have diminished QOL prior to commencement of use. The 
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findings for this thesis are suggestive of a causal relationship, but much more research is 
required, and as such the relationship between QOL and drug use remains uncertain.  
 
Implications 
A low QOL in adolescence may be used as an indicator of people who are likely to use 
substances, that is, a marker for early intervention.  The adverse impact drug use has on QOL 
provides a potentially novel and useful adjunct to prevention and harm reduction strategies. 
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CHAPTER ONE: INTRODUCTION 
Psychoactive drug use, whether licit or illicit is widespread, particularly among adolescents 
and young adults (Australian Institute of Health and Welfare, 2011; European Monitoring 
Centre for Drugs and Drug Addiction, 2014; United Nations Office on Drugs and Crime, 
2014; Ventegodt & Merrick, 2003; Gore et al., 2011; Reavley et al., 2010; Santelli & Galea, 
2011).  Psychoactive drugs, including alcohol, tobacco, cannabis, medications and illicit 
opioids have the capacity to alter mood, perception, cognition and behaviour (Whelan, 2004) 
and, therefore, have the potential to influence, either positively or negatively, quality of life 
(QOL).  Drug use can affect many aspects of life, including physical and psychological 
functioning, social and other relationships as well as employment capacity (Laudet, 2011; De 
Maeyer et al., 2013; 2010; Fakhoury & Priebe, 2002; Marini et al., 2013; Zubaran & Foresti, 
2009).  This raises the question about the extent to which persons who use drugs obtain the 
benefits that they seek.  If drug use is intended to improve a person’s emotional state, then to 
what extent does this happen?   
 
The purpose of this thesis, therefore, is to investigate the QOL of psychoactive drug users and 
the judgements that are made about their QOL.  In this study the specific focus is on those 
users living and functioning in the broader population, rather than on clinical or treatment 
populations.  Here QOL is conceptualised as a judgement encapsulating subjective 
evaluations of one’s life, moderated by a range of objective factors, at a given point in time 
(Andrews & Withey, 1976; Campbell et al., 1976; Headey & Wearing, 1992; Phillips, 2006; 
Ventegodt & Merrick, 2003; Verdugo et al., 2005).  Investigating QOL provides an 
understanding of what life is like for drug users above and beyond the harms and motivations 
associated with use. 
 
1.1 RATIONALE 
QOL has now been of academic and research interest for more than 30 years.  The term has 
become part of the common vernacular and is used in everyday parlance.  It has become a 
concern for interest groups, researchers and clinicians as something important and desirable 
(Hornquist, 1982; Verdugo et al., 2005; Bache, 2015).  Increasingly QOL has become 
embedded in a range of policies and strategies from global institutions, including the World 
2 
Health Organization (WHO), as well as a range of government authorities.  QOL is perceived 
as an important factor to both those who ‘have it’ and to those who believe others ‘should’ 
have it.   
 
QOL assessments are common in chronically ill populations where the focus is on health-
related QOL.  However, until recently, the QOL of drug users has largely been neglected 
(Laudet, 2011; Best et al., 2013; Assari & Jafari, 2010; Zubaran & Foresti, 2009; Tracy et al., 
2012).  This is surprising given the WHO’s definition of QOL as “an individual’s perception 
of their position in life in the context of the culture and value systems in which they live and 
in relation to their goals, expectations, standards and concerns” (p.1,403 The WHOQOL 
Group, 1995).  A focus on the person rather than the drug use provides a more comprehensive 
understanding of the motivations for and the impact drug use may have on an individual’s 
life.  A better understanding of the QOL experienced by drug users can then be applied to 
policy formulation, decision making, program implementation, and for monitoring treatment 
progress (Dolan et al., 2011; Goldin et al., 2014).  
 
Current perspectives focus on drug use as a form of ‘pathology’ (Coveney & Bunton, 2003; 
Moore, 2008; Mugford, 1988) and on risk (Coveney & Bunton, 2003; Hunt et al., 2007; 
Moore, 2008), or, alternatively, on drug use as a source of pleasure (Holt & Treloar, 2008; 
Measham, 2004).  However these perspectives are narrow and are more concerned with the 
acute stage of use, often associated with intoxication. To date the QOL focus in the alcohol, 
tobacco and other drugs literature has been on treatment populations (Maremmani et al., 
2007; Tracy et al., 2012), yet these populations do not represent the majority of drug users 
(Assari & Jafari, 2010; Di Giusto & Treloar, 2007; Perkonigg et al., 2006).  Studies of drug 
users recruited in community settings have largely been cross-sectional in nature.  Of these, 
few studies have assessed the QOL of young people, particularly their QOL in association 
with drug use.  Nor do we know if QOL varies by drug type or by frequency of use. 
 
To be able to address the potential harms, and benefits perceived to be obtained from drug 
use, it is first necessary to describe the QOL of users, and to understand whether drug use 
enhances or diminishes the QOL of users.  To understand the impact of drug use it is crucial 
to address the temporal sequence between QOL and drug use, that is, does poor QOL precede 
drug use or vice versa; and whether drug type and/or frequency of drug taking influences 
QOL assessments.  
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1.2 THESIS AIMS 
This thesis therefore aims to further our understanding of the QOL of drug users, particularly 
among adolescent and young adult users who are not dependent.  Here the focus is on 
describing the QOL of users of a range of drugs, examining the association between QOL and 
drug use, how drug type and frequency of use may affect QOL assessments (and the reverse) 
and the potential temporal association between QOL and drug use.  
 
1.3 RESEARCH QUESTIONS 
This thesis addresses the following questions: 
1. What is the QOL of drug users? 
2. Does the QOL of drug users vary by drug type and frequency of use? 
3. What could be the temporal sequence between drug use and QOL? 
4. Does drug use enhance or diminish drug users’ QOL? 
 
1.4 THESIS STRUCTURE 
The thesis is structured around 10 chapters (including this Introduction).  Chapter 2 reviews 
the literature on drug use (including a published paper on use of treatment services by drug 
users). Chapter 3 considers the motivations behind drug use, provides a definition to QOL 
and discusses the extant literature on the QOL of drug users.  Chapter 4 provides general 
details about the methodology used in this thesis.  Specific methods and details associated 
with each publication are described within each results chapter.  The data for this thesis are 
taken from a number of sources including the Mater Hospital, University of Queensland 
Study of Pregnancy (MUSP) which is a 21 year, longitudinal birth cohort study undertaken in 
Brisbane, Australia.  Data from the 5, 14 and 21 year follow-ups are used in this thesis.  
Behaviours of interest are alcohol consumption, tobacco smoking, cannabis use, medication 
use and people who inject opioids.  Data have also been obtained from publicly available 
national data sets to investigate treatment rates and injecting drug use, particularly for opioid 
use.   
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Following the Methodology chapter are a series of results chapters.  These are presented as 
published papers or manuscripts submitted to peer reviewed journals.  Chapters 5-8 use data 
from MUSP, Chapter 9 uses data from a Needle and Syringe Program in inner city Brisbane, 
Australia.  Chapter 5 examines the QOL, age of onset of alcohol use and alcohol use 
disorders in adolescence and young adulthood.  Chapter 6 focuses on childhood and 
adolescent psychopathology and subsequent tobacco smoking in young adults.  Chapter 7 
examines cannabis use and QOL of adolescents and young adults.  The early life course 
predictors of medical and non-medical medications use by young adults forms the focus of 
Chapter 8. The QOL of people who inject drugs, namely opioids, provide the content of 
Chapter 9.  The final chapter (Chapter 10) discusses principle findings related to the research 
questions, possible mechanisms and implications of the QOL experienced by drug users.  
 
1.5 CHAPTER SUMMARY 
The purpose of this thesis is to investigate the QOL of drug users, focusing upon adolescents 
and young adults.  This is a population study of persons living in the community rather than 
using clinical samples.  Study in this area is in its infancy. The thesis findings will add to the 
evidence base and will inform the development of further theory and knowledge about the 
QOL experienced by drug users.  
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CHAPTER TWO: LITERATURE REVIEW  
This chapter includes the following published paper: 
FISCHER, J.A., CLAVARINO, A.M. & NAJMAN, J.M. 2012. Drug, sex and age 
differentials in the use of Australian publicly funded treatment services. Drug Abuse: 
Research and Treatment, 6, 13-21. 
 
2.1 INTRODUCTION 
The purpose of this chapter is to review the literature on drug use.  First, what is meant by 
‘drug’ is defined.  Then global and Australian patterns of drug use are described to illustrate 
that enormous variation exists in substance use.  Thirdly, well-established indicators of harm 
are considered. These key indicators are mortality, burden of disease, dependence, 
comorbidity and health service contact, primarily collected under the auspices of the 
Australian Institute of Health and Welfare (AIHW).  Drug use patterns of Australian sentinel 
drug using populations are also examined. The chapter concludes that the existent indicators 
suggest that most drug users do not experience drug related harm,  however very little is 
known about the QOL of these users.  
 
2.2 DRUG USE DEFINITION 
The most commonly used psychoactive drugs form the basis of this thesis. These are alcohol, 
tobacco, cannabis, medications (prescribed and over-the-counter) and the illicit use of 
opioids.  These are all psychoactive drugs with the capacity to alter mood, perception, 
cognition and behaviour (Whelan, 2004). Psychoactive drugs may be categorised in a variety 
of ways.  They may be classified according to their impact upon public health.  For example 
in Australia what constitutes low risk and risky alcohol consumption has been determined by 
the National Health and Medical Research Council (NHMRC).  According to these 
guidelines alcohol may be consumed by healthy male and female adults at low risk in the 
short term (no more than four glasses) or ‘risky’ (five or more glasses) in any one session 
(NHMRC, 2009).  Alternatively, drugs may be classified according to their legal status (e.g. 
licit or illicit).  For instance alcohol is largely considered a licit or legal drug, whereas 
cannabis is largely considered an illicit (i.e. illegal) drug.  Drugs can also be defined on the 
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basis of whether they are ‘used appropriately’ or are ‘misused’.  Current debates about how 
medications may be taken are a case in point.  Although there is no commonly agreed 
definition of what constitutes medications ‘misuse’ (Larance et al., 2011), medications may 
be ‘used appropriately’ or ‘misused’ depending upon whether or not they have been taken as 
prescribed or in accordance with written instructions.  The term ‘extra-medical’ medication 
use has also been coined to describe medicine misuse which is outside of a doctor’s 
prescription [or directed dose] (Degenhardt et al., 2008).   
 
The same drug may also be treated differently, depending upon its derivative, such as 
opioids. Under the Australian Standard for the Uniform Scheduling of Medicines and Poisons 
(Therapeutic Governance Authority) heroin is designated a prohibited substance (Schedule 
9). In contrast other opioids (e.g. morphine and methadone) are categorised as controlled 
substances, requiring a government authority (Schedule 8) for dispensing.   
 
Another approach is to delineate drug use on the basis of how particular drugs are 
administered. Most commonly drug users are defined on the basis of whether or not they take 
drugs intravenously.  For example surveys regularly ask respondents ‘do you inject’? or ‘have 
you ever/recently injected’? Subsequently study participants are categorises as ‘injectors’, or 
increasingly, people who inject drugs (PWID), or not.  
 
2.3 PATTERNS OF USE 
2.3.1 GLOBAL PATTERNS OF USE  
Globally alcohol and tobacco are the most commonly used drugs.  According to the World 
Health Organization (WHO), 8.3% of the world’s population aged 15 years and over 
consumed alcohol in the previous 12 months (WHO, 2014a). For example, in Australia, over 
80% of the population drinks alcohol (AIHW 2014a). World-wide about 16.0% of drinkers 
aged 15 years or older engage in heavy episodic drinking at least weekly (WHO, 2014a). The 
international definition of heavy episodic drinking is 6 or more standard drinks (i.e. 60 grams 
of alcohol) on at least one occasion per month (WHO, 2014a).  
 
The use of alcohol is underpinned by complex socio-demographic, economic and cultural 
factors.  Table 1 compares countries with similar social, economic and cultural backgrounds 
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(Australia, Britain and Northern Ireland, Canada and New Zealand)and highlights differences 
in heavy drinking between countries Prevalence is also generally higher in wealthier than in 
poorer countries (Loring, 2014). Young adults consume greater amounts of alcohol than older 
people (Ferriter & Ray, 2011; Lyvers et al., 2010; McCoy & Nieland, 2011), although 
women are universally less likely to consume alcohol than males (WHO, 2011).   
  
Table 1: Prevalence of alcohol consumption (in litres of pure alcohol) and of heavy 
episodic drinking* by both sexes, aged 15 years and older, in comparable countries, 
2010 
Country Total alcohol per capita 
consumption, drinkers only, 
both sexes 
% 
Prevalence of heavy episodic 
drinking 
Population 
% 
Drinkers Only 
% 
Australia 14.5 10.9 13.0 
Britain & Northern Ireland 13.8 28.0 33.4 
Canada 13.2 17.8 23.1 
New Zealand 13.7 4.5 5.6 
* Consumed at least 60 grams or more of pure alcohol on at least one occasion in the past 30 days. 
Source: World Health Organization (2014a) 
 
 
According to the most recent report available, world-wide, tobacco is used by 967 million 
people (95%CI: 944-989 million) (Ng et al., 2014). Global prevalence of daily tobacco 
smoking in 2012 was 31.1% (95%CI: 30.2%-32.0%) (Ng et al., 2014).  As with alcohol the 
prevalence of tobacco smoking varies even between comparable highly developed countries, 
as illustrated in Table 2.  Experimentation with tobacco smoking by children, adolescents and 
young adults has declined in some ‘developed’ countries (e.g. Australia, United States) whilst 
prevalence of tobacco smoking has increased in ‘less developed’ countries (e.g. China) (Ng et 
al., 2014).  Males are more likely to be current smokers than females (World Health 
Organization, 2012; Ng et al., 2014).  
 
Table 2: Age-standardised prevalence estimates for tobacco smoking among persons 
aged 15 years and over, 2011, in comparable countries* 
Country Age-standardized prevalence estimates for 
tobacco smoking among persons aged 15 years 
and over, 2011 
Males 
% 
Females 
% 
Both sexes 
% 
Australia 21.0 19.0 20.0 
Great Britain & Northern Ireland 22.0 22.0 22.0 
United States of America 21.6 16.5 19.0 
New Zealand 21.0 19.0 20.0 
Source: WHO (2014b) *Canada data unavailable 
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Cannabis 
The most widely used illicit drug in the world is cannabis (European Monitoring Centre for 
Drugs and Drug Addiction, 2010; United Nations Office on Drugs and Crime, 2011).  World-
wide the number of cannabis users has been estimated to be between 125-203 million persons 
(Whiteford et al., 2013), with between 2.7 and 4.9 per cent of the global population aged 15-
64 years having used cannabis in the past year  (United Nations Office on Drugs and Crime 
2014). However there are very large differences in the prevalence of cannabis use between 
countries (see Figure 1). According to the World Drug Report (United Nations Office on 
Drugs and Crime 2014) countries in West and Central Africa, North America and Oceania 
and have prevalence rates considerably higher than the global average.  Frequency of 
cannabis use varies between age groups.  For example, in the European Union, 22% of adults 
aged 15-64 years have used cannabis at least once in their lifetime, this decreased to 5.3% 
who have used cannabis in the last year and 1% who use cannabis weekly or more often 
(European Monitoring Centre for Drugs and Drug Addiction, 2014).    
 
 
Figure 1: Prevalence of cannabis use globally, in 2012 (or latest year available) 
Source: United Nations Office on Drugs and Crime (2015) 
 
Medications 
Medication ‘misuse’ is as a relatively new issue. Consequently the epidemiological data is 
limited when compared with other drugs, considered in this thesis. Indeed a report 
commissioned by the United Nations Office on Drugs and Crime has stated that “existing 
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available information about the non-medical use of prescription drugs is insufficient to 
estimate the scale of the problem with accuracy” (Fischer, 2011 pp5).  
 
The prevalence of over-the-counter and prescribed medication misuse is increasingly being 
recognised .  This is especially the case in Canada, the United States and Australia (Nicholas 
et al., 2011; Roxburgh et al., 2011; Calcaterra et al., 2013; Cerda et al., 2013; Pain & Policy 
Studies Group 2013). In these countries the concern is focused on the extent of opioids 
prescribing  for chronic non-malignant pain. Figure 2 compares prescribed opioid use in 
terms of morphine equivalent dose, the gold standard, in high use countries. 
 
 
Figure 2: Opioid Consumption among high use countries 
Source: Pain and Policy Study Group (2013) 
 
Illicit Opioid Use  
Opioids may also be used illicitly that is, they may be use not as prescribed, without a 
prescription, or used illegally, as in the case of heroin. The following figure (Figure 3) 
presents the prevalence of illicit opioid use in 2012 (or latest available) An estimated 14 
million people inject drugs., In Australia, Europe and North America the majority of users 
inject opioids illicitly (United Nations Office on Drugs and Crime, 2013).   
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Figure 3: Prevalence of opioids globally, in 2012 (or latest year available) 
Source: United Nations Office on Drugs and Crime (2015) 
 
2.3.2 AUSTRALIAN PATTERNS OF USE 
PREVALENCE 
Amongst Australians alcohol, tobacco and cannabis are the most commonly used drugs. This 
is consistent with global patterns.  The main source of population data on the prevalence of 
drug use in Australia is collected through the Australian National Drug Strategy Household 
Survey (NDSHS).  Triennially since 1985 two constant NDHS measures are ‘lifetime’ and 
‘recent’ use.  The former is use at least once in a lifetime and the latter refers to use in the 
previous 12 months (AIHW, 2011a).   
 
Ever and recent use of selected drugs amongst Australians aged 14 years and older at 
triennial intervals between 2001 and 2013 is presented in Table 3.  This data shows that 
alcohol use over the past decade has remained relatively stable with nearly eight in 10 
Australians reporting recent consumption (AIHW, 2011a).  During the same time period 
cannabis use has also remained relatively stable, with about 10% of the Australian population 
reporting recent use (AIHW, 2011a; 2014a).  The incidence of injecting drugs by Australians 
has remained consistent, with 0.3% (about 75,000 people) reporting recent injection. 
Similarly the incidence of ever and recent use of heroin has remained stable since 2001. 
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Table 3: Prevalence of ever and recent use of selected drugs amongst Australians aged 
14 years and over, 2001, 2003, 2007, 2010, 2013 
Drug NDSHS Year 
2001 
% 
2004 
% 
2007 
% 
2010 
% 
20132 
% 
Ever Recent Ever Recent Ever Recent Ever Recent Ever Recent 
Alcohol 90.4 82.4 90.7 83.6 89.9 82.9 87.9 80.5 n.a. n.a. 
Tobacco 49.4 23.2 47.1 20.7 44.6 19.4 42.2 18.1 n.a. n.a. 
Cannabis 33.1 12.9 33.6 11.3 33.5 9.1 35.4 10.3 34.8 10.2 
Pharmaceuticals1 3 8.8 3.9 7.7 3.8 7.5 3.7 7.4 4.2 11.4 4.7 
Injected drugs3 1.8 0.6 1.9 0.4 1.9 0.5 1.8 0.4 1.5 0.3 
Heroin3 n.a. 0.2 n.a. 0.2 n.a. 0.2 1.4 0.2 1.2 0.1 
1painkillers/analgesics, tranquillisers/sleeping pills, steroids, methadone or buprenorphine & other opiates; 2alcohol & 
tobacco ever and recent use had not been disaggregated by 01.09.14; 3AIHW data for heroin is reported separately to 
methadone, buprenorphine and other opiates; n.a. not available 
 Sources: AIHW (2011; 2014) 
 
Table 3 also shows changes in the prevalence of tobacco smoking and medications use. 
NDSHS data shows declines in the prevalence of tobacco smoking, although at least two in 
10 Australians continue to smoke (AIHW, 2011a).  In 2013 the NDSHS found that 12.8% of 
Australians were daily smokers and a further 3% smoked tobacco weekly or less than weekly.  
The NDSHS data also shows an increase in recent medication ‘misuse’ (AIHW, 2014a), 
rising from 3.7% in 2007 to 4.7% in 2013 (AIHW, 2014a).   
 
FREQUENCY OF USE 
The frequency with which drugs are used is generally accepted to lie on a continuum. On one 
end of the continuum lies ‘non-use’ and at the other is ‘dependence’ (Zinberg 1975; 1984).  
In between are points of occasional, recreational and regular use.  For example 6.5% of 
Australians aged 14 years and over consume alcohol daily, 37.3% consume alcohol weekly, 
34.5% less often and 13.8% report never having consumed a full serve of alcohol (AIHW, 
2014a).  By way of contrast 3.9% of Australians have used cannabis in the last week and 
10.3% in the last year (AIHW, 2011a; 2014a).  Frequency of use is only one indicator of 
dependence (see Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5), 
(American Psychiatric Association, 2013), There is evidence (Di Giusto & Treloar, 2007; 
Perkonigg et al., 2006) that a relatively small proportion of people who use licit and illicit 
drugs are dependent, however, from this data it is not possible to clearly distinguish between 
use and dependence.  For example, use in the last year may have been hazardous or 
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dependent use, but the person may have ceased use because of harms associated with use and 
so are current abstainers – while still having used that substance in the preceding 12 months. 
 
DRUG USE ACROSS THE LIFE COURSE 
Drug use varies across the life course.  As can be seen in Table 4, using 2010 NDSHS data, 
adolescents and young adults are the most frequent users of the most popular drugs in the 
population  that form the focus of this thesis.  In particular, drug use is most common among 
20-29 year olds.  It is also relatively common in the 14-19 and 30-39 year old age groups.  
This data indicates that young adults have higher rates of exposure to drugs and 
consequently, as a group, are at increased risk of the harms associated with use (Table 4).  
 
Table 4: Recent alcohol, tobacco, cannabis, painkillers or analgesics and other 
tranquillisers or sleeping pills, by age group 
Recent Drug Use Age Group Test Statistic 
14-19 
% 
20-29 
% 
30-39 
% 
40-49 
% 
50-59 
% 
60+ 
% 
Alcohol1 Risky 
Low Risk 
Abstainer 
7.7 
3.7 
12.0 
21.9 
9.3 
8.8 
22.8 
16.7 
13.1 
19.0 
17.3 
11.5 
15.4 
18.4 
14.6 
13.2 
34.6 
40.1 
χ2= 2311.98 
df 10 
p≤0.001  
Tobacco 2 Current 
Former 
Never 
3.5 
0.7 
10.0 
17.2 
6.1 
14.2 
20.9 
16.2 
17.3 
21.2 
17.8 
14.6 
19.6 
20.0 
14.6 
17.6 
39.2 
29.3 
χ2= 1778.06 
df 10 
p≤0.001  
Cannabis2 Yes 
No 
10.9 
5.8 
28.6 
10.9 
26.8 
16.7 
19.6 
16.5 
11.8 
17.6 
2.2 
32.5 
χ2= 1478.13 
df 5 
p≤0.001  
Painkillers or 
analgesics2,3 
Yes 
No 
5.2 
6.2 
15.8 
12.5 
17.9 
17.7 
14.3 
16.9 
15.4 
17.1 
31.3 
29.7 
χ2= 13.29 
df 5 
p=0.021 
Tranquillisers 
or sleeping 
pills2,3 
Yes 
No 
4.6 
6.2 
22.8 
12.4 
23.8 
17.5 
15.3 
16.8 
12.8 
17.1 
20.7 
30.0 
χ2 =59.24 
df 5 
p≤0.001 
1 In the past month; 2In the past 12 months; 3for non-medical purposes  
Source: AIHW (2011) 
 
Illicit opioids primarily administered via injection are also a focus of this thesis.  In contrast 
to the more commonly used drugs, there are very few users of illicit opioids, particularly 
opioid injectors in the general population (Table 3: 0.1% recently; 0.3% lifetime).  As the 
proportion of illicit opioid users in the general population is so small, this data has been 
omitted from the AIHW National Household Alcohol and other Drug Survey Reports and 
therefore has not been included  Table 4. 
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2.4 HARMS 
Psychoactive drug use can result in substantial harms for the individual and also for the 
community.  Harms may occur anywhere along the continuum of use, including occasional 
users, and may not come to the attention of authorities, For example as occurs when someone 
is absent from school or from work as a result of their drug use. For policy and intervention 
purposes data are, however, collected on specific indicators of harm. The most commonly 
reported indicators of alcohol and other drug-related harm include mortality, disease burden, 
health service contact and dependence. These key indicators which are examined below. 
 
2.4.1 MORTALITY 
Relatively few Australian deaths are primarily due to drugs.  Table 5 provides underlying 
cause of death data for tobacco, alcohol, cannabis and opioids. This Table shows that less 
than 0.5% of all deaths are due to drug use (Australian Bureau of Statistics, 2014). Table 5 
does not include external causes of death, such as poisonings (ICD T codes). However, when 
poisonings data were examined, relatively few deaths were due to drug poisonings. For 
example, in 2013, narcotic poisoning was the underlying cause of 286 deaths and alcohol 
poisoning was the underlying cause of 67 deaths (Australian Bureau of Statistics (2014). 
 
Table 5: Underlying cause of death, selected ICD-10 codes, 2003-2012 
Year Cause of Death  Total 
ICD-F00-
F99 
F10-19  
% of 
ICD-10- 
F00-F99 
 deaths 
Total  
Deaths 
F10-19 
% of 
Total 
deaths 
Tobacco 
F17 
Alcohol 
F10 
Cannabis 
F12 
Opioids 
F11 
Any  
F10-19 
2003 82 248 0 61 428 3,241 13.21 132,292 0.32 
2004 91 222 1 30 371 3,414 10.87 132,508 0.28 
2005 84 246 1 8 366 3,367 10.87 130,714 0.28 
2006 80 259 0 2 360 5,139 7.01 133,739 0.27 
2007 105 277 1 3 411 5,693 7.22 137,854 0.30 
2008 104 291 0 9 424 6,377 6.65 143,946 0.29 
2009 70 257 1 10 361 6,518 5.54 140,760 0.26 
2010 63 281 1 19 398 7,035 5.55 143,473 0.28 
2011 64 269 4 28 399 7,644 5.22 146,932 0.27 
2012 55 234 0 42 382 8,120 4.70 147,098 0.26 
Source: Australian Bureau of Statistics (2014) 
 
2.4.2 BURDEN OF DISEASE 
The burden of disease is the proportion of deaths or disease burden caused by specific risk 
factors compared with all other conditions (Lim et al., 2012).  Burden of disease is commonly 
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described in terms of ‘disability adjusted life years’ (DALYs).  DALYS consists of ‘years of 
life lost’ (YLL) through premature mortality and ‘years lived with a disability’ (YLD) (Lopez 
& Murray, 1998; Murray & Lopez, 1994). 
 
GLOBAL BURDEN OF DISEASE 
Alcohol use disorders (AUD) accounts for 9.6% (7.7%-11.8%) of the global burden of 
disease (Whiteford et al., 2013).  Amongst young adults, aged 12-24 years, alcohol-related 
harm is a leading risk factor for disability. These harms include accidents and injury (Gore et 
al., 2011; Santelli & Galea, 2011; United Nations Office on Drugs and Crime, 2014). 
Tobacco smoking is a leading factor contributing to the global burden of disease (Lim et al., 
2012), although primarily amongst older age groups who experience tobacco-smoking related 
diseases and cancer. 
 
Globally nearly 7.5% (range: 6.2%-8.6%) of the burden of disease is attributable to illicit 
drug use disorders (SUD) (Reavley et al., 2010).  SUD and mental health disorders (MHD), 
accounted for 175.3 million YLD, or 22.9% of all causes of the non-fatal burden of disease in 
2010 (Whiteford et al., 2013). Cannabis dependence accounts for 2 million DALYS (0.08% 
95%CI: 0.05%-0.12%), mainly amongst young adults (Whiteford et al., 2013). 
 
BURDEN OF DISEASE IN AUSTRALIA 
In Australia the burden of disease from alcohol in 2010 was 188,538 DALYs.  Injuries were 
responsible for the greatest number of DALYs in males (38%), while cancers were 
responsible for the greatest number of DALYs in females (Gao et al., 2014).  Tobacco 
smoking is a leading risk factor (8%) of the total burden of disease in Australia. Tobacco 
smoking is the major contributor to the fourth most common form of death, lung cancer (6% 
of all deaths), and other leading causes of death, chronic obstructive pulmonary disease 
(principally emphysema and chronic bronchitis) (AIHW, 2014b).   
 
SUD are accounted for in the burden of disease under the category of mental and behavioural 
disorders. Mental and behavioural disorders accounted for 23% of the Australian total for 
non-fatal burden of disease in 2010 (AIHW, 2014b).  The burden of disease attributed to 
medications and associated harms are difficult to disentangle.  However drug-related 
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hospitalisations increased for antidepressants and antipsychotics, opioids and non-opioid 
painkillers between 2003-04 and 2011-12 (AIHW, 2014b). 
 
2.4.3 DEPENDENCE 
Drug dependence can potentially affect most domains of life, for example physical and 
psychological functioning – social relationships and roles, capacity to work, individual safety 
and wellbeing (American Psychiatric Association, 1994).  According to the DSM-IV, 
dependence is clinically defined as a ‘cluster of cognitive, behavioural, and physiological 
symptoms indicating that the individual continues using the drug despite significant drug-
related problems’ (American Psychiatric Association, 2013).  Globally about 3% of the 
world’s population have an AUD (men: about 6%; women: about 1%) (Rehm, 2009).  In 
2014 the estimated number of people dependent on illicit drugs world-wide ranged between 
16-39 million (United Nations Office on Drugs and Crime, 2014).  Arguably the best 
international data on world-wide dependence derives from Degenhardt et al. (2013) study of 
the Global burden of disease attributable to illicit drug use and dependence.  These data show 
variability in illicit drug use dependence between regions and also between different illicit 
drugs (Table 6). 
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Table 6: Estimated number of cases and age-standardised prevalence of cannabis, 
amphetamine, cocaine, and opioid dependence in 2010, for selected regions and gender 
Country Age –Standardised Prevalence 95% (CI) 
Cannabis Amphetamines Cocaine Opioids 
High-income Asia Pacific 0·28 (0·18–0·41) 0·24 (0·17–0·34) 0·06 (0·05–0·07) 0·28 (0·17–0·44) 
Southeast Asia 0·15 (0·11–0·19) 0·42 (0·34–0·54) 0·02 (0·01–0·02) 0·15 (0·11–0·20) 
Australasia 0·68 (0·60–0·78) 0·41 (0·29–0·56) 0·14 (0·09–0·20) 0·46 (0·41–0·53) 
Caribbean 0·16 (0·12–0·21) 0·20 (0·16–0·25) 0·33 (0·26–0·42) 0·26 (0·18–0·36) 
Eastern Europe 0·22 (0·15–0·33) 0·14 (0·11–0·19) 0·05 (0·04–0·07) 0·27 (0·17–0·44) 
Western Europe 0·34 (0·28–0·41) 0·26 (0·24–0·28) 0·18 (0·16–0·19) 0·35 (0·32–0·39) 
Central Latin America 0·09 (0·07–0·13) 0·30 (0·23–0·39) 0·12 (0·09–0·14) 0·24 (0·17–0·35) 
North Africa & Middle East 0·14 (0·12–0·18) 0·24 (0·20–0·28) 0·14 (0·11–0·17) 0·29 (0·22–0·37) 
North America 0·60 (0·53–0·68) 0·23 (0·18–0·28) 0·53 (0·39–0·72) 0·30 (0·25–0·36) 
West.  sub-Saharan Africa 0·08 (0·06–0·11) 0·24 (0·19–0·32) 0·05 (0·04–0·07) 0·15 (0·11–0·20) 
Women 0·14 (0·12–0·16) 0·18 (0·16–0·22) 0·06 (0·05–0·07) 0·14 (0·12–0·16) 
Men 0·23 (0·20–0·27) 0·31 (0·27–0·37) 0·14 (0·12–0·16) 0·31 (0·27–0·35) 
Overall 0·19 (0·17–0·21) 0·25 (0·22–0·28) 0·10 (0·09–0·11) 0·22 (0·20–0·25) 
Source: Degenhardt et al. (2013) 
 
Opioid dependence is one of two (the other being amphetamines) most common forms of 
illicit drug dependence (15.4 million people globally) (Whiteford et al., 2013).  In the 
European Union, there were about 1.3 million dependent opioid users in 2014 (European 
Monitoring Centre for Drugs and Drug Addiction, 2014) whilst cannabis dependence ranged 
from 0.1 to 10% (Whiteford et al., 2013) of all cannabis users. 
 
There is also emerging concern regarding the increasing prevalence of medication use and the 
potential for overdose and the development of iatrogenic dependence. This has become a 
particular concern in the United States (Calcaterra et al., 2013; Cerda et al., 2013) and in 
Australia (Nicholas et al., 2011; Roxburgh et al., 2011). 
 
In Australia approximately 8% of the adult population annually experience a SUD, 6% an 
AUD (N=813,637), 2.2% a cannabis use disorder (n=302,246) and 0.3% an opioid use 
disorder (N=38,9222) (Teesson & Proudfoot, 2003; Mills et al., 2006).  The prevalence of 
dependence varies across age groups.  Prevalence of SUD in the Australian population is 
highest in the 16-24 year age group (12.7%, 95%CI: 10.7%-14.7%), followed by the 25-44 
year age group (5.9%, 95%CI: 4.5%-7.3%) and the 45-85 year age group (2.66%, 95%CI: 
1.3%-2.7%) (Reavley et al., 2010).  
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2.4.4 CO-MORBIDITY 
Comorbidity is the co-occurrence of two health conditions, most commonly a SUD and a 
mental health disorder (MHD).  People who are dependent quite often experience 
comorbidity, possibly due to similar underlying factors (Krueger, 1999; Krueger et al., 1998; 
Krueger & Markon, 2006).  Amongst Australians, it is estimated that approximately 3.6% of 
the adult population have both a SUD and an anxiety disorder whilst a further 1.4% of adult 
Australians have both a SUD and an affective disorder (Teesson & Proudfoot, 2003).  
 
Some drug users, who are not dependent, may also experience psychological distress. 
However, not all psychological distress will be associated with their drug use.  Data from the 
2010 NDSHS suggest that tobacco smokers are twice as likely to have been diagnosed or 
treated for a mental illness or to have experienced high or very high levels of distress 
compared with non-smokers.  Recent cannabis users also reported higher levels of 
psychological distress when compared with irregular cannabis users (AIHW, 2011a).  
However psychological distress does not seem to be consistent across drugs.  People who 
abstain from alcohol are more likely to have high or very high psychological distress 
compared with recent drinkers (AIHW, 2011a).  
 
2.4.5 HEALTH SERVICE CONTACT 
Another approach to assessing the extent of harm associated with drug use is by examining 
health service contact.  Drug users seek help to stop or reduce their drug use, not as an end in 
itself, but as a means of reducing negative consequences of use and of improving their lives 
(Laudet, 2011).  Australia has a number of national administrative systems which 
systematically collect information from publicly funded health services about service 
utilisation.  As there are quite different health systems between countries, only Australian 
data and Australian-based studies are considered in this thesis. 
 
GENERAL PRACTITIONER ENCOUNTERS 
Problems associated with alcohol use are the most common reason for health service contact.  
Chalmers and Ritter (2014) recently examined administration data to calculate health service 
contact for SUD in Australia.  They found that 58% of all general practitioner encounters for 
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drug use, excluding opioid substitution, are due to AUD and a further 8% are due to 
medicinal (prescribed) drug use disorders (Chalmers & Ritter, 2014).  
 
EMERGENCY DEPARTMENT PRESENTATIONS  
Australian data on presentations to public hospital emergency departments are measured as 
‘occasions of service’.  An occasion of service refers to any examination, consultation, 
treatment or other service provided to a patient in each functioning unit of a health service 
establishment each time a service is provided (AIHW, 2007).  The data includes all publicly 
funded primary health care services (e.g. alcohol and drug services) in a State or region 
served by an emergency department (ED).  The quality of these data can be variable.  
 
Australian studies show that relatively few ED presentations to public hospitals are for drug 
use per se.  Kinner et al. (2005), in a study conducted in one ED over 14 consecutive days, 
for 24 hours per day, found that 7.7% of all presentations involved the use of an illicit drug in 
the 24 hours prior to attendance (Kinner et al., 2005).  Similarly, Indig et al. (2010) in a study 
of ED nursing triage records (N=263,937) found that 5% of presentations were alcohol-
related and a further 2% were other drug related (Indig et al., 2010).   
 
PUBLIC HOSPITAL ADMISSIONS 
The National Minimum Dataset for Admitted Patient (NMDAP) care is the national data 
collection system for all Australian public and private hospital admissions. In this publicly 
available dataset, the unit of analysis is ‘separations’.  A separation refers to a completed 
episode of admitted patient care for an identified type of care (AIHW, 2007).  Separation 
coding for drug-related hospital separations is based upon the International Statistical 
Classification of Disease and Related problems (ICD-10) (World Health Organization, 1993).  
A ‘separation’ is coded on the basis of the principal diagnosis – that is the primary reason 
responsible for the episode of admitted patient care. There may be other secondary reasons 
for admission, but only the primary reasons are considered in this context. 
 
Table 7 shows separation statistics by principal diagnosis based on ICD-10 codes for the 
period 1998-99 to 2009-10 for drug use (ICD codes F10-19).  This data shows that there are 
far fewer drug use separations compared with those involving mental and behavioural 
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disorders (i.e. other ICD F codes) and to all hospital separations (AIHW, 2011b).  Although 
there has been an overall increase in the number of hospital separations, the proportion of 
separations where drug use was the primary diagnosis has remained fairly consistent. 
Between 1998 and 2010 the proportion of hospital separations where the primary diagnosis 
was drug use averaged 4% a year with the proportion of mental and behavioural hospital 
separations where drug use was the primary diagnosis remained around 16.5% respectively, 
indicating that admission for drug use has not increased over time.  
 
 
Table 7: Count of hospital separations (total, mental and behavioural disorders and 
drug use) and percentage for drug use, by principal diagnosis using ICD-10-, Australia 
1998-99 – 2009-10 
Financial 
Year 
Hospital Separations 
Counts Drug Use 
% 
Drug 
Use 
(IC-10: F10-F19) 
Mental & 
Behavioural 
Disorders 
(ICD-10:F) 
Total 
(ICD-10) 
Mental & 
Behavioural 
Disorders 
(ICD-10:F) 
Total 
(ICD-10) 
1998-99 38,392 239,098 5,735,049 16.06 4.17 
1999-00 39,364 244,717 5,898,804 16.09 4.17 
2000-01 41,688 254,794 6,153,769 16.36 4.15 
2001-02 43,058 264,472 6,398,171 16.28 4.14 
2002-03 44,159 278,829 6,644,984 15.84 4.13 
2003-04 47,898 287,059 6,841,225 16.69 4.20 
2004-05 49,297 291,984 7,018,850 16.88 4.20 
2005-06 53,267 297,362 7,311,983 17.91 4.16 
2006-07 56,145 304,977 7,602,917 18.41 4.07 
2007-08 58,077 307,061 7,873,946 18.91 4.01 
2008-09 60,914 324,064 8,152,170 18.80 4.00 
2009-10 64,310 341,581 8,530,993 16.06 4.17 
 Source: Australian Institute Health and Welfare 1998/99 – 2009/10 data cube 
 
 
ALCOHOL AND OTHER DRUG TREATMENT 
Any structured intervention aimed specifically at addressing a person’s drug use can be 
considered to represent drug treatment (United Nations Office on Drugs and Crime, 2006).  
Recognising the methodological problems associated with treatment counts, Chalmers and 
Ritter estimated that in any one year the total number of Australians in receipt of treatment 
ranges from 141,938 to 236,878 (Chalmers & Ritter, 2014).  This is consistent with previous 
work (Fischer et al., 2012; Roxburgh & Degenhardt, 2008).   
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Chalmers and Ritter also examined specific engagement in alcohol and other drug treatment, 
recorded in the Alcohol and Other Drug National Minimum Dataset. In this publicly available 
dataset, the unit of analysis is ‘closed treatment episodes’.  This refers to a completed episode 
of treatment (AIHW, 2003). In 2011-12 there were 145,225 closed treatment episodes 
(alcohol: 67,370, other drugs: 77,856).  Of these, counselling treatment was most commonly 
provided (41.2%; alcohol: 43.8%, other drugs 39.0%) followed by withdrawal management 
(16.6%; alcohol: 18.5%, other drugs 14.9%) (Chalmers & Ritter, 2014). 
 
2.5 ANNUAL STUDIES OF REGULAR DRUG USING POPULATIONS 
Australia has well established drug information systems with a number of national data 
collections publicly available (Shand et al., 2003; Hando et al., 1998; Ministerial Council on 
Drug Strategy 2004; AIHW 2009).  Two of the most well-established information systems 
are the Ecstasy and Related Drug Reporting System (EDRS) and the Illicit Drug Reporting 
System (IDRS).  
 
Both the EDRS and the IRDS rely upon “sentinel populations” of drug users. Sentinel 
populations are surveillance groups that point towards alcohol and other drug use trends, 
risky behaviours and help seeking (Shand et al., 2003; Hando et al., 1998). Patterns of use, 
potential harms and help seeking amongst these two populations are examined below.  
 
2.5.1 ECSTASY AND DRUG RELATED REPORTING SYSTEM (EDRS) 
The EDRS is an annual Australian surveillance system of the price, purity and availability of 
ecstasy, amphetamines and other drugs.  Participants in the EDRS are people who are aged 
18 years and over, and who are regular ecstasy or amphetamine users. A regular ecstasy or 
amphetamine user is defined as someone who has used ecstasy or amphetamines at least 
monthly in the six months immediately preceding the survey.  
 
Key characteristics of participants in the 2010, 2012 and 2014 EDRS data collections are 
provided in Table 8. EDRS participants in 2010, 2012 and 2014 used multiple drugs in the six 
months prior to interview, most commonly alcohol, tobacco and cannabis. Many participants 
reported drug related problems such as relationships with family, friends and at work and 
interference with associated familial social and work-related responsibilities. Participants 
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typically experienced high to very high psychological distress in comparison with general 
population samples (Sindicich & Burns, 2011, 2013, 2015)  
 
Table 8: Characteristics of regular and current ecstasy and/or amphetamine users 
(since 2012) participating in the ERDS, 2010, 2012 and 2013 
Characteristics 2010 
N= 693 
% 
2012 
N=607 
% 
2014 
N=800 
% 
Demographics Unemployed 14 16 15 
Currently in drug treatment 4 5 2 
Prison history 4 5 4 
Recently injected any drug 10 13 5 
Patterns of use* Alcohol 97 99 98 
 Median days used  60 48 48 
Tobacco 78 83 91 
 Median days used  175 180 170 
Cannabis 80 82 83 
 Median days used  24 60 32 
Health Help-seeking 24 13 94 
Non-fatal overdose#    
 Stimulant1  13 27 16 
 Depressive2 10 17 6 
Psychological distress (K10) No or low (score 10-15)  37 32a 40b 
Moderate (score 16-21)  37 38 36 
High  (score 22-29)  or very high (score 
30-50) 
26 24 24 
Mental health problems*   29 32 28 
Drug-related Functioning* Relationship problems with family, 
friends or colleagues  
20 25 19 
Legal problems  5 6 5 
Interference with home/work/school 
responsibilities  
34 39 28 
Risk Behaviours* Place self in at-risk situations when 
under influence  
38 36 34 
Injecting 10 7 5 
Median times injecting under the 
influence 
15 (1-
500) 
12 (1-
288) 
3 (1-180) 
Casual sexual partners (penetration) 62 66 64 
 Condom always used when 
under the influence  
30 NR 30 
Risky alcohol consumption (AUDITC 
score 8 or above) 
84 83 82 
Arrested in past 12 months 14 14 12 
* in last six months; # in last 12 months 
1Ecstasy, Ice/crystal, Speed, Cocaine, Base, Pharmaceutical stimulants, Other; 2Alcohol, heroin, GHB, benzodiazepines, 
other opiates, other; 3Of those who sought help; 4ERSS or alcohol; NR: not reported 
Sources: Sindicich & Burns (2011, 2013, 2015). 
 
2.5.2 ILLICIT DRUG REPORTING SYSTEM (IDRS) 
The IDRS is an annual Australian surveillance system of the price, purity and availability of 
injectable drugs.  The eligibility criteria for participating in the IDRS is: aged 18 years and 
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over, and who regularly inject drugs. A regular injector is defined as someone who has 
injected at least monthly in the six months immediately preceding the survey.  
 
Key characteristics of PWID in the 2010, 2012 and 2014 IDRS data collections are provided 
in Table 9.   IDRS participants in 2010, 2012 and 2014 normally injected opioids. The most 
common opioid injected was heroin, followed by morphine. Participants consistently reported 
multiple, complex issues including homelessness, prison histories, mental health problems, 
and unemployment in conjunction with undertaking risky behaviours including sharing 
injecting equipment and risky drinking.  Nearly half of each group of participants were 
currently in drug treatment. Typically participants experienced high to very high 
psychological distress (Stafford & Burns, 2013) and diminished personal well-being in 
comparison with general population samples (Stafford & Burns, 2011).  
 
Table 9: Characteristics of regular and current people who inject drugs participating in 
the IDRS, 2010, 2012 and 2013 
Characteristic Year 
2010 
N=902 
% 
2012 
N=924 
% 
2014 
N=898 
% 
Demographics Transient accommodation 39 24 29 
Prison history 52 54 55 
Currently in treatment 47 44 47 
Unemployed 81 84 84 
Opioid Patterns of Use Opioid of choice    
 Heroin 54 54 50 
 Morphine 10 11 10 
 Oxycodone 1 2 1 
 Methadone 2 2 4 
Most commonly injected*    
 Heroin 43 42 41 
 Morphine 19 16 16 
 Oxycodone 3 4 2 
 Methadone 7 5 4 
Health Heroin overdose# 20 19 15 
Mental health problem~ 49 43 39 
Psychological Distress (K10) None 19 20 24 
Moderate 22 24 23 
High 28 30 27 
Very High 32 26 26 
Dependence+ Stimulant (cut off 4 or more) 44 43 69 
Opioid (cut off 5 or more) 77 76 41 
Risk behaviours & activities Injecting *    
 Burrowed syringe 10 7 6 
 Shared equipment  39 25 25 
 Injected in private home 78 80 77 
Arrested# 39 33 33 
AUDIT-C (5 or more) 38 56 59 
* past month; ~ past six months; # in last year; + SDS Sources: Stafford, J. and Burns (2001,2013, 2015) 
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2.6 LIMITATIONS  
There are a number of limitations to population health indicators of the impact of drug use 
and their utility for monitoring drug related harm (Lopez et al.,  2006; Degenhardt et al., 
2011; Degenhardt et al., 2014; Gowing et al., 2015; Lloyd & Livingston, 2009). These 
limitations include reliance upon expert knowledge of alcohol and other drug use and 
associated harms, accurate coding by health service staff; timeliness in data collection and 
difficulties in integrating and assessing data from a wide variety of sources.  The 
development of the data collection systems discussed above is a relatively recent 
phenomenon with substantial gaps in basic epidemiological parameters (Degenhardt et al., 
2014).  Causation is difficult to establish when drug use-related harm is implicated in many 
health conditions.  There can also be considerable time lags between data collection, 
cleaning, public release and dissemination.  There is little literature available on the utility of 
data collection systems or the application of the data collected to population health needs. 
 
The causes of death data (see (2.4.1 mortality) does not count drug use as a contributing 
factor to mortality, only as a primary factor. Alcohol and other drug use can contribute to a 
variety of deaths, illnesses and diseases. For example alcohol is associated with over 60 
medical conditions (Babor et al., 2003).  In Australia the number of deaths attributed to 
alcohol in 2010 was 5,554 (Gao et al., 2014).  Alcohol-related deaths amongst males are 
commonly associated with injury, violence, cancers and digestive diseases, whereas amongst 
females alcohol related deaths are associated with injury, cardiovascular diseases and cancers 
(Laslett et al., 2010; Gao et al., 2014).  The number of deaths attributed to tobacco is 
approximately 15,000 annually (Gao et al., 2014).  Tobacco-related deaths are most 
commonly linked with lung cancer, chronic obstructive pulmonary disease and ischaemic 
heart disease (Scollo & Winstanley, 2012).  
 
The data obtained from sentinel populations as part of the Australian drug information 
systems has its own recognised limitations.  The data are intended to identify emerging issues 
(e.g. Sindicich & Burns, 2015; Stafford & Burns, 2011). The results are not representative of 
all users of those substances (e.g. Sindicich & Burns, 2015; Stafford & Burns, 2011). 
Therefore the results are biased towards very frequent users of the ecstasy, amphetamines and 
people who inject drugs. In the case of the IDRS they are also biased towards users who have 
regular contact with needle and syringe programs. 
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Researchers suggest that few drug users actually have contact with health services (Di Giusto 
& Treloar, 2007; Perkonigg et al., 2006).  To investigate this, as part of this thesis, Australian 
population rates of publicly funded, community based, specialised alcohol and other drug 
treatment and in-patient hospital care by those ‘at risk’, by drug type, sex and age were 
examined.  This study also showed that  that people who drink alcohol or who use illicit 
drugs infrequently access hospitals or treatment services, suggesting that there is a gap in the 
evidence regarding what life is like for the vast majority of users who do not contact health 
services (Fischer et al., 2012).  See published paper below.   
 
The formal citation for this investigation is: 
FISCHER, J.A., CLAVARINO, A.M. & NAJMAN, J.M. 2012. Drug, sex and age 
differentials in the use of Australian publicly funded treatment services. Drug Abuse: 
Research and Treatment, 6, 13-21. 
 
Box 1: Summary of Treatment Paper  
Study 
Purpose 
To determine Australian population rates of those ‘at risk’ of harm from 
substance use, by age, gender & drug. 
Main 
Variables 
• Recent use of alcohol, cannabis, amphetamines & ecstasy by Australians 
aged 14 years and over, adjusted for age and gender 
• Specialised community or hospital service treatment counts. 
Key 
Findings 
• Relatively few substance users are engaged in specialised treatment 
services 
• Alcohol & cannabis are the substances which is associated with the 
greatest demand for treatment. 
Additional 
Information 
Tables 
Table 1: Population estimates of those using at ‘at risk’ levels and service 
use, hospital and community 
Table 2: Relative rate (M:F) of use of treatment, National Hospital 
Minimum Dataset 2006-2007 and National Minimum Dataset 
2006-2007, for alcohol, cannabis, ecstasy and amphetamines, by 
age group 
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Abstract
Context: Little is known about the proportion of the Australian population using alcohol or other drugs who may seek treatment. There 
is a need to have some additional estimates of population morbidity which reflect harms associated with use.
Objective: To determine Australian population rates of publicly funded community based specialised alcohol and other drug treatment 
and in-patient hospital care by those ‘at risk’, by drug type, sex and age.
Design and setting: The design is secondary data analysis of publicly available datasets. We use the latest available complete data on 
Australian general population incidence of alcohol, cannabis amphetamines and ecstasy use (2007 National Drug Strategy House-
hold Survey) and nationally collected administrative data on publicly funded specialised alcohol and other drug treatment services 
(2006–2007 Alcohol and Other Drug Treatment Services National Minimum Dataset) and public hospitals (2006–2007 National Hos-
pital  Morbidity Minimum Dataset) to calculate rates of drug treatment and in-patient hospital care per 1000 Australians. ‘At risk’ for 
alcohol is defined as being at risk of short term harm, as defined by the National Health and Medical Research Council (2001). ‘At risk’ 
for illicit drugs is defined as those exposed to potential harm through at least weekly use of cannabis, amphetamines and ecstasy use.
Results: Risky alcohol consumption followed by recent cannabis use appears to lead to most harm. Greater harm seems to be 
 experienced by males rather than females. Younger adults (15–19 years) and older adults (40+ years) seem also to experience the 
 highest rates of harm.
Conclusions: It is possible to derive population estimates of harms associated with licit and illicit drugs use. Treatment rates vary across 
drug type, gender and age. Alcohol and cannabis are the substances whose use leads to the greatest demand for services. Ecstasy appears 
to generate few presentations for treatment. Publicly available data can be used to estimate harms associated with the use of particular 
substances. Such estimates are best interpreted in the light of other ways of estimating harms.
Keywords: drug treatment, sex, age, population datasets
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Introduction
The development of alcohol and other drug (AOD) 
treatment services should be guided by an understand-
ing of the level and types of need which exists in the 
general population.1,2 Australia has well established 
drug information systems with a number of national 
data collections publicly available.3–7 However the 
Australian population who may be ‘at risk’ of requir-
ing treatment and the extent that those with problems 
have sought treatment is uncertain; as is whether there 
may be drug specific, sex and age differences in 
 treatment. These variables may provide important 
descriptive information for service planning and for 
monitoring policy outcomes.
AOD use by females was once considered to be 
relatively uncommon8 with research and treatment 
focusing on the experiences and needs of males.9,10 Yet 
about a third of illicit drug users are female8,10–12 and 
there seems to be increasing female AOD use in 
younger age cohorts.11–13 There is a suggestion that 
females are under-represented as drug treatment 
clients.8,14 A number of investigators have argued that 
females with AOD problems find treatment inaccessi-
ble because they may experience more stigma and 
marginalisation by the community generally and by 
treatment services specifically.15,16 For example females 
may experience judgemental attitudes from treatment 
staff10,17 particularly if they are the primary caregivers 
for children.9 Female treatment participation may be 
inhibited by concerns about losing custody of their 
children17–19 and the lack of child care options.20–22
AOD use occurs across the life course, with age 
related declines in AOD prevalence and incidence the 
norm.23,24 However there is some concern that the prev-
alence and incidence of AOD use amongst older per-
sons will increase in the near future. In the United States, 
researchers have become concerned about a combina-
tion of lifetime prevalence and recent increases in AOD 
use by ‘baby boomers’ (persons born 1946–1964). 
Given the ageing Australian population, an understand-
ing of AOD use by older persons will also become 
increasingly important for policy makers.23 Despite this 
our understanding of treatment engagement by older 
people, and its implications for health care delivery25–29 
has been largely overlooked.21,23,25,28,30–32
The need to enter treatment reflects problematic 
drug use, associated with adverse effects on the health 
of individuals.33 This need is likely to involve a 
 subjective perception based upon actual and  perceived 
problems associated with use. Generally treatment 
services are not focused on a particular substance but 
are provided for those who self-select because they 
use pattern is troubling to them. Arguably then the 
rates of service use provide an indication of sub self-
perceived distress associated with the use of a partic-
ular substance. Further it can be argued that the use of 
hospital services represent a greater level of distress 
and a higher level of impairment and function.
The question of the number of people at risk in need 
of treatment however is often unknown as there are 
few available studies of sex and age differences in 
treatment engagement.34–36 Several researchers37–39 have 
explored methods to investigate the relative harms of 
different drugs. Whilst these approaches remain con-
tentious, nationally collected data should be able to be 
used by policy makers and service providers as an indi-
cation of the availability of treatment and also as indi-
cator of harms associated with use.38,40 Indeed to deliver 
appropriate services we need to know core information 
about the client group. Two potential indicators of the 
client group using publicly funded treatment use are 
rates of people choosing to seek help to reduce their 
alcohol/drug use and people forced to seek help because 
of direct/indirect harms from their alcohol/drug use. 
Using publicly available data it is possible to calculate 
rates of service use by these using at ‘at risk’ levels for 
particular substances.
Methods
Data sources
This is a comparative descriptive epidemiological 
study using the latest complete data from three national 
Australian data collections, the 2007 National Drug 
Strategy Household Survey 2007 (NDSHS),3,12,41 the 
2006–2007 Alcohol and Other Drug Treatment Ser-
vices National Minimum Dataset (NMDS)7,42 and the 
2006–2007 National Hospital Morbidity dataset 
(NHMD).43–45 The NDSHS provides triennial data on 
the number of Australians aged 14 years and over3 at 
risk of short term harm from alcohol consumption and 
who have recently used cannabis, amphetamines and 
ecstasy. The NMDS consists of nationally collected 
data items on completed federally funded government 
and non-government community-based treatment 
episodes.46–48 In 2006–2007 this was 633 agencies.48 
For this study AIHW ‘data cubes’ ( interactive 
Sex and age differences in drug treatments
Substance Abuse: Research and Treatment 2012:6 15
 spreadsheets) from the 2006–2007 NMDS was used.49 
The NHMD consists of standard data items collected 
by publicly funded hospitals on all completed episodes 
of in-patient care.45,50 For this study, data from the 
2006–2007 NHMD data cube were used.43
‘At risk’ measure
‘At risk’ is defined as those who have been exposed to 
cannabis, amphetamines and ecstasy through at least 
weekly use. For alcohol, it is those at risk of short 
term harm, as defined by the National Health and 
Medical Research Council12 and used by the NDSHS 
2007. For males this is the consumption of seven or 
more standard drinks in any one day and for females 
it is the consumption of five or more standard drinks 
on any one day.41,51
A consistent definition of ‘at risk’ across all drugs 
investigated is not possible. Although there are guide-
lines for alcohol, there is no consensus on ‘risky’ can-
nabis, ecstasy or amphetamine use. The criteria for 
risky use may vary by drug and frequency of use. 
Despite this there is a need to develop one consistent 
measure to estimate what constitutes problematic use. 
As there is consistent data on at least weekly use for 
all illicit drugs, we have used that measure here.
Statistical analysis
The numerators are completed treatment and hospital 
episodes by drug type, sex and age group. For com-
pleted treatment episodes these are the counts of each 
principal drug of concern (ie, alcohol, cannabis, 
amphetamines, ecstasy). The principal drug of con-
cern is self-reported by the client and represents the 
drug which led them to seek treatment.12,46 For com-
pleted hospital episodes these are the counts of the 
designated ‘principal diagnosis’ codes from the Inter-
national Statistical Classification of Disease and 
Related problems (ICD-10)50 for which code F10,52 
F12 (cannabinoids) and F15 (due to use of other stim-
ulants) have been used.
Neither the NMDS nor NHMDS record the num-
ber of concurrent or consecutive treatment episodes 
for any one individual. This is a limitation of the 
data.42 Therefore there are likely to be multiple con-
tacts in both data sources. Hence in the analyses 
allowances could not be made for repeaters (relapses) 
which may account higher usage rate of AOD treat-
ment and hospital inpatient care.
The denominator is the number of persons exposed 
and therefore ‘at risk’. The denominators are the 
 population point estimates for self-reported recent 
use (at least weekly) by cannabis, ecstasy and 
amphetamines12,41 by specific sex and age groups. As 
the level of risk associated with weekly use may vary 
by the substance used, interpretations of findings are 
subject to this caveat. Population point estimates were 
obtained by identifying the number of at last week 
users (recent users). Use in the last week was obtained 
from the NDSHS 2007 dataset. The proportion (in 
percentage) of those in the last 12 months who had 
recently used was than calculated. This percentage 
was multiplied by the population estimate of users in 
the last 12 months to obtain the population estimate 
for number of recent users. Hence the analysis pre-
sented consists of rates of treatment and hospital epi-
sodes per 1000 recent users, by drug type, sex and 
age group.
Results
Table 1 presents details of overall levels of those who 
use ‘at risk’ levels and the level of service use by sub-
stance and sex. The population ‘at risk’ was generally 
highest for those using alcohol or cannabis. By con-
trast only relatively modest numbers are using ecstasy 
and amphetamines. Both treatment and hospital use is 
a dominated by those seeking help for alcohol prob-
lems and then cannabis. A moderate number of those 
Table 1. Population estimates of those using at ‘at risk’ 
levels and service use, hospital (national hospital Mini-
mum Dataset (nhMD)) and community (national Minimum 
Dataset (nMDS)).
Drug Males Females
population estimates of those at risk
Alcohol 317,773 239,413
cannabis 424,229 204,600
ecstasy 110,993 76,748
Amphetamines 55,357 22,871
service use – hospital (nHMD)
Alcohol 23,741 19,262
cannabis 2,157 938
ecstasy Data not available Data not available
Amphetamines 2,356 1,098
service use – community (nMDs)
Alcohol 40,857 17,957
cannabis 22,017 9,368
ecstasy 768 231
Amphetamines 11,466 5,743
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seeking services were using amphetamines and very 
few of those using ecstasy were seeking help.  Hospital 
service use is dominated by those seeking help for an 
alcohol problem with very small  numbers being 
admitted to hospital for problems associated with 
cannabis and amphetamines. The numbers admitted 
to hospital for a problem associated with their ecstasy 
use is so few that numbers have not been provided.
Table 2 presents details of male to female treat-
ment and hospital episode rates by age group. There 
are consistently higher rates of treatment for males 
compared to females across all age categories. Indeed 
in some instances the treatment episode rate for males 
using at risky levels is two to three times that for 
females, particularly for alcohol and ecstasy use in 
the 20–29 years age group, and in hospital episode 
rates amphetamines in the 40 plus year age group.
Discussion
Following the work of Fischer et al (1997), Nutt et al 
(2007), and Caulkins et al (2011), we have provided 
broad population data of harm and treatment cover-
age associated with the most common drugs used by 
Australians. Overall, we found evidence for  population 
differentials (drug type, sex and age) in Australian 
publicly funded service utilisation with particularly 
high service use for alcohol, for males and for the 
15–19 years and 40+ year age groups.
Alcohol and cannabis were the major drugs used at 
‘at risk’ levels of harm in the community with com-
paratively fewer ‘at risk’ of harmful use evident for 
ecstasy and amphetamines. This partly reflects the 
prevalence of risky alcohol consumption in the 
 Australian general population. It confirms the priority 
implicit in recent national campaigns to reduce the 
harm associated with alcohol consumption in the 
Australian general population the need to consider 
the comparative number of users39 in primary preven-
tion initiatives.
Treatment rates were higher for males than for 
females. This challenges the frequently reported find-
ing that females are more likely to seek health care for 
a problem then are males53–55 but does confirm previ-
ous findings from studies with convenience samples.8,14 
It may be that females present to generalist health 
services8,20 such as general practitioners but this 
 unlikely.56 We have also noted that only a small pro-
portion of GP contacts are for alcohol or drug related 
health problems.57 However it is possible that prob-
lematic use is not routinely detected in general  practice. 
For instance few older adults with substance problems 
seek specialised treatment.21,23 Rather they may pres-
ent to generalised health services58,59 with ‘atypical 
presentations’31 such as chronic non-malignant pain60 
or with other long term and chronic conditions.23,28,36,61 
This may also be the case for females.
Limitations
There remains much contest over measuring ‘harms’ 
from drug use.37–39 We have used criteria for use that 
are generally associated with problematic patterns of 
use. However, frequency of illicit drug use is only 
one of the factors determining harmful use62 and can-
not replace a comprehensive individual or sample 
assessment of drug use. A range of factors influence 
the number of treatment episodes, including co- 
morbidity and age of treatment participants. Some of 
these details are not available. If other factors around 
drug use, such as quantity, risk behaviours and the 
co-occurrence of mental illness were also taken into 
account, it is likely that the assessment of ‘at risk’ 
Table 2. Relative rate (M:F) of use of treatment, national 
hospital Minimum Dataset (nhMD) nhMD 2006–2007 and 
national Minimum Dataset (nMDS) 2006–2007, for alcohol, 
cannabis, ecstasy and amphetamines, by age group.
Age 
group
nHMD nMD
Males Females M:F Males Females M:F
Alcohol
15–19 1,267 1,031 1.23 3,111 1,238 2.51
20–29 2,680 1,834 1.46 10,194 3,296 3.09
30–39 4,512 3,263 1.38 11,778 5,354 2.20
40+ 15,282 10,134 1.51 15,764 8,069 1.95
cannabis
15–19 334 138 2.42 4,986 2,147 2.32
20–29 902 404 2.23 9,264 3,671 2.52
30–39 662 290 2.28 5,216 2,393 2.18
40+ 259 106 2.44 2,551 1,157 2.21
ecstasy
15–19 Data not available 204 83 2.51
20–29 459 104 4.41
30–39 89 34 2.62
40+ 16 10 1.6
Amphetamines
15–19 144 115 1.25 864 662 1.31
20–29 935 516 1.81 5,152 2,668 1.93
30–39 950 362 2.62 4,157 1,907 2.18
40+ 327 103 3.17 1,293 506 2.56
Data sources: nMDS 2006–2007, nhMDS 2006–2007.
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illicit drug using populations would differ from those 
estimated here.
Aggregating data from a range of drug information 
systems has methodological problems.63,64  Consequently 
there are a number of technical limitations to the 
 analysis. Our analysis is based upon the most recently 
used data taken from similar years. Whether these rates 
are stable across time is unknown. In this study we 
were also confronted by differences in drug use termi-
nology and counting methods. For instance we were 
unable to obtain hospital separation data for ecstasy, as 
this may be accounted for in more than one ICD10 
code. It also does not take into account situations in 
which AOD may be a secondary diagnosis which 
would increase separation rates.
There were a number of additional ICD codes that 
can be defined as drug-related hospital treatment such 
as drug-related injuries and poisoning, however these 
have not been included in this analysis. If included, 
these would increase the rate of treatment in special-
ised facilities. Similarly as the NMDS and the NHMD 
count treatment episodes and hospital admissions, 
there are likely to be multiple contacts for any one 
individual. Hence there is uncertainty over whether 
there is a small sub-section of drug users very heavily 
engaged in services.
We have used as our measure of harm completed 
treatment and hospital episodes and our exposed 
groups as the number of persons in the general popu-
lation who have frequently used the specific 
 substances. The harms associated with and treatment 
coverage is likely to vary drastically between 
 countries. Therefore in broader application of the 
analysis we recommend clearly defining dataset 
nuances and applying locally relevant measures of 
harm and treatment.37,38
conclusion
Treatment rates vary across drug type, gender and 
age. It is salutary to note that alcohol and cannabis, in 
that order, remain the substances which lead to the 
greatest demand for treatment services. It is possible 
to calculate population estimates of ‘at risk’ for licit 
and illicit drugs use and AOD treatment utilisation 
within the Australian setting. The policy and political 
environment of AOD services is intensely political 
and contested. Although there is some disagreement 
around harm, there is consensus for developing an 
evidence base inclusive of risk and benefits  associated 
with AOD use. In constricted financial and political 
environments it is necessary to consider current treat-
ment coverage and where policy should be focused to 
reduce the most harm from AOD use. Publicly avail-
able data can be used to estimate harms associated 
with the use of particular substances. Such estimates 
are best interpreted in the light of other ways of esti-
mating harms.
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Appendix
Appendix. completed hospital (nhMD 2006–2007) and treatment episodes (nMDS 2006–2007) Per 1000 recent alcohol, 
cannabis, ecstasy and amphetamines users, by sex and age group.
Age 
group
population 
estimate 
in the last week
nHMD nMDs
Hospital  
episodes
per 1000 Treatment  
episodes
per 1000
Males
Alcohol#
 15–19 26,282* 1,267 48.21 3,111 118.37
 20–29 73,562 2,680 36.43 10,194 138.58
 30–39 63,864 4,512 70.65 11,788 184.43
 40+ 154,065 15,282 99.19 15,764 102.32
cannabis
 15–19 35,699 334 9.36 4,986 139.67
 20–29 152,988 902 5.90 9,264 60.55
 30–39 96,663 662 6.85 5,216 53.96
 40+ 138,879 259 1.86 2,551 18.37
ecstasy
 15–19 7,157 Data not available 204 28.50
 20–29 68,220 459 6.73
 30–39 26,550 89 3.35
 40+ 9,066 16 1.77
Amphetamines
 15–19 1,063 144 135.47 864 812.79
 20–29 31,746 935 29.45 5,152 162.29
 30–39 19,602 950 48.46 4,157 212.07
 40+ 2,948 327 110.92 1,293 438.60
Females
Alcohol#
 15–19 23,802 1,031 43.32 1,238 52.01
 20–29 62,940 1,834 29.14 3,296 52.37
 30–39 50,583 6,263 123.82 5,354 105.85
 40+ 102,088 10,134 99.27 8,069 79.04
cannabis
 15–19 34,988 138 3.94 2,147 61.36
 20–29 70,844 404 5.70 3,671 51.82
 30–39 51,767 290 5.60 2,393 46.23
 40+ 47,001 106 2.26 1,157 24.62
ecstasy
 15–19 11,438* Data not available 83 7.26
 20–29 31,520 104 3.30
 30–39 30,030 34 1.13
 40+ 3,760 10 2.66
Amphetamines
 15–19 4,392 115 26.18 662 150.73
 20–29 10,260 516 50.29 2,668 260.04
 30–39 7,072 362 51.19 1,907 269.66
 40+ 1,147 105 91.54 506 441.15
Data sources: 2007 nDShS First Results and Detailed Findings, nMDS 2006–2007, nhMDS 2006–2007.
notes: *nDShS general population rate is 14–19 years, #risk of alcohol harm in the short term.
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The approach to drug use has traditionally been based on a pathology paradigm (Moore, 
2008; Mugford, 1988).  Indeed the concept of risk has become a defining feature of alcohol 
and other drug biomedical and epidemiologically oriented work (Hunt et al., 2007; Moore, 
2008).  The almost exclusive focus on drug use harm and the  burden of disease and of health 
service contact has meant that there is little known about the potential benefits that users 
experience when they use particular drugs (Moore, 2008; Coveney & Bunton, 2003).  As 
noted by O’Malley and Valverde, rarely do screening instruments ask: “how often do you 
enjoy (a particular drug)?” (O'Malley & Valverde, 2004).   
 
2.7 CHAPTER SUMMARY 
Drug use has the potential for harm. However, few people who use substances experience 
problems that result in contact with health services. The existing literature provides 
incomplete explanations of the benefits of drug use, particularly in terms of enhanced well-
being acting as a motivating factor in drug use.  Using a QOL perspective provides a broader 
approach to understanding drug and the impact of drug use than simply examining drug use 
within the more common pathology/harm frameworks.  
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CHAPTER THREE: MOTIVATIONS, QUALITY OF 
LIFE AND DRUG USE 
3.1 INTRODUCTION 
This chapter reviews the literature on quality of life (QOL) and drug use.  The chapter 
commences by considering the motivations behind drug use, with a particular focus on the 
concept of pleasure.  The chapter then turns to defining and conceptualising QOL.  Within 
this context the chapter reviews three related sets of literature on the QOL of drug users: 
dependent users, adult drug users not in treatment and young adults.  The chapter concludes 
that our understanding of the QOL of drug users is in its infancy and there are large gaps in 
the current evidence.  
 
3.2 MOTIVATIONS FOR USE  
There are a variety of motivations for psychoactive drug use. In this section two approaches 
to motivations for use are considered. These are the normalisation hypothesis and pleasure.  
 
3.2.1 NORMALISATION HYPOTHESIS 
The ‘normalcy’ of drug use was articulated a decade ago in the ‘normalisation hypothesis’ 
(Measham et al., 1994; Parker et al., 1998).  The normalisation hypothesis asserts that people 
take drugs because they enjoy or otherwise obtain benefits from some of the effects of use 
(Hammersley, 2005); and that some forms of drug use are generally socially and culturally 
accepted by nonusers (Measham et al., 1994; Parker et al., 1998). According to this 
hypothesis drug use is ordinary (Schnuer, 2013) and, an unremarkable (Measham & Shiner, 
2009) part of life, not its defining feature (Parker et al., 2002; Hammersley, 2005).   
 
The normalisation hypothesis is suggestive of ‘QOL’ being an important component of drug 
use.  Important to the normalisation hypothesis is the examination of drug use from the 
perspective of the user (Moore, 2008; O'Malley & Valverde, 2004; Pennay & Moore, 2010; 
Valentine & Fraser, 2008), with the primary evidence being ‘lay knowledge’ rather than 
epidemiological data (Hunt et al., 2007).  
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A central tenet of the normalisation thesis is that pleasure is a crucial component of drug use 
(Jarvinen & Ostergaard, 2011; Holt & Treloar, 2008; Measham, 2004; O'Malley & Valverde, 
2004).  As the normalisation hypothesis, and this thesis also contends, focusing attention on 
the beneficial aspects of drugs use, namely pleasure, has the potential for new understandings 
of drug use (Moore, 2008; O'Malley & Valverde, 2004; Valentine & Fraser, 2008).  A 
pleasure perspective represents a positive health approach to drug use (Ryff & Singer 1998). 
 
3.2.2 PLEASURE 
‘Pleasure’ as a concept is difficult to define.  A google search using the question “what is 
pleasure?’ returns with ‘about 424,000,000 results’.  Narrowing the search in google scholar 
returns ‘about 1,920,000 results, with ‘about 29,600 results’ in the first ten months of 2014.  
The word ‘pleasure’ in the English language is a noun, an adjective and a verb.  It is a thing, a 
description and an action.  In the context of drug use, it can be a process (of acquisition, 
sharing, consumption), an enhancer (e.g. of social activity) or an experience (Brock, 1983). 
 
Pleasure is intimately related to the consumption of all the drugs examined in this thesis 
(Coveney & Bunton, 2003; Holt & Treloar, 2008; Schnuer, 2013).  Although largely 
neglected in the drug use literature (O'Malley & Valverde, 2004; Holt & Treloar, 2008), 
pleasure, it has been contended, is a legitimate motive for drug use (Becker, 1953; Holt & 
Treloar, 2008; Measham, 2004; O'Malley & Valverde, 2004).  This is based on the premise 
that there are beneficial aspects from the process of drug use (Duff, 2004; 2008; Moore, 
2008; O'Malley & Valverde, 2004) and also its outcomes.  
 
CHEMICAL BASIS OF PLEASURE 
Based on the clinical characteristics of each of the drugs forming the focus of this thesis there 
appears to be a physiological or psychological basis to the pleasurable effects obtained from 
drugs.   
 
Alcohol 
There are hundreds of different types of alcohol (Inaba & Cohen, 2007).  Alcohol is 
technically a depressant (Inaba & Cohen, 2007; Rang et al., 2011).Low to moderate alcohol 
consumption is commonly associated with the experience of slight sedation, muscle 
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relaxation and a sense of warmth (Inaba & Cohen, 2007).  It lowers inhibitions, increases 
self-confidence, and promotes sociability (Inaba & Cohen, 2007).  Drinkers often report a 
sense or euphoria after the first few drinks (Baker-Dennis & Pryor, 2014).  
 
Tobacco 
Nicotine, the active ingredient in tobacco has multiple effects on the human body (Julien, 
2001).  Nicotine is a stimulant causing neuronal excitation, and also desensitisation (Rang et 
al., 2011).  Nicotine is rapidly absorbed by the body and results in increased psychomotor 
activity, cognitive function, sensorimotor performance, attention and memory consolidation 
(Julien, 2001).  
 
Cannabis 
The physiological and psychological appeal of cannabis appears to be related to the effects of 
tetrahydrocannabinol which enhances dopamine neuronal firing and synaptic dopamine levels 
in the reward pathway of the brain (Baker-Dennis & Pryor, 2014).  Cannabis is commonly 
used to enhance mood, (Becker, 1953; Boys & Marsden, 2003; Green et al., 2004; Hallstone, 
2002; Hammersley et al., 2001; Hirsch et al., 1990; Santelli & Galea, 2011), facilitate 
pleasure (Becker, 1953; Hirsch et al., 1990; Hallstone, 2002; Harris et al., 2000), minimise 
discomfort (Swift et al., 2005) and to improve well-being (Becker, 1953; Hirsch et al., 1990; 
Schafer & Brown, 1991; Hammersley et al., 2001; Hallstone, 2002; Boys & Marsden, 2003).   
 
Medications  
Medications are, generally, used to reduce pain, improve mobility and enhance daily 
functioning as well as  to manage illness symptoms (Fischer & Rehm, 2007; Cooper, 2013). 
Medications may also be used not as prescribed to alleviate psychosomatic pain (Fischer & 
Rehm 2007, Zullig & Divin 2012). They are not being used as a  response to actual disease, 
but to psychological distress (Johnston 2009, Zullig and Divin 2012). Medication use in this 
manner by young people may also be for the self-treatment of physical pain (McCabe, Teter 
et al. 2005). Several studies of life satisfaction and young adults have found that young adults 
may take extra medications for health conditions and ailments that they have not gone to see 
a doctor or other health professional about (Chen, Cohen et al. 2004, Zullig, Bogart, Collins 
et al. 2007).  
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Medications are also used or ‘misused’ for pleasurable purposes. In cross-sectional studies of 
US College students non-prescribed medication use most commonly occurs between friends 
for a broad range of reasons (McCabe, Teter et al. 2005). These reasons include for becoming 
intoxicated (McCabe, Teter et al. 2005), to help with partying (Teter, McCabe et al. 2005, 
Arria, Caldeira et al. 2008), for improving concentration and alertness (Teter, McCabe et al. 
2005), and for sensation seeking (Arria, Caldeira et al. 2008).  
 
 
Opioids 
Opiates, particularly when injected or snorted, can produce flushing and an intensely 
pleasurable and diffuse bodily sensation that has been likened to an orgasm (Baker-Dennis & 
Pryor, 2014).  The initial rush is followed by a sense of well-being (Baker-Dennis & Pryor, 
2014).   
 
Central to pleasure is examining use from the perspective of the user (Moore, 2008; O'Malley 
& Valverde, 2004; Pennay & Moore, 2010; Valentine & Fraser, 2008), with lay knowledge at 
least as important as epidemiological data (Hunt et al., 2007).  However ‘pleasure’ is 
concerned with the positive aspects of drug use.  There is a need for a more overarching 
approach that accounts for the potential for harm, as illustrated in the previous chapter, and 
also the beneficial aspects of drug use, pleasure.  A better perspective is considering and 
assessing the QOL of drug users.  
 
 
3.3 DEFINING QUALITY OF LIFE 
QOL is a multidimensional, subjective, concept that encompasses perceptions of both the 
positive (Cummins, 2005) and negative (Diener, 1994; Ware, 1987) aspects of life, at a given 
point in time.  Definitions of subjective QOL are not dissimilar to those of ‘subjective well-
being’.  Subjective well-being can be considered an engagement in living, involving 
expression of a broad range of human activities, including difficult experiences, pain and 
struggle, as a part of and in response to, intellectual endeavours, social relations, emotional 
attachment and mental well-being (Andrews & Withey, 1976; Ryff & Singer, 1998; The 
WHOQOL Group, 1995; Campbell et al., 1976).  As Campbell et al. (1976) noted a general 
sense of well-being is derived from a life that is stimulating, rewarding and secure – that is 
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the goodness of life.  At the core of these perspectives is a focus on the individual’s 
perception of their life circumstances and expectations (Laudet et al., 2009; Veenhoven, 
2010), in other words, it is a subjective assessment of life.  This approach offers a 
complementary perspective to that of the more common clinical assessments of QOL, where 
clinicians tend to focus on symptoms and associated client/patient well-being (Laudet, 2011). 
Assessments of well-being, happiness and psychological distress appear to be consistent 
predictors of the more global construct, QOL (Constanza et al., 2006; Cummins, 2005; 
Headey & Wearing, 1992; Veenhoven, 2000).  This is a broader conceptualisation of QOL 
than that associated with the assessment of health-related QOL with its pathology focus, and 
is relatively new in the field of drug use and dependence research (Tracy et al., 2012).  
 
Well-being is a general evaluation of one’s life in terms of two key aspects, satisfaction and 
affect (both positive and negative) (Bowling, 2005; Keys et al., 2002). Happiness is generally 
considered a measure of short term affect, of how much people enjoy their lives (Campbell et 
al., 1976; Organisation for Economic Co-operation and Development, 2013; Radcliff, 2013) 
whilst satisfaction is the extent to which a person’s needs are satisfied (Veenhoven, 2013) 
and tends to be a more stable judgement.  Happiness and satisfaction are complementary 
measures of well-being (Bowling, 2005).  Both can be considered to be ‘democratic’ 
measures (Diener & Oishi, 2000) which enable people to appraise their own lives, rather than 
relying on proxy judgements made by clinicians and scholars (Blanc et al., 2014; Hamilton & 
Redmond, 2010; Lora, 2008; Plege & Hunt, 1997). 
 
3.3.1 HAPPINESS  
Happiness is a measure of short term affect, which may fluctuate daily in response to ongoing 
events (Campbell et al., 1976).  There are many definitions of happiness (Veenhoven, 2012), 
but there is some consensus that happiness is more than a reflection of material conditions 
(Easterlin, 1974).  Experiencing happiness is believed to be central to well-being (Headey & 
Wearing, 1992; Veenhoven, 2012; Phillips, 2006).  Indeed happy people are likely to 
experience more events that are considered desirable and some also have a propensity to 
interpret and recall ambiguous events as good (Seidlitz & Deiner, 1993; Lyubomirsky et al., 
2005; Tadic et al., 2013).  Although there is still work to be done on understanding the 
temporal sequence of happiness (Brockmann & Delhey, 2010; Parks et al., 2012), happiness 
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measures are considered a valid and reliable assessment of the extent to which particular 
aspects of life are favourable at any given point in time (Veenhoven, 1991).   
 
3.3.2 SATISFACTION  
Satisfaction, on the other hand, is an assessment of ones aspirations, achievements and 
perceived reality in comparison with peers (Constanza et al., 2006; Proctor et al., 2009) and 
with societal norms (Bowling, 2005; Organisational for Economic Co-operation and 
Development, 2013).  Satisfaction appears to be a more stable component of well-being than 
happiness and is less likely to reflect or respond to ongoing, short term, life events (Verdugo 
et al., 2005). In a study of 222 college students satisfaction with life was best predicted by 
positive feelings and an absence of negative feelings.  People high in purpose in life reported 
enhanced levels of life satisfaction even when they were only experiencing moderate levels in 
their current mood state.  Life and self-satisfaction were predicted significantly by purpose in 
life even after controlling for physical pleasure and affect balance, suggesting that they are 
more than just hedonic variables (Diener et al., 2012). 
 
Several researchers (Diener et al., 2013; Felce, 1997; Laudet, 2011), have argued that life 
satisfaction is an essential QOL criterion because individuals differ in what they enjoy, what 
they want from life and find important.  The stability of life satisfaction scores across time 
and situations suggests that consistent psychological processes are involved and similar 
information is used when people report their satisfaction (Diener et al., 2013).  The reference 
points for this comparison are believed to include a broad variety of factors encompassing 
outlook on life, aspirations and achievements, social and economic circumstances and 
activities as well as individual needs (Diener et al., 2013; Neugarten et al., 1961).  The 
reliability and validity of life satisfaction measures have also been well established (Diener et 
al., 2013).   
 
3.3.3 PSYCHOLOGICAL DISTRESS  
Mental functioning is particularly affected in those with drug use disorders (SUD) (Smith & 
Larson, 2003; Volk et al., 1997).  There is little agreement about the ways in which the 
dimensions of well-being and distress co-occur and whether these represent one single 
dimension or are separate dimensions of this construct (Beckie & Hayduk, 1997; Fayers & 
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Hand, 1997).  The basis for this argument is that the relationship between well-being and 
distress is complex (Andrews & Withey, 1976; Headey & Wearing, 1992).  High positive 
affect appears to be related to the pleasantness of life, whereas low positive affect appears to 
be associated with depression (Watson & Kendall, 1989).  Anxiety, on the other hand is not 
significantly related to low positive affect.  In other words, depression but not anxiety is 
related to the experience and reporting of low positive affect or well-being (Clavarino, 1996). 
 
 
3.4 MAKING JUDGEMENTS ABOUT QOL 
3.4.1 UNIQUE SELF-REFLECTIONS  
QOL judgements represent unique self-reflections of personal perspectives and experiences 
(Cummins, 2005; Ryan & Deci, 2001; Haase et al., 2012; Bonomi et al., 2000; Schlenk et al., 
1997; Blanc et al., 2014).  The approach to  QOL taken here emphasises the point of view of 
the person (Fakhoury & Priebe, 2002; Awad et al., 1997; Blanc et al., 2014).  Subjective 
assessments are underpinned by reflection and appraisal of ego (a sense of self), relationships 
with others, the degree of individual autonomy, having a purpose in life, possessing positive 
self-regard and perceived mastery over one’s immediate environment (Antonovsky, 1987; 
Ryff & Singer, 1998; Verdugo et al., 2005). 
 
How individuals judge their QOL does not always equate to what their objective situation 
may suggest (Albrecht & Devlieger, 1999; Fellinghauer et al., 2012; Sprangers & Schwartz, 
1999; McClimans et al., 2013).  According to the disability paradox (Albrecht & Devlieger, 
1999) individual judgements about QOL may be independent of their current or potential 
future health status or the presence of illness or symptoms of disease (Cummins, 2005; 
Headey & Wearing, 1992; Hensel et al., 2002).  A person may see their QOL as satisfactory 
when objective criteria might suggest that QOL should be low (Maremmani et al., 2007; 
Albrecht & Devlieger, 1999; Brown & Brown, 2005).  For example, although populations 
with long term health problems report poorer QOL when compared with the general 
population, the range of QOL judgements, from poor to excellent, can be found by in all 
populations and across age groups (Albrecht & Devlieger, 1999; Fellinghauer et al., 2012; 
Clavarino, 1996). 
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This seems to be counter-intuitive.  If QOL is used as a measure of treatment outcome (as it 
often is), then it is to be expected that those with worse health will express a poorer QOL. 
Although changes in expectation may be modified when mood states are particularly labile, 
for example, in those with psychosis, depression and euphoria (Gazalle et al., 2007; 
Voruganti et al., 2007), other factors also seem to be involved when making judgements 
about QOL.  On the one hand the observation that subjective judgements of QOL are largely 
independent of indicators of physical health raises questions about the use of QOL as a 
measurement of health outcomes (Brown & Brown, 2005; Maremmani et al., 2007).  On the 
other hand self-reports or judgements about QOL seem to have a high level of face validity 
(Brockmann & Delhey, 2010; Parks et al., 2012; Ryan & Deci, 2001; Veenhoven, 1991). 
 
3.4.2 QOL IS MULTI-DIMENSIONAL 
Most researchers agree that QOL is a multi-dimensional construct (Bowling, 2005; Bramston 
et al., 2005; Cummins, 2005; Felce, 1997; Schalock, 2004; Najman & Levine, 1981).  It 
seems to involve a complex interaction of individual (age, sex, socio-economic status, 
employment) social (children, relationships, activities), health and spiritual domains.  Being a 
multi-dimensional construct, QOL assessments appear to transcend singular domains 
(Zubaran & Foresti, 2009; Fakhoury & Priebe, 2002).  Arguably then the QOL experienced 
by drug users is likely to represent more than the effects or consequences of frequency and/or 
quantity of the drugs used (Tiffany et al., 2012). 
 
3.4.3 QOL IS DYNAMIC 
QOL assessments also tend to be dynamic, that is they may change over time and in response 
to different life events.  Across the life-course individuals tend to alter their expectations of 
what constitutes QOL (Schwartz & Strack, 1999; Wood-Dauphinee, 1999).  For example 
subjective well-being appears to take on a ‘u’ shape across the life course (Blanchflower & 
Oswald, 2008). These changes in QOL seem to occur because the value individuals place 
upon what is important to them changes with time (McClimans et al., 2013; Muldoon et al., 
1998) and context (Diener et al., 1997; Sansoni, 1995; Schwartz & Strack, 1999).  These 
adjustments seem likely to be influenced by a combination of circumstance, coping methods 
and expectations (Bonomi et al., 2000; McClimans et al., 2013; Wood-Dauphinee, 1999).  
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3.5 QOL AND DRUG USE 
This next section reviews the literature on the QOL of drug users. First the QOL of drug users 
who are dependent and/or in treatment are considered.  Second the QOL of adult drug users 
recruited in community settings are examined.  Third the QOL of adolescent and young adult 
drug users is reviewed.  However there are large gaps in the evidence regarding to the QOL 
of drug users, especially regarding adolescent/young adult drug users in the community. 
 
3.5.1 QOL OF DEPENDENT TREATMENT POPULATIONS  
A search of the literature was undertaken to identify reviews and studies that had examined 
the QOL of dependent drug users receiving treatment.  Eight literature reviews were found.  
Two of these reviewed QOL measurements (Donovan et al., 2005; Luquiens et al., 2012) and 
one the effect of treatment programs on client assessments of QOL (Feelemyer et al., 2013).  
The remaining five reviews focused on the QOL of users of a variety of different drug types.  
Of these five reviews three reviews (Donovan et al., 2005; Foster et al., 1999; Rudolf & 
Watts, 2005) examined QOL and alcohol use. One review examined the QOL of alcohol and 
heroin users (Connor et al., 2006) and the remaining review examined the QOL of opioid 
users (de Maeyer et al., 2010).  
 
An important finding of these reviews, and of more recent studies, was the multi-dimensional 
nature of the QOL assessments. Miller et al. (2014), in a recent cross-sectional study of 
participants in outpatient treatment (N=201), found that subjective well-being was predicted 
by mental health and employment but not by severity of dependence (Miller et al., 2014).  
Similarly de Maeyer et al. (2013) in a Belgium study found that different profiles of QOL 
exist for opioid dependent individuals (De Maeyer et al., 2013).  These profiles were based 
upon perceptions of safety, living conditions, and social exclusion.  Best et al. (2013) 
(N=10,470) also found that that treatment clients who reported engagement in meaningful 
activities had significantly higher QOL than those that did not (Best et al., 2013).  
 
Whilst the ultimate aim of treatment is to improve QOL through abstinence (Laudet, 2011), 
enhanced QOL seems to go beyond abstinence (Tracy et al., 2012; de Maeyer et al., 2010; 
Garner et al., 2014).  Changes in QOL assessments seem to encompass perceived changes to 
subjective domains (Tiffany et al., 2012; Laudet, 2011).  These domains include social 
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relationships (Tracy et al., 2012; Marini et al., 2013; De Maeyer et al., 2013), social activities 
(Best et al., 2013), employment (Marini et al., 2013) and living conditions (Tracy et al., 2012; 
Marini et al., 2013; De Maeyer et al., 2013).  
 
There are several limitations to these studies.  Participants who experience drug use 
dependence generally have additional problems. As Connor et al. (2006) concluded people 
typically seek assistance when in crisis and this may be reflected in lower QOL assessments.  
The findings of these studies are generalisable only to drug users who are both dependent and 
in treatment.  As we have seen from the previous section, few drug users are dependent. The 
studies included in these reviews did not have comparator drug using populations therefore it 
cannot be concluded with confidence poor QOL assessments are a consequence of drug use 
per se, or due to the extreme nature of their use, that is dependence.  The studies included 
here only examined adult participants.  Youth and young adults were absent from the 
literature reviewed.  As was seen in an earlier Chapter of the thesis, section young adults are 
the most frequent users of psychoactive drugs.   
 
 
3.5.2 QOL OF DRUG USERS IN COMMUNITY SETTINGS 
Not surprisingly there is considerably less literature available on the QOL of community-
based drug users. There is some evidence to suggest that QOL is poorer among people who 
are drug dependent and those not in treatment than in cohorts without drug use dependence 
(Donovan et al., 2005; Rudolf & Watts, 2005; Smith & Larson, 2003; Volk et al., 1997). 
 
ALCOHOL 
The available evidence on the QOL of adult alcohol drinkers suggests a dose-response 
relationship.  ‘Binge’ drinking by adults has been associated with reports of significantly 
worse health-related QOL than abstinence and low risk drinking (Okoro et al., 2004; Paul et 
al., 2011).  Older drinkers (50+ years) who had reduced their alcohol intake, also report a 
reduced QOL compared with moderate drinkers in the same age range (Kaplan et al., 2012).  
These studies, in conjunction with the studies of QOL of alcohol users in treatment (that is 
dependent users), suggest that the amount of alcohol consumed may influence judgements 
about QOL (Foster et al, 1999; Donovan et al. 2005; Connor et al., 2006).  
53 
TOBACCO  
Four studies have examined the QOL of tobacco smokers, without chronic illnesses, after 
smoking cessation (McCarthy et al., 2002; Piper et al., 2012; Wang et al., 2014; Wilson et al., 
1999).  There is consistent evidence to suggest that cessation of cigarette smoking enhances 
QOL (McCarthy et al., 2002; Wang et al., 2014; Wilson et al., 1999).  This association has 
also been found with cessation attempts (Piper et al., 2012).  All studies found enhanced QOL 
to be associated with smoking cessation. In the first study the QOL of smokers and non-
smokers (N=254) was assessed over time (McCarthy et al., 2002).  Participants who had 
ceased smoking reported better QOL than participants who continued to smoke tobacco.  In 
another study (Piper et al., 2012), researchers examined changes in life satisfaction three 
years after a cessation attempt (N=1,504).  The study found that any quit attempt enhanced 
QOL, with the greatest enhancements being found in participants who had ceased smoking.   
 
CANNABIS 
When compared with the general population cannabis users generally have lower QOL scores 
than the general population (Ventegodt & Merrick, 2003).  This association has also been 
found in a study of recreational cannabis users compared with dependent cannabis users 
(Barnwell et al., 2006).  Gender differences have also been reported.  Lev-Ran et al. (2012) in 
a national survey of 43,093 adults over 18 years of age found gender differences in health-
related QOL among cannabis users, with cannabis use and dependence being associated with 
lower self-reported mental health QOL, amongst female users (Lev-Ran et al., 2012).  In 
contrast, studies of medical users of cannabis have found that cannabis users report enhanced 
QOL compared with their QOL prior to use (Barnwell et al., 2006; Harris et al., 2000; Swift 
et al., 2005).  
 
MEDICATIONS 
use of medications to feel better is common practice (Fischer & Rehm, 2007). Medications 
can help individuals manage symptoms of illness (Cooper, 2013) and can enhance QOL.  
However, the extra-medical use of medications has being labelled an emerging public health 
crisis (Spoth et al., 2008).  There is a dearth of studies on the QOL of people who use 
medications not as prescribed, with seemingly the only study on the subject over thirty years 
old (Caplan et al., 1984).  In this study, Caplan et al. (1984) found that the use of valium was 
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weakly associated with QOL but with longitudinal analyses showing no effect of valium use 
on QOL.  
 
OPIOIDS  
A search of the literature was undertaken to identify studies that had examined the QOL of 
people who inject opioids. Eight studies of the QOL of people who inject drugs (PWID) and 
who were not in treatment; who did not have blood-borne infections or mental health 
disorders were found (Table 1).  Participants were recruited from needle and syringe 
programs (NSPs) or through respondent driven sampling (snowballing or convenience 
sampling).  The main opioid of concern was heroin.  A number of different measurers were 
used to measure QOL. These measures included the Injecting Drug Users QOL Scale 
(IDUQOL Scale), World Health Organization QOL – (WHOQOL-BREF) and the Personal 
Well-being Index (PWI). Studies had been conducted most commonly in Australia (n=3) 
(Conroy et al., 2008; Dietze et al., 2010), Canada (n=2) (Brogly et al., 2003; Hubley et al., 
2005), India (N=2) (Sarin et al., 2013; Armstrong et al., 2013), Ireland (n=1) (Rooney et al., 
2002) and Scotland (n=1) (McDonald et al., 2011) 
 
These studies highlight the subjective components of QOL.  For PWID important factors 
affecting judgements of QOL included health status, experiencing stigma and social 
exclusion.  In an Australian wide-sample the life areas most commonly selected by 
participants as important in determining their QOL were family, health, money, housing and 
partnerships (Dietze et al., 2010).  McDonald et al. (2013) found that belief in being HCV 
positive was associated with reduced QOL, lower than even PWID who actually were HCV 
positive (McDonald et al., 2013).  Similarly Armstrong et al. (2013) found diminished QOL 
was positively correlated with socio-economic status, including issues relating to  social 
exclusion (Armstrong et al., 2013). 
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Table 1: Studies of the quality of life of people who inject drugs (PWID) 
Author, Year, 
Country 
Study 
Design 
Recruitment 
Locations 
Sample 
Size 
Main  Drug 
Injected 
QOL 
Measure 
Findings 
Armstrong et 
al. (2013), 
India 
Cross-
sectional 
Convenience 
NSP 
N=423 
Males: 100% 
Mean age: 36.7 Years 
25% 45years≤ 
Heroin 
Buprenorphine 
WHOQOL, 
adapted 
Diminished QOL was positively correlated with 
socio-economic status, including social exclusion. 
Brogly et al. 
(2003), Canada 
Prospective 
follow-up 
Convenience N=61 Opioids IDUQOL Scale Validation study. 
Conroy et al. 
(2008), 
Australia 
Cross-
sectional 
Convenience 
Health 
services 
N=260 
Males: 57% 
Mean age: 33 years 
Heroin 
Morphine 
Amphetamines 
IDUQOL Locality per se was not associated with QOL 
assessments. 
No association was found between QOL & injecting 
practices. QOL assessments were mediated by non-
health factors, e.g. relationships & money.  
Dietze et al. 
(2010),  
Australia 
Cross-
sectional 
Convenience 
NSPs 
N=8812 
Male: 64% 
Modal age: 30-39 
Heroin Personal 
Wellbeing Index 
PWID scores were significantly lower than the 
general population on the PWI. Lower PWI scores 
were associated with drug use, socio-demographic & 
other health & social characteristics.   
Hubley et al. 
(2005), Canada 
Validation Convenience 
NSPs 
N=241 
Age range: 19-61 years 
Not Stated IDUQOL Need for clarity in assessing PWID QOL e.g. unclear 
whether dissatisfaction was due to lack of drug 
availability or to the impact of drugs in their lives. 
Rooney et al. 
(2002), Ireland 
Case-Control Convenience 
NSPs & 
treatment 
services 
N=72 
 
Opioids SF36 & 
HADS1 
Methadone maintenance participants experienced 
lower QOL than harm reduction programme clients.  
McDonald et 
al., 2013 
Cross-
sectional 
Convenience 
NSPs 
N=2898 
Median age: 34 years 
Male: 72.2% 
Heroin EQ-5D HCV+ Stigma  was associated with diminished QOL 
Sarin et al. 
(2013), India 
Cross-
sectional 
Convenience 
 
N=343 
18+ years 
Buprenorphine WHOQOL-
BREF, Hindi 
version 
Diminished QOL compared to international 
WHOQOL- BREF validation study. Diminished QOL 
associated with a broad range of factors including 
physical and verbal abuse, contact with law 
enforcement & lack of health information & services. 
Social Functioning - 36 item and the Hospital Anxiety and Depression Scale 
 2 predetermined quotas in each Australian jurisdiction 
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3.5.3 QOL OF ADOLESCENT & YOUNG ADULT DRUG USERS 
The previous sections have focused on the QOL experienced by adult drug users.  This 
section turns to the QOL experienced by adolescent and young adult drug users.  As reported 
previously, young adults are the most likely age group to frequently use drugs and are also at 
greatest risk of short term harm.  The purpose of this section is to identify, synthesise and 
review the published research on the QOL experienced by young drug users.  It is designed to 
answer the following questions: 
1. What is the QOL of youth drug users?  
2. Is QOL associated with drug types and frequency of use? 
3. What is the temporal association between QOL and drug use? 
4. What are the current limitations and gaps in the evidence? 
 
There is no consensus as to what constitutes adolescence and young adulthood.  The wide age 
ranges included can be seen in Table 2.  The terms ‘childhood’, ‘young adult’ and ‘youth’ are 
often used interchangeably. However, for the purposes of this thesis adolescence is defined as 
13-17 years and young adulthood as 18-22 years inclusive. This is consistent with previous 
work undertaken by Dingle et al. (2010). 
 
Table 2: Adolescent and young adult age ranges reported in a selection of studies 
Study Terms & Age Ranges 
Hamilton & Redmond (2010) Child: 0-12; Young people: 13-25 
Pichler (2006) Young adults 15-29 
Jorngarden et al. (2006) 13-23 
Beccaria et al. (2012) 25-34 
Becker et al. (2011) 13-21 
Sumnall et al. (2001) Young people: 16-35 
 
 
METHODS 
A systematic review of the literature was undertaken to examine the literature on the QOL of 
adolescent and young adult drug users.  This review entails specific inclusion/exclusion 
criteria which are set out in Table 3.   
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Table 3: Systematic review inclusion/exclusion criteria 
Criteria 
Inclusion Exclusion 
• Measured QOL or QOL indicators (i.e. 
subjective well-being, satisfaction) 
• Study participants: adolescent &/or young 
adult (youth) drug users  
• Published in peer review journals in the 
English language between 1 January 1990 
& 1 February 2014 
• Concerned with hedonism or pleasure, without 
reference to QOL 
• Participants were in treatment 
• QOL was not an outcome measure 
• Study was experimental in design. 
 
Searches were conducted using several electronic databases (Drug, PsycINFO/Medline, and 
PubMed) and by reviewing the reference lists of obtained articles.  MeSH (and other database 
thesaurus) headings, boolean terms and keywords were systematically combined into search 
strings.  The main search terms used were: 
• QOL / satisfaction / happiness / subjective well-being / well-being 
• drug (ab) use / drug (ab) / addiction 
• adolescent/s / young adults / young people. 
 
Studies underwent a two stage screening process. First the titles and abstracts were reviewed 
for the purposes of removing irrelevant studies.  Second the title, abstract, and if clarification 
was required the article was perused to assess whether the study was likely to meet the 
inclusion criteria. For those studies meeting the inclusion criteria the full text was reviewed. 
Data extracted from the studies included the following: author details, country of origin, 
methodology (study design, participant characteristics, QOL measures) and findings. 
 
RESULTS 
In all 2,301 articles were found. After the removal of duplicates 278 studies remained.  After 
the second screen 88 studies were left.  After these 88 articles were examined, 28 articles 
remained and were included in this review (Figure 1). 
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Figure 1: Flow diagram of study selection for systematic review of published research 
on quality of life of adolescent and young adult drug users 
 
Only two included studies (Topolski et al., 2001; Vaez & LaFlamme, 2003) investigated the 
QOL of young adult drug users.  These were both cross-sectional studies of students, one of 
school students (Topolski et al., 2001) and the other of university students (Vaez & 
LaFlamme, 2003).  Both studies examined QOL in association with alcohol and tobacco use. 
One (Topolski et al., 2001) used the Youth QOL instrument whilst the other (Vaez & 
LaFlamme, 2003) assessed QOL using a single 10 point scale item (Table 3).  
 
The other studies included in the review (n=26) most commonly applied QOL indicators, 
subjective well-being (n=7) or satisfaction (n=10).  Studies which examined satisfaction 
focused on specific domains: life (n=12), family (n=3), work (n=2) or school (n=2).  The 
majority of studies were cross-sectional (n=19).  Participants were commonly school or 
university/college students.  Most studies investigated two or three drugs, particularly 
combinations of alcohol, tobacco and/or cannabis.  Nine studies did not specify the drug 
being investigated (Table 4). 
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Table 4: Studies included in the systematic review of the QOL experienced by adolescent and young adult drug users 
Author (year) 
Country 
Study Design Participants 
Instrument 
Drug 
X-Sect Cohort N School Uni/Coll Other Alcohol Tobacco Cannabis Other 
Quality of Life 
Topolski et al. (2001), USA   2,801    Youth QOL    NS 
Vaez & Laflamme. (2003), Sweden   3,229    Single item (1-10 scale)     
Subjective Well-being 
Griffin (2002), USA  T1: 7
th grade 
T2: 9th grade 1,184    
3 items     
Katja et al. (2002), Finland   245    Berne SWB Finnish SWB    NS 
Lanier (2001), USA1    772    GWB    NS 
Mason & Spoth (2011), USA  T1: 11 yrs T2: 21 yrs 208    
6 items     
Molnar et al. (2009), USA  T1: 1
st year 
T2: 3rd year 467    
Single item 
(1-10 scale)     
Phillips-Howard et al. (2010),  
England   3,641    
CYSHS     
Schulenberg et al. (2000), USA  T1: 18 years T3: 19/20 yrs 3,912    
3 items    NS 
Life Satisfaction 
Beccaria et al. (2012) France, Italy, 
Netherlands   4,841   25-34 yrs 
Single item 
(1-10 scale)     
Bogart et al. (2007), USA 
 
T1: 13 years 
T2: 18 years 
T3: 29 years 
23,76    
Single item 
    
Clifford & Edmundson (1991), USA   683    Summary score    Tranq 
Grant et al. (2009), 30 countries   17,246    Single item     
Farhart et al. (2011), USA   1,465    Single item (1-10 scale)     
Fergusson & Boden (2008), NZ  T1: 14 years T2: 25 years 1,265   
Birth 
Cohort 
12 item 
customised     
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Author (year) 
Country 
Study Design Participants 
Instrument 
Drug 
X-Sect Cohort N School Uni/Coll Other Alcohol Tobacco Cannabis Other 
Kuntsche & Gmel (2004), Switz.   3,861    Single item (1-10 scale)     
Murphy et al. (2005), USA   353    SWLS     
Newcomb et al. (1986), USA 
 T1: 15-18 years T2: 19-22 years 722    
3 items: 
(school, work, 
parents) 
    
Sumnall et al. (2010), 9 European 
Cities   1,341   
Night life 
goers 
Single item    NS 
Swain et al. (2012),  NZ 
 
T1: 18 yrs 
T2: 21 yrs 
T3: 25 yrs 
T4: 30 yrs 
987   Birth cohort 
12 item 
custom 
measure     
Zullig et al. (2001), USA   5,032    TDS     
Family Satisfaction 
Surkan, et al. (2012), France   1,101   National sample 
Single item     
Henry et al. (2008), USA   214    Single item    NS 
Hong & Faedda (1996), Australia   203   Korean adoles. 
Family, life 
SAT Index     
School Satisfaction 
Hoff et al. (2010), Denmark   1,317    Five items     
Takakura et al. (2010), Japan   3,248    Summary score     
Work Satisfaction 
Power & Estaugh (1990), Britain  T3: 16 years T4: 23 years 16,457   
Birth 
cohort 
Three items     
Stein et al. (1993), USA  T1: 1971-73 T2: 1981 785    
Single item     
Abbreviations: X-sect: Cross-sectional; Uni/Coll: university or college; adoles: adolescents; NS: Not stated; SAT: Satisfaction; CYSHS: Canadian Youth Sexual Health Survey; GWB: General 
Well-being Survey; TDS: Terrible - Delighted Scale1 random sample 
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FINDINGS 
Studies most commonly found that drug use was associated with diminished QOL (Topolski 
et al., 2001; Vaez & LaFlamme, 2003), reduced subjective well-being (Phillips-Howard et al., 
2010; Batki et al., 2009; Katja et al., 2002; Lanier, 2001), or dissatisfaction (Farhat et al., 
2011; Murphy et al., 2005; Kuntsche & Gmel, 2004; Zullig et al., 2001; Sumnall et al., 2010).  
In contrast only two studies (Molnar et al., 2009; Clifford & Edmundson, 1991) found that 
drug use may enhance QOL in adolescents or young adults.  Molnar et al. (2001) in a cohort 
study of school students from age 11 to 21 years found that drug use was associated with 
increased subjective well-being, although increasing numbers of adverse consequences 
mediated the effect between subjective well-being and drug use.  
 
QOL, Drug Type and Frequency of Use 
Study findings were inconclusive regarding the association between QOL and drug type or 
frequency of use.  Several studies found a possible dose-response relationship between QOL 
and drug use, with QOL or its indicators, negatively correlated with increased frequency of 
drug use (Clifford & Edmundson, 1991; Farhat et al., 2011; Phillips-Howard et al., 2010; 
Sumnall et al., 2010; Topolski et al., 2001). 
 
QOL, Dynamic Assessments 
The third question of interest was whether QOL alters (and how) as a consequence of drug 
use. Therefore it is necessary to establish the QOL of adolescents and young adults prior to 
commencement of use.  This review found that no studies reported the QOL of participants 
prior to first use.  Two studies (Zullig et al., 2001; Sumnall et al., 2010) did find a 
relationship between age of commencement of drug use (retrospectively obtained) and QOL 
judgements.  Sumnall et al. (2001) in a study of regular night life users aged 16-35 years of 
age recruited in several European cities found that participants who initiated alcohol, 
cannabis, cocaine, or ecstasy prior to 16 years of age were significantly more likely to report 
being dissatisfied with life at the time of the study.  Similarly Zullig et al. (2001) found that 
first alcohol use before 13 years of age was significantly associated with reduced life 
satisfaction at the time of interview.  
 
Some studies examined participant response shifts in QOL over time by collecting QOL and 
drug use data at two or more time points.  These studies (Griffin et al., 2002; Mason & Spoth, 
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2011; Fergusson & Boden, 2008) reported mixed findings.  Griffin et al. (2002) found that 
positive subjective well-being at time one was associated with reduced drug use at time two.  
Mason and Spoth (2011) found that adolescent alcohol use was not a predictor of later 
subjective well-being whereas Fergusson and Boden (2008) found that increased frequency 
of cannabis use was associated with later life dissatisfaction. 
 
The temporal assocation may be moderated by a number of confounders (Swain et al., 2012; 
Schulenberg et al., 1996).  After adjusting for fixed confounding sources and the variable 
‘time’ alcohol and cannabis use was not associated with reduced life satisfaction (Swain et 
al., 2012).  Similarly Schulenberg et al. (2000) found that positive subjective well-being was 
associated with drug use if participants were in college, but negatively associated if 
participants were married and had children.  Bogart et al. (2007) in a cohort study also found 
that tobacco and ‘hard’ drug use at age 18 were associated with lower life satisfaction at age 
29, but that low income, poor health and tobacco use in adulthood independently mediated 
the relationship between adolescent tobacco use and adult life satisfaction (Bogart et al., 
2007).   
 
LIMITATIONS  
Most studies were cross-sectional in nature and involved school or university students. Only 
two studies investigated QOL.  Rather most examined components of QOL, such as 
subjective well-being or aspects of satisfaction, such as life, work, school or family.  The 
generalisability of these studies is therefore limited to the QOL of drug users engaged in 
educational institutions at a specific point in time.  Several studies reported outcomes of 
combined drug use, thereby making it difficult to disentangle whether specific drugs were 
associated with enhanced or diminished QOL, or whether it is the combination of poly-drug 
use which is associated with QOL judgements.  
 
Similarly cohort studies also had methodological limitations.  The cohort studies mainly 
recruited adolescent or young adult students.  These longitudinal studies also did not measure 
participants QOL prior to commencement of their drug use; or established their cohort in 
early adolescence or young adulthood. Thus they have not been able to determine whether 
QOL was actually enhanced or diminished by drug use.   
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3.6 CHAPTER SUMMARY 
Current perspectives of drug use focus on either its adverse or pleasurable aspects. The later 
approach suggests that, despite the potential for adverse consequences, drug users negotiate 
the risks of use to maximise the benefits, whether this be for pleasure or for an improved state 
of subjective well-being. However whether drug users achieve these positive outcomes is 
uncertain. Assessing the QOL of drug users provides an overarching perspective of the 
consequences of drug use, that is, its potential for both harm and pleasure.  
 
QOL is an innately personal judgement. QOL involves an overarching assessment of multiple 
life domains.  It is also dynamic and liable to change across the life course.  These QOL 
characteristics are especially apparent in adolescence and in young adulthood, when these age 
groups undergo considerable biological, social and emotional development.  The approach to 
QOL used here addresses the positive as well as potentially negative aspects of drug use.   
 
The current evidence illustrates that it is possible to assess the QOL of drug users.  Three 
associations between QOL and drug use are possible.  Drug use may be associated with 
diminished QOL, it may be associated with enhanced QOL, or the association may be due to 
other factors.  However the study of the QOL of psychoactive drug users recruited from 
community settings is in its infancy and there are large gaps in the evidence.  These gaps 
include whether QOL varies by drug type and frequency of use, the temporal sequence 
between QOL and drug use, and how drug use may influence QOL.  
 
There is a need to better understand the subjective components of drug use.  Brulde has 
argued that while successful mood enhancement may be achieveable through drug use, the 
effect on the happiness, satisfaction, well-being or QOL of the drug user is uncertain (Brulde, 
2007). The evidence base can be enhanced by addressing the following questions: 
• What is the QOL of drug users? 
• Does QOL vary by drug type and frequency of use? 
• What is the temporal sequence? 
• Does drug use enhance or diminish drug users QOL? 
 
To be able to address the potential harms, and benefits perceived to be obtained from drug 
use, it is first necessary to describe the QOL of life of users, whether drug use is an advantage 
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or disadvantage to users QOL; age of first use, the temporal sequence between QOL and drug 
use, and whether drug type or drug taking frequency influences QOL assessments.  The next 
chapter describes the methods used in this thesis to answer these research questions.  
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CHAPTER FOUR: METHODOLOGY 
4.1  INTRODUCTION 
This thesis examines the quality of life (QOL) of drug users, using secondary data.  This 
examination occurred in three phases.  The first phase involved determining what proportion 
of Australian drug users have accessed specialist treatment services or have been admitted to 
hospital for their substance use.  The second phase involved investigating the QOL 
experienced by a prospective longitudinal cohort of young adults.  The third phase describes 
the QOL experienced by people who inject drugs (PWID).  This chapter therefore presents 
information regarding the methods, including data examined, participants, measurement of 
variables and statistical analyses used in these investigations.  
 
4.2 TREATMENT RATES 
The first phase of this thesis entailed describing the proportion of Australian drug users who 
have accessed health services for specialised treatment, by gender, age and drug type.  
 
4.2.1 PARTICIPANTS 
Study participants were the Australian population aged 14 years or older who had used 
alcohol, cannabis, amphetamines or ecstasy in the previous 12 months.  
 
4.2.2 DATA 
Three datasets were used to calculate treatment rates.  These were the Alcohol and Other 
Drug Treatment Services National Minimum Dataset (AOD-NMDS), the National Hospital 
Morbidity Minimum Dataset (NHMD), and the National Drug Strategy Household Survey 
(NDSHS). AOD-NMDS data are annually collected from Australian Commonwealth 
government funded agencies which specialise in alcohol and other drug community based 
services (Australian Institute of Health and Welfare, 2008).  NHMD data are also collected 
annually on all publicly admitted hospital patients.  Both datasets consist of ‘national 
minimum data items’, which are standard items of information that all Australian 
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State/Territory health agencies have agreed to collect and supply to the Australian Institute of 
Health and Welfare (AIHW) (Australian Institute of Health and Welfare, 2014a) for synthesis 
at a national level.  The third dataset, the NDSHS, consists of quantitative alcohol, tobacco 
and other drug use data.  NDSHS data are collected triennially using a multi-stage, stratified, 
random sample, based on households aged 12 years and over (Australian Institute of Health 
and Welfare, 2011).  Ethical clearances were not required for using these publicly available 
datasets.   
 
4.2.3 DATA QUALITY 
The datasets used in this thesis are part of Australia’s well-established drug information 
systems (Fitzgerald & Sewards, 2002, Ministerial Council on Drug Strategy, 2004, Shand et 
al., 2003).  In some instances, as with AIHW data, there are legal and/or fiscal requirements 
underpinning their collection.  Aggregating data from a range of drug information systems 
has acknowledged methodological problems (Mounteney et al., 2010).  For example, 
variables may be measured differently between datasets.  The NDSHS reports on recent drug 
use of those aged 14 years and over whereas the AOD-NMDS and the NHMD record from 15 
years of age.  There may also be discrepancies in drug use terminology between data 
collections, for example ‘amphetamines’ and ‘methamphetamines’.  However there are 
standardised definitions and methods for data collection and for data cleaning.   
 
4.2.4 VARIABLES AND MEASUREMENTS  
The exposures of interest were alcohol, cannabis, amphetamines and ecstasy use in the 
previous 12 months, adjusted for gender and age.  The NDSHS report provides counts and 
percentages of use of these drugs stratified by gender and age group (<25, 25-34, 35-44, 
45+).  Australian census data were used to establish adjusted gender and age populations.  
 
Two outcomes were examined.  The first outcome was public hospital admissions for 
alcohol, cannabis, amphetamines and ecstasy use.  The unit of measurement here was counts 
of ‘hospital separations’ using International Classification 9th and 10th edition codes for 
substance use (ICD-9/10 F10-F19).  A hospital separation is an episode of care for an 
admitted patient, which can be a total hospital stay (from admission to discharge, transfer or 
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death), or a portion of a hospital stay beginning or ending in a change of type of care (for 
example, from acute to rehabilitation) (Australian Institute of Health and Welfare, 2014b).  
The second outcome of interest was engagement in alcohol or other drug treatment.  The 
measurement here was counts of ‘closed treatment episodes’ for each principal drug of 
concern (i.e. alcohol, cannabis, amphetamines and ecstasy).  A closed treatment episode is a 
period of contact with defined dates of commencement and cessation between a client and a 
community based alcohol and other drug treatment services, excluding pharmacotherapy 
treatment (Australian Institute of Health and Welfare, 2008).  For completed treatment 
episodes these are the counts of each principal drug of concern (i.e. alcohol, cannabis, 
amphetamines and ecstasy).  The principal drug of concern is self-reported by the client and 
represents the drug which led them to seek treatment.   
 
4.2.4 STATISTICAL ANALYSES 
The analysis for this study consisted of rates of hospital and treatment episodes per 1,000 
recent users. The numerators were completed hospital and treatment episodes and by drug 
type.  The denominator was the number of persons who had used the drugs under 
consideration and were therefore ‘at risk’.  The proportion (percentage) of those in the last 12 
months who had recently used a drug of interest was then calculated using Excel (Microsoft, 
2003).  This percentage was multiplied by the population estimate of users in the last 12 
months to obtain the population estimate for number of recent users.  Rates were 
subsequently adjusted for gender and age group. 
 
4.3 PROSPECTIVE LONGITUDINAL COHORT 
The second phase of this thesis investigated the QOL of adolescent and young adult drug 
users.  
 
4.3.1 PARTICIPANTS 
The data for this phase of the study were taken from the Mater-University of Queensland 
Study of Pregnancy (MUSP).  Between 1981 and 1983, interviewers approached 8,556 
women at their first antenatal visit at the Mater Misericordiae Hospital in Brisbane, Australia 
to participate in a prospective study, of which 8,458 (98.9%) agreed.  The cohort consists of 
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7,223 women who delivered a live singleton baby who was not adopted out.  This represents 
87% of all women who attended the antenatal clinic during the study period (Najman et al., 
2005).  Mothers and their children were followed-up when the children were 3–5 days old, 6 
months old, and 5, 14 and 21 years later, with children self-completing questionnaires at the 
14 and 21 year follow-ups.   
 
This thesis uses data only from the five, 14 and 21 year follow-ups. At the 21 year follow-up 
the average age of participating children was 20.4 years (SD=0.8), 51.0% were female, 
24.6% had tertiary education, 54.6% had completed high school and 20.8% had some 
primary or secondary school education (Najman et al., 2008).  Figure 1 provides an 
illustration of maternal/children recruitment and follow-up to the 21 years stage.  For all data 
collection periods ethical clearances were obtained from the Mater Hospital and The 
University of Queensland Human Research Ethics Committees. 
 
 
Figure 1: Overview of recruitment, follow-up monitoring and data collection within 
MUSP 
 
4.3.2 VARIABLES AND MEASUREMENTS  
QUALITY OF LIFE 
At both the 14 and 21 year follow-ups the MUSP children cohort were asked to assess their 
happiness and satisfaction.  To measure ‘happiness’ respondents were asked “how would you 
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say you feel these days? Would you say you are: very happy, happy, not too happy or 
unhappy”.  This data was recoded into: very happy, happy and unhappy. Unhappy consisted 
of not too happy and unhappy.  To measure ‘satisfaction’ respondents were asked “how 
satisfied are you with your life as a whole these days?  What would you say you are: very 
satisfied, satisfied, dissatisfied or very dissatisfied”.  This data were recoded into: very 
satisfied, satisfied and dissatisfied.  The dissatisfaction option consisted of dissatisfied and 
very dissatisfied.  Table 1 shows the prevalence of happiness and satisfaction amongst the 
MUSP children at the 14 and 21 year follow-ups. 
 
Table 1: Happiness and satisfaction amongst MUSP children at the 14 and 21 year 
follow-ups 
Variable Follow-up 
14 Years 21 Years 
% N % N 
Happiness Very happy 
Happy 
Unhappy 
25.5 
60.6 
13.8 
1,005 
2,389 
545 
21.5 
60.2 
8.3 
1,183 
2,259 
311 
Satisfaction Very satisfied 
Satisfied 
Dissatisfied 
28.1 
56.8 
6.1 
1,104 
2,588 
239 
26.6 
61.4 
11.9 
9,99 
2,303 
448 
 
INTERNALISING, EXTERNALISING AND ATTENTION PROBLEM 
BEHAVIOURS 
In the tobacco paper, to measure early life QOL, internalising, externalising and attention 
problem behaviours were used as indicators of QOL.  These were measured using the Child 
Behaviour Checklist (CBCL) at 5 year follow-up (Achenbach, 1991a) and the Youth Self 
Report (YSR) at 14 and 21 year follow-ups (Achenbach, 1991b).  Both instruments consist of 
standardised checklists for child and adolescent behaviour problems and competencies 
(Achenbach, 1991a, Achenbach, 1991b, Petty et al., 2008).  The internalising measures used 
included internalising at 5 years and anxious/depressed symptoms at 14 and 21 years.  The 
externalising measure included aggression at 5 years and externalising at 14 and 21 years.  
The attention problems measure included social/attention/thought problems (of which five of 
the 10 are measures of attention) at 5 years and attention problems at 14 and 21 years 
(Achenbach, 1991a, Achenbach, 1991b).  
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A modified (short form) of the CBCL was completed by the mothers at 5 years.  It included 
33 of the 113 items from the original scale.  Items selected assessed the most commonly 
occurring behaviours in 5-year-olds. Mothers rated items as occurring ‘often’, ‘sometimes’ or 
‘never’, rather than on a three-point scale ranging from 0 ‘not true’ to 2 ‘very true’ to 3 ‘often 
true’, as described in the original scale.  Factor analyses and reliability estimates of subscales 
have produced results consistent with Achenbach’s data (Najman et al., 2001).  In addition, a 
sample of 76 parents whose 6-year-old children were at school also completed the long form 
of the CBCL.  There were also very strong correlations (externalizing r = 0.94, internalizing r 
= 0.89) between the short and full forms of the CBCL (Najman et al., 2001). 
 
At the 14-year follow-up the YSR was self-completed by the children.  The YSR has been 
shown to be reliable and provides arguably valid indicators of problem behaviour (Wiznitzer 
et al., 1992).  In this study the complete A–D scale (Cronbach’s a = 0.84) and T–P scale 
(Cronbach’s a = 0.94) were used and respondents were given the modified options of: often, 
sometimes, rarely and never at the 14-year follow-up. 
 
The early use of indicators of QOL was primarily directed to two issues. For the first of these 
there was an interest in what, as it were, constitutes a life well lived – a life characterised by 
pleasure and satisfaction. In this use of the term the intent was to identify those aspects of life 
that contribute positively to well-being. These early studies provided surprising results 
namely that marriage quality and family life were the most important contributors to a sense 
of well-being (Campbell, 1976). However income and measures of economic standing were 
relatively weak predictors of QOL. While the poor may not be asset rich, they feel as 
positively about their lives as their wealthier counterparts. This early research also 
emphasised the extent to which objective circumstances were often reinterpreted in 
assessments of QOL. For example poor older black Americans had a better subjective sense 
of well-being than their younger counterparts. From the perspective of the current study this 
suggests that the QOL of persons who use a variety of substances may only be weakly related 
to their patterns of substance use. 
 
The second use of indicators of QOL was to assess treatment outcomes. With regard to 
indicators of QOL to assess treatment outcomes, the choice of indicators was partly 
determined by the underlying condition which was being treated. Someone being treated for a 
stroke might receive questions relating to their mobility and activities of daily living. By 
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contrast someone affected by say caring for a relative with a terminal illness, might be 
assessed by questions relating to their emotional or mental health. 
 
As a recent review notes (Moons, Budts and Geest, 2006) a wide variety of indicators have 
been used in what are a very large number of studies now available. These indicators may 
involve subjective criteria, objective criteria, or a mixture of the two. Four of these measures 
of QOL have been applied to young persons. Despite a prolific literature there is no 
consensus about what constitutes an “ideal” measure of QOL. To the extent that Achenbach 
CBCL syndromes have been used as markers of QOL, they have the advantage that such 
measures are consistent with QOL indicators used in other studies (see Moon, Budts and 
Geest, 2006). 
 
SUBSTANCE USE 
Data on the use of alcohol, tobacco, cannabis by MUSP children were obtained at both the 14 
and 21 year follow-ups (Table 2). Data on medications use (Ritalin, Dexedrine, pain killers, 
ventolin, steroids, sedatives and tranquilisers) were only obtained at the 21 year follow-up.  
The prevalence of alcohol, tobacco and cannabis amongst the MUSP offspring cohort is 
provided below. 
 
Table 2: Use of selected drugs amongst MUSP children at the 14 and 21 year follow-ups 
Variable Mean age  
of first use 
Years 
Follow-up 
14 Years 21 Years 
% N % N 
Alcohol use 
in last year 
Few times a week or more 
Few times a month 
Few times a year 
Rarely/Never 
15.88 
1.2 
4.0 
7.1 
87.7 
60 
205 
367 
4,525 
32.8 
38.5 
10.8 
12.6 
1,235 
1,450 
406 
675 
Tobacco use 
in last year 
Current, regular 
Current, occasional 
Former/one or so only 
Never 
15.45 
4.3 
2.9 
5.0 
87.8 
224 
147 
259 
4,527 
25.6 
12.1 
12.3 
50.0 
967 
457 
465 
1,886 
Cannabis use 
in last month 
Every day 
Every few days 
Once or so 
Used, but not in last month 
Never  
15.81 NR NR 
5.5 
6.9 
11.2 
26.2 
50.2 
206 
259 
422 
984 
1,883 
Medications Medically Indicated Only 
Without medical intent Only 
Both 
None 
NR NR NR 
62.8 
13.0 
4.3 
19.9 
2356 
487 
161 
716 
NR: not reported 
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Alcohol 
Children were asked about the frequency and quantity of alcohol consumed in the past year at 
the 14 and 21 year follow-ups.  At these times the children were asked: “how often do you 
drink alcohol?” and “how much alcohol do you usually drink at those times?”  At both time 
points the possible response options for frequency of alcohol consumption were: daily, a few 
times a week, a few times a month, a few times a year, rarely/never.  At the 14 years follow-
up alcohol consumption was categorised as monthly quantities based upon the frequency and 
quantity of consumption.  These categories were: never used, less than 1 glass or 1 glass or 
more per month.  At the 21 years follow-up responses were categorised as less than one glass, 
1-15 glasses, 16-30 glasses or 31 glasses or more per month. 
 
To determine whether respondents had experienced an alcohol use disorder (AUD) by the 21 
year follow-up the Composite International Diagnostic Interview (CIDI-Auto) alcohol 
disorders module was administered (Andrews & Peters, 2003).  The CIDI is a structured 
diagnostic interview that can produce clinical diagnoses. The CIDI-Auto is a fully 
computerized version of the standard CIDI, which can be administered either by an 
interviewer or completed by the respondent.  The CIDI-Auto has good inter-rater reliability, 
test–retest reliability and acceptable validity (Andrews & Peters, 2003).  
 
As part of the AUD assessment the children were asked how old they were when they first 
experienced alcohol dependence and/or abuse symptoms (e.g. drinking a large amount to 
obtain an effect, experienced withdrawal symptoms, not able to stop when wanting to).  If the 
respondent was assessed as ever having an AUD, according to the DSM-IV, data were coded 
according to respondent’s age at the time (15 years or less, 16-17 years of age, 18 years or 
older) when they first experienced AUD symptoms.  
 
Tobacco 
Information on tobacco smoking was obtained at both the 14 and 21-year follow-ups.  At 
these times the children were asked “which of the following best describes your smoking 
status now”, with response options as follows: “I have never smoked, I used to smoke, now 
smoke occasionally and I now smoke regularly”.  These data were recoded into smoking and 
not smoking at both 14 and 21 year follow-ups, with not smoking consisting of never 
smokers and former smokers. At the 21-year follow-up the CIDI-Auto was used to assess 
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nicotine dependence according to DSM-IV diagnostic criteria (Alati et al., 2006, American 
Psychiatric Association, 1994, Hayatbakhsh et al., 2008).  The DSM-IV diagnosis of nicotine 
dependence was used as a measure of outcome.  
 
Cannabis 
Age of first use of cannabis was obtained at the 21 year follow-up.  At these times the 
children were asked “in the last month how often did you use cannabis, marijuana, pot etc?”.  
Possible response options were recoded into: no use (“have never used these, no use”), 
sometimes (“once or so”) and frequently (“at least every few days/every day”).  
 
Medications 
At the 21 years follow-up respondents were asked “during the last 12 months how often have 
you used the following for non-medical purposes”? For each medication (Ritalin and 
Dexedrine, painkillers like panadol and codeine, ventolin, steroids, sedatives like sleeping 
pills, barbituates or downers, tranquilisers like valium, rohypnol or mogodon) possible 
response options were: used only for medical purposes, have never used at all, not used 
during the past year, a few times during the year, a few times a month, a few times a week. 
Nearly twenty per cent (19.9%) had not used any medications, 62.8% had used a medication 
for medical purposes only, 13.0% had used one or more without medical intent, and 4.3% had 
used for both medical and non-medical intent. For analyses purposes the latter two categories 
were merged. The following three categories were therefore created: no use (never used 
medications), medical use only (use for medical purposes only) and non-medical use (use for 
medical and non-medical purposes).  
 
COVARIATES 
Demographic Characteristics 
Demographic characteristics were primarily treated as covariates.  These covariates are 
children and maternal socio-demographic characteristics.  Table 3 overviews MUSP 
children’s socio-demographic characteristics that were collected at the 21 years follow-up. 
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Table 3: MUSP children socio-demographic characteristics at the 21 year follow-up 
Demographic Characteristic Response Options 
Gender male, female 
Main job last week wage, salary earner/own business/unpaid work, no 
job 
Received government benefits last six months yes, no 
High school exit score Overall Position (continuous variable) 
Highest level of education completed university, other including primary school only 
Currently attending education institution yes, part-time/yes, full-time/no 
Living arrangements with parents/renting/other 
Have boy/girlfriend Yes, no 
Number of children no children/one child/more than one child 
 
Maternal Characteristics 
Anxiety and Depression 
The Delusions-Symptoms-States-Inventory (DSSI) (Bedford & Foulds, 1977, Bedford et al., 
1976) was used to measure maternal anxiety and depression. The DSSI is an 84 item self-
report of current mental state. The instrument comprises 12 domains (anxiety, depression, 
elation, symptoms of conversion, dissociation, phobia, compulsiveness, rumination; delusions 
of persecution, grandeur, contrition and disintegration) (Bedford & Deary, 1999). For this 
thesis only the two domains, anxiety and depression, were used. Each of these domains 
comprises seven items.  In this study the Cronbach’s α coefficient at the 5-year follow-up was 
0.835 (anxiety), and 0.856 (depression); and at the 14-year follow-up: 0.845 (anxiety) and 
0.877 (depression).  
 
Poverty 
At each phase of the study mothers were asked about their family income.  A poverty 
variable was created by averaging income data collected up to and including the 5- year 
follow-up and consists of three levels: consistent poverty, mid-income and consistent mid to 
high income. 
 
Changes in Marital Status  
In order to determine mothers’ marital status changes, mothers reported the number of 
divorces, separations and changes in partners they had at both the 5 and 14 year follow-ups. 
Mothers’ changes in marital status were obtained by a simple count of maternal partners at 
these time points.  
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4.3.3 STATISTICAL ANALYSES 
Analysis was restricted to children who could be located at all phases of data collection and 
who responded to the questions concerning happiness, satisfaction and to the relevant 
substance use questions.  Consistent with previous research, to examine the role of predictive 
variables on specific QOL dimensions (Urzua et al., 2013) analyses were undertaken using 
multinomial logistic regression (Verdugo et al., 2005).  These analyses enable odds ratios of 
an outcome with various levels of exposure using categorical data to be established.  A higher 
odds ratio means a higher risk of dissatisfaction and unhappiness.  Data analyses were 
undertaken using the statistical package STATA (StataCorp., 2009). 
 
4.3.4 STUDY LIMITATIONS 
Selection bias occurs when there are systematic differences in the characteristics between 
those who take part in the study and who do not (Last, 2001).  In the MUSP dataset a range of 
validity analyses have been previously conducted, with the conclusion that selection bias 
does not substantially affect estimates of association (Najman et al., 2008).   
 
Selective loss to follow-up is a characteristic of many longitudinal studies, and this finding is 
replicated in MUSP. Mothers selectively lost to follow-up are more likely to be teenagers at 
FCV, not married at FCV, and tend to be smokers and middle range consumers of alcohol 
(see Table 4). Mothers more likely to be lost to follow up are also more likely to be depressed 
and/or anxious at their FCV. While this pattern produces bias in the characteristics of the 
sample available for follow-up, it is less clear that this pattern of attrition poses problems for 
estimates of association.  
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Table 4: MUSP – Percent Lost to Follow-up for selected variables at 14 and 21 year 
follow-ups 
Variable % Lost to F/U at 
14 yrs 
% Lost to F/U at 
21yrs 
Maternal age - FCV 13-19 39.0 58.3 
20-34 26.3 45.7 
35+ 26.2 44.4 
X2, p-value p<.001 P<.001 
Maternal marital status - FCV Single 40.5 60.6 
Living together 42.5 60.3 
Married  23.8 43.3 
Sep-div-wid 46.4 62.9 
X2, p-value  p<.001 P<.001 
Maternal smoking - FCV Nil smoker 23.7 43.3 
Smoker (1-19) 32.1 51.3 
Heavy (20+) 34.8 53.7 
X2, p-value p<.001 P<.001 
Maternal alcohol - FCV Nil  32.3 47.7 
0.1 to 0.49 G/D 25.7 55.1 
0.5 to 0.99 G/D 26.0 54.9 
1.0 or more G/D 34.5 47.2 
X2, p-value p<.001 P<.001 
Maternal Depression (DSSI) - 
FCV 
Not depressed  27.6 46.6 
Depressed  40.0 61.9 
X2, p-value p<.001 P<.001 
Maternal Anxiety (DSSI) - FCV Not anxious 27.0 45.9 
Anxious  37.1 58.9 
X2, p-value p<.001 P<.001 
 
In this study children lost to follow-up were more likely to be from families with low income 
at birth, to have mothers who smoked tobacco throughout their pregnancy and to have parents 
with low educational attainment (Mamun et al., 2006).  Najman and colleagues (2008) has 
previously examined participant drop out by 21 years, and found that that participants with 
higher levels of child behavioural problems at age 5 years and higher anxiety/depression at 
age 14 years, were more likely to be lost to follow-up by 21 years (p <0.05).  However, the 
results from sensitivity analyses based on these factors, including inverse probability 
weighting, did not differ from the unweighted analyses, suggesting that selection bias does 
not substantially affect study results.  As participants lost to follow-up may have worse health 
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profiles, the estimates of the strength of the relationships found is likely to be conservative 
(Najman et al., 2008). 
 
When data from longitudinal datasets are used, their initial purpose of their data collection 
may be different to how they are applied in other studies.  Measures once considered ‘gold 
standard’ may become superseded by the time of follow-up several years later.  Where 
possible in this thesis measures have known robust psychometric properties 
(validity/reliability).  In circumstances where such scales were not available measures have 
been selected where there is a strong suggestion of content and face validity. 
 
Studies examining personal behaviour may be influenced by social desirability/acceptability 
bias.  This may result in some participants either minimising or to exaggerating their actual 
level of exposure to appear more acceptable to the interviewer (Hennekens & Buring, 1987, 
Schaeffer, 2000). 
 
4.4 OPIOIDS  
The third phase of this thesis was a comparative, cross-sectional study of the QOL of people 
who inject opioids in comparison with other populations with chronic conditions. 
 
4.4.1 PARTICIPANTS 
Participants were a self-selected sample of 483 current people who inject drugs (PWID) 
accessing a major inner-city needle and syringe program (NSP) in Brisbane, Australia, over a 
2-week period in October 2009. The mean age of our sample was 33.75 years (range 15–66 
years) and for the NSP 33.83 years (range 16–70 years).  
 
4.4.2 DATA 
Data were obtained from the bi-annual Australian Needle and Syringe Program Survey 
(ANSP).  The ANSP is a well-established biannual survey of PWID who obtain their 
injecting equipment from NSPs (de Wit et al., 2011, Macdonald et al., 1997).  The purpose of 
this data collection is to monitor injecting and risk patterns, and the incidence of blood-borne 
infections within the Australian PWID population.  
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4.4.3 VARIABLES AND MEASUREMENTS  
QOL 
To examine the QOL experienced by PWID, the World Health Organisation Quality of Life - 
BREF (WHOQOL-BREF) (The WHOQOL Group, 1995) was added to the ANSP survey 
self-administered to participants recruited at the Biala NSP in Brisbane, Australia.  The 
WHOQOL-BREF is an internationally validated instrument consists of 26 items, of which 24 
items measure four potentially independent QOL domains: physical health (six facets), 
psychological (six facets), social relationships (three facets) and environment (eight facets). 
The two remaining WHOQOL-BREF items rate overall subjective QOL and satisfaction with 
health. Consistent with WHOQOL recommendations, domain scores were transformed to a 
score out of 100, with higher scores indicating a better QOL (Murphy et al., 2000).  
 
DEMOGRAPHIC CHARACTERISTICS 
Age, gender, injecting patterns, current drug treatment status and hepatitis C status measures 
were also used.  Injecting related questions from the ANSP dataset included were “what was 
the last drug you injected” (heroin, amphetamines, prescription opioids), “how often do you 
inject” with the following response options: not in last month, less than weekly, more than 
weekly, not daily, once a day and more than once a day.  
 
COMPARISON STUDIES 
A search of the literature identified eight studies which reported WHOQOL-BREF 
transformed scores. These reported the QOL for the general Australian population and for 
Australian and international samples involving a range of health conditions.  
 
4.4.4 STATISTICAL ANALYSES 
WHOQOL-BREF scores for each domain were each transformed into scores out of 100. To 
examine associations between PWID characteristics and WHOQOL-BREF domain scores, 
analyses of variance were performed using Statistical Programs for the Social Sciences (IBM 
CORP. 2010). To compare the mean WHOQOL-BREF domain scores of our participants 
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with results reported in other published studies, tests for differences in means were performed 
using MedCalc version 12.1.3 (MEDCALC Software).  
 
4.5 CHAPTER SUMMARY  
To examine the QOL a series of investigations, in three phases were conducted using 
secondary data analyses. The first phase involves ascertaining the proportion of Australian 
substance users who access health services. The second phase involves investigating the QOL 
experienced by a adolescent and young adult alcohol, tobacco, cannabis and medication 
users. Third describes the QOL experienced by PWID and compares their experiences with 
populations with other conditions. As this thesis comprises a series of investigations, the 
following table summarises the methods used in tabular format (Table 5). The results of these 
investigations are provided in the following chapters. 
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Table 5: Thesis studies: overview of investigation methodologies 
Topic Purpose Study Design Dataset/s Measures Analysis 
Treatment 
Rates 
To determine 
Australian population  
rates of those ‘at risk’ 
of harm from substance 
use, by age, gender & 
drug 
Comparative 
descriptive 
epidemiological 
2007 NDSHS 
2006-07 AOD-
NMD 
2006-07 NHMD 
Drugs: alcohol, cannabis, amphetamines 
& ecstasy  
Recent substance use in the Australian 
population, adjusted for age, gender  & 
drug type 
Specialised community or hospital 
service treatment counts 
Drug treatment & in-patient 
hospital care rates per 1000 
cannabis, amphetamines & 
ecstasy users; & by sex & age 
groups from 14 years & older 
Alcohol To describe & examine 
the temporal association 
between QOL & 
alcohol use & alcohol 
use disorders 
Descriptive & 
longitudinal 
MUSP: 14 & 21 
year follow-ups 
QOL (happiness & satisfaction) 
Alcohol:  age of first use, frequency & 
quantity, alcohol use disorders 
Children demographic characteristics 
Descriptives 
Temporal associations 
Tobacco To determine the 
temporal sequence 
between 
psychopathology & 
commencement of 
tobacco smoking  
Descriptive & 
longitudinal 
MUSP: 5, 14 & 21 
year follow-ups 
Psychopathology (internalising, 
externalising & attention problems) 
Tobacco: age of first use, dependence 
Children & maternal demographic 
characteristics 
Descriptives 
Temporal associations 
Cannabis To describe & examine 
the association between 
QOL & age of first 
cannabis use 
Descriptive & 
longitudinal 
MUSP: 14 & 21 
year follow-ups 
QOL (happiness & satisfaction) 
Cannabis: age of first use, frequency 
Children demographic & depression 
characteristics 
Descriptives 
Temporal associations 
Medications To describe & examine 
the association between 
QOL & medications at 
14 & 21 year follow-
ups. 
Descriptive & 
longitudinal 
MUSP: 14 & 21 
year follow-ups 
QOL (happiness & satisfaction) 
Medications:  specific medications & 
frequency 
Children demographic & other drug use 
characteristics 
Descriptives 
Temporal associations 
People who 
inject drugs 
(PWID) 
To describe the QOL of 
PWID & to compare 
with populations with 
chronic conditions. 
Comparative 
descriptive 
cross-sectional 
2009 ANSP 
Survey 
WHOQOL-BREF  
Demographic characteristics & injecting 
patterns 
Descriptives 
Comparison of WHOQOL-
BREF scores with published 
studies 
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CHAPTER FIVE:  ALCOHOL CONSUMPTION 
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Box 1: Summary of Chapter Five: Alcohol Consumption 
Study  
Purpose 
To describe and to examine the temporal association between QOL & 
alcohol use and alcohol use disorders (AUD), between adolescence (14 
years of age) and young adulthood (21 years of age), in an Australian birth 
cohort.   
Main 
Variables 
• QOL (happiness and satisfaction) at the 14 and 21 year follow-ups 
• Alcohol: age of onset, frequency, quantity and AUDs  
• Demographic characteristics at the 21 years follow-up. 
Key 
Findings 
• Poor QOL is associated with the early age of onset of alcohol use and 
AUD 
• Alcohol consumption is associated with diminished QOL, although the 
association is modest and inconsistent. 
Additional 
Information 
Tables 
Table 1: Association between quality of life (satisfaction and happiness) 
and quantity of alcohol consumed in the past month at the 14 
and 21 year follow-ups 
Table 2: Quality of life at 14 years predicting age of onset of alcohol use 
disorders by 21 years (DSM-IV) 
Table 3: Age of onset alcohol use disorders by 21 years predicting quality 
of life at 21 years adjusted for pre-existing demographic 
characteristics and quality of life at 14 years 
 
Quality of life, age of onset of alcohol use and alcohol use disorders
in adolescence and young adulthood: Findings from an Australian
birth cohort
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ALEXANDRA M. CLAVARINO1
1Pharmacy Australia Centre for Excellence, The University of Queensland, Brisbane, Australia, 2School of Population
Health, The University of Queensland, Brisbane, Australia, and 3School of Social Sciences, The University of Queensland,
Brisbane, Australia
Abstract
Introduction andAims.Alcohol consumption among adolescents and young adults is a persistent community concern.Little
is known about the short-term effects on the young adult drinker’s quality of life (QOL), particularly prior to the first use of
alcohol and the effect of alcohol consumption on subsequent QOL assessments.There is a need to know more about the QOL
of those who decide to use alcohol in adolescence and the effect of alcohol consumption on young adult QOL. Design and
Methods. This is a prospective longitudinal study of a birth cohort. Data were taken from the 14- and 21-year follow ups.
At both time points, QOL was indicated by a measure of happiness and satisfaction.Alcohol use was also measured at 14- and
21-year follow ups. At the 21-year follow up, alcohol use disorder (AUD) was assessed using the Composite International
Diagnostic Interview.Results.At the 14-year follow up, there was a strong association between QOL and quantity of alcohol
consumed. QOL at 14 years also predicted more frequent alcohol use at 21 years of age. Poor QOL at 14 years was a strong
predictor of earlier age of onset of an AUD. However, when age of onset of AUD was used to predict subsequent QOL, the
associations were weak and inconsistent.Discussion and Conclusion.Poor QOL was associated with the early age of onset
of alcohol use and AUDs. Addressing adolescent and young adult QOL may reduce the early onset of alcohol use and its
potential for harm. [Fischer JA, Najman JM, Plotnikova M, Clavarino AM. Quality of life, age of onset of alcohol use
and alcohol use disorders in adolescence and young adulthood: Findings from an Australian birth cohort. Drug
Alcohol Rev 2015;34:388–96]
Key words: quality of life, alcohol, adolescent, young adult, longitudinal.
Introduction
Alcohol consumption by adolescents and young adults
is a persistent community concern. Early age of alcohol
use is an established risk factor for subsequent harm
[1–6] and among young adults, excessive alcohol con-
sumption is a firmly established pattern of behaviour
[7–10]. This is despite alcohol-related harm being a
leading risk factor for disability among young people
[11,12] including for some the development of an
alcohol use disorder (AUD) [2,13,14]. Alcohol use can
be conceptualised as a form of self-medication intended
to enhance mood and/or social interaction. While this
may be the case, in the very short term, little is known
about the extent to which alcohol use confers benefits.
In particular, little is known about the quality of life
(QOL) of adolescents prior to their first use of alcohol
and the effect of alcohol consumption on subsequent
QOL assessments.There is a need to know more about
the QOL of those who decide to use alcohol in adoles-
cence and the effect of alcohol consumption on young
adult QOL.
QOL
QOL can be conceptualised as global judgement at a
given point in time [15–25]. QOL has been measured
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by assessing [19–21,25] subjective or objective dimen-
sions [26]. Subjective dimensions reflect perceptions of
the respondents [23,27,28], whereas objective markers
of QOL are characteristics that are attributed by exter-
nal observers [28].
For the purposes of this study, QOL is conceptual-
ised as encapsulating subjective well-being (happiness
and satisfaction). This is consistent with the seminal
work on QOL by Campbell and colleagues [15],
Andrews and Withey [22] and Najman and Levine
[17]. Happiness is generally considered a measure of
short-term affect, of how much people enjoy their lives
[15,23,29]. It is also an assessment of hedonism—the
extent to which a person’s needs are satisfied [28].
Satisfaction is generally considered to reflect broader
aspirations, achievements and perceived reality in com-
parison with peers [30,31] and with societal norms
[23,27].
QOL and age of onset of alcohol use
Age at which alcohol is first consumed is predictive of
later harms [1–6]. A number of factors have been impli-
cated in the early age of onset of alcohol use and AUDs
including parental [32,33] and peer/friendship [34–36]
influences. However, whether age of onset or quantity
of alcohol consumed independently predicts young
drinkers’ QOL [31,37] or whether the association is
bidirectional [38,39] is uncertain. No studies have pro-
spectively examined respondents’ QOL prior to com-
mencement of alcohol use.
QOL and alcohol use in young adulthood
Adolescents and young people have a broad range
of motivations for drinking alcohol [40]. These have
often been placed within a pleasure paradigm [41–44]
and specifically considered as ‘calculated hedonism’
[45,46].Young adults may view alcohol consumption as
a negotiation for obtaining an optimal mix of benefit
and risk [47,48]. For some young people, social motives
[7,49–51] and pleasure are paramount [42,50]. Others
may consume alcohol in order to avoid or delay nega-
tive affective states or pain [52,53].
While consuming alcohol may have immediate pleas-
urable effects, how youth evaluate these effects in the
short- and long-term is uncertain [40]. Alcohol use may
enhance QOL, even among adolescents with a good
QOL [54]. In one US longitudinal study of students
(n = 640), early alcohol use was associated with
improved life satisfaction [54]. In another, of rural US
students (n = 208), positive subjective well-being pre-
dicted increased alcohol use by 18 years of age [40].
However, in an English study (n = 3641), students with
positive well-being were less likely to have ever con-
sumed alcohol [55].
The quantity of alcohol consumed may also be
important in QOL assessments. A Swedish study of
first-year university students (n = 3229) found a nega-
tive correlation between quantity of alcohol consumed
and QOL [56]. Other cross-sectional studies have
found that among young adult binge drinkers, life sat-
isfaction is diminished [37–39]. In adult alcohol-
dependent populations, QOL improves with reduced
quantity of alcohol consumed [57]; however, these
studies have focused upon populations in treatment.
Although the prevalence of AUD is high among young
adults, few seek treatment [13]. Whether alcohol-
dependent users have poor QOL prior to commence-
ment (in either adolescence or young adulthood) or in
the early stages of their drinking is unknown.
There are also well-established associations between
patterns of alcohol use and various young adult socio-
demographic characteristics (e.g. Little et al. and other
several studies [6,40,49,52,58–60]). Longitudinal
studies suggest that the association between QOL and
alcohol use might be due to these covariates. A study of
New Zealand young adults (n = 987) found that life
satisfaction was not reduced after adjusting for time
dynamic variables, such as employment, life events and
comorbidity [61]. Similarly, a study of rural adolescents
(n = 2376) found that alcohol use at 18 was not signifi-
cantly associated with later life satisfaction at 29 years
of age [62]. By contrast, a Canadian study of college
students (n = 627) found that while greater alcohol use
predicted higher subjective well-being, adverse alcohol-
related consequences predicted lower subjective
well-being [63].
One of the difficulties with the above studies is their
measurement of QOL. Apart from two studies, which
assessed subjective well-being [55,63], the above
studies (i.e. Zullig et al. and other several studies [37–
39,54,56,61–63]) focused on one dimension of QOL,
life satisfaction. Two of the three longitudinal studies
similarly focused on life satisfaction. Bogart et al. [62]
assessed life satisfaction using one item while Swain
et al. [61] administered a custom instrument consisting
of 12 satisfaction domains. In contrast Molnar et al.
[63] assessed subjective well-being using a combination
of one global item of life satisfaction and a 20-item
positive and negative affect schedule score.
The aim of the present study was to examine the
temporal sequence between QOL and alcohol use and
AUDs between adolescence (14 years of age) and
young adulthood (21 years of age) in an Australian
birth cohort. The study examines the relationship
between QOL and alcohol use at both 14 and 21 years
of age and whether respondents with a lower QOL prior
to alcohol use are more likely to use alcohol and to
develop AUDs. It is necessary to distinguish the short-
and medium- to long-term associations between QOL
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and alcohol use. The immediate consequences of
alcohol use are not addressed in this paper. Our interest
is in the medium- to long-term consequences of a
pattern of alcohol use.
Methods
Respondents
Data used in this study were collected as part of the
prospective longitudinal Mater Misericordiae Hospital
and University of Queensland Study of Pregnancy.
Between 1981 and 1983, interviewers approached 8556
women at their first antenatal visit at the Mater
Misericordiae Hospital in Brisbane, Australia to partici-
pate in the study, of which 8458 (98.9%) agreed. The
cohort consists of 7223 women who delivered a live
singleton baby who was not adopted out. This repre-
sents 87% of all women who attended the antenatal
clinic during the study period [64]. Mothers and off-
spring have been followed up when the children were
3–5 days old, 6 months old, and 5, 14 and 21 years
later, with offspring self-completing questionnaires at
the 14- and 21-year follow ups. Offspring data from the
14- and 21-year follow ups were used in this study.
Ethical clearances were obtained from the Mater
Misericordiae Hospital and The University of Queens-
land Human Research Ethics Committees.
Measures
QOL. At both the 14- and 21-year follow up, happi-
ness and satisfaction were measured. ‘Happiness’ was
assessed by asking respondents ‘How would you say
you feel these days? Would you say you are . . . (very
happy/happy/unhappy)?’ ‘Satisfaction’ was assessed by
asking respondents ‘How satisfied are you with your life
as a whole these days? Would you say you are . . . (very
satisfied/satisfied/dissatisfied)?’
Alcohol. Respondents were also asked about the fre-
quency and quantity of alcohol consumed in the past
month at the 14- and 21-year follow ups. At the 14-year
follow up, alcohol consumption was categorised as
monthly quantities based upon the frequency and
quantity of consumption. Categories were never used,
less than one glass or one glass or more per month. At
the 21-year follow up, responses were categorised as
less than 1 glass, 1–15 glasses, 16–30 glasses or 31
glasses or more per month.
To determine whether respondents had experienced
an AUD by the 21-year follow up, the Composite Inter-
national Diagnostic Interview alcohol disorders module
[65] was administered.This module operationalises the
Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition (DSM-IV) criteria to assess for alcohol
use dependence and/or abuse. As part of this assess-
ment, respondents were asked how old they were when
they first experienced 11 alcohol dependence and/or
abuse symptoms (e.g. drinking a large amount to obtain
an effect, experienced withdrawal symptoms, not able
to stop when wanting to). If the respondent was
assessed with ever having AUD, according to the DSM-
IV, data were coded according to respondent’s age at
the time (15 years or less, 16–17 years of age, 18 years
or older) when they first experienced AUD symptoms.
Covariates. Other factors relevant to the QOL of
young adults and also to patterns of alcohol consump-
tion in young adulthood [31,60,66] at the 21-year
follow up were operationalised as covariates. These
were gender, employment status in the last week
(job/no job), received government benefits in the last 6
months (no/yes), highest level of education completed
(college, technical and further education, university,
other/secondary school/primary school), high school
exit score (an indicator of academic achievement), cur-
rently attending education institution (yes, part-time/
yes, full-time/no), living arrangements (with parents/
renting/other), have boy/girlfriend (no/yes), number of
children (no children/one child/more than one child)
and tobacco smoking (current/former/never).
Statistical analyses
Analyses were restricted to offspring who were located
and had responded to the happiness, satisfaction and
alcohol questions at the 14- and 21-year follow ups.
Data management has been integral to the project since
its conception, with a designated Mater Misericordiae
Hospital and University of Queensland Study of
Pregnancy data manager throughout. Consistent with
previous research, to examine the role of predictive
variables on specific QOL dimensions [67,68], analyses
were undertaken using multinomial logistic regression
[69].The datasets met requirements for these statistical
tests. These analyses enable odds ratios of an outcome
with various levels of exposure using categorical data to
be established.
Results
QOL and alcohol use at 14-and 21-year follow ups
At 14 years of age, most respondents (62.1%) had
never used alcohol. In the past month, 26.1% had con-
sumed less than one glass and 8.8% had consumed one
glass or more of alcohol (table not shown).The odds of
consuming alcohol in the past month and satisfaction
and happiness is examined in Table 1, with the
reference category of very satisfied/never used and very
happy/never used, respectively. Lower QOL was
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associated with the amount of alcohol consumed in the
past month. Respondents who had consumed at least
one glass of alcohol were seven times more likely to be
dissatisfied (odds ratio 7.67, 95% confidence interval
4.97, 11.83) and three times more likely to be unhappy
(odds ratio 3.28, 95% confidence interval 2.31, 4.65)
than respondents who had never used alcohol at 14
years of age.
By 21 years of age, most respondents had consumed
alcohol in the past month (84.7%). In the past month,
26.3% of respondents had consumed 15–29 glasses of
alcohol, 29.9% had consumed 1–14 glasses of alcohol
while 28.5% had consumed 30 or more glasses of
alcohol (table not shown). Much higher levels of
alcohol consumption at the 21-year follow up were
associated with lower levels of satisfaction and happi-
ness at 14 years.
QOL at 14 years and age of onset of AUDs by 21 years
By the 21-year follow up, 27.8% of respondents had
experienced an AUD, according to DSM-IV criteria. Of
all respondents, 14.1% first experienced AUD symp-
toms when they were aged 18 years or older, 9.5%
between the ages of 16 and 17 years, and 4.2% when
they were 15 years of age or younger (table not shown).
Respondents with the lowest QOL (satisfaction and
happiness) at the 14-year follow up had a significantly
higher risk of experiencing an AUD. The odds ratios
pointed to strong associations between low QOL in the
adolescent period (14 years of age) and a younger age
of onset of dependence or abuse of alcohol by the
21-year follow up (Table 2).
Multinomial regression was then conducted to
examine whether after adjustment for various
covariates, age of onset of AUD predicted QOL at the
21-year follow up (Table 3).The unadjusted association
between AUD and QOL suggested that the younger age
of onset of alcohol use and AUD predicted satisfaction
and happiness at 21 years. After the first adjustment
(happiness and satisfaction at 14 years of age), only
respondents who experienced an AUD by 15 years of
age were at risk of higher levels of dissatisfaction (odds
ratio 3.01, 95% confidence interval 1.35, 6.69). After
the second adjustment (socio-demographic variables),
respondents who experienced an AUD were signifi-
cantly at higher risk of dissatisfaction. After the third
adjustment, earlier age of onset of an AUD was only
weakly, and not consistently, related to the respondents’
QOL at the 21-year follow up.
Discussion
This study examines the relationship between QOL
and alcohol use at both 14 and 21 years of age and
whether respondents with a lower QOL prior to alcohol
use are more likely to use alcohol and to develop AUDs.
This study has enabled alcohol users’ QOL to be inves-
tigated prior and post to first onset of their use, and also
whether their quantity of alcohol consumption predicts
their QOL
Table 1. Association between QOL (satisfaction and happiness) and quantity of alcohol consumed in the past month at the 14- and 21-
year follow ups
Volume of alcohol consumed
(average number of
glasses per month)
QOL
Satisfaction—14 years Happiness—14 years
Very
satisfied Satisfied Dissatisfied
Very
happy Happy Unhappy
14-year
follow up
Never used 1 1 1 1 1 1
Less 1 glass
OR (95% CI)
1 1.52 (1.28, 1.80) 2.18 (1.57, 3.03) 1 1.46 (1.22, 1.74) 1.68 (1.31, 2.15)
1 glass and more
OR (95% CI)
1 2.34 (1.71, 3.21) 7.67 (4.97,11.83) 1 1.37 (1.02, 1.84) 3.28 (2.31, 4.65)
21-year
follow up
>1 glass or
never used
1 1 1 1 1 1
1–14.9 glasses
OR (95% CI)
1 1.27 (1.01, 1.60) 1.43 (0.99, 2.07) 1 1.29 (1.04, 1.60) 1.12 (0.76, 1.66)
15–29.9 glasses
OR (95% CI)
1 1.25 (0.99, 1.58) 1.39 (0.96, 2.03) 1 1.31 (1.05, 1.64) 1.07 (0.71, 1.61)
30 glasses≤
OR (95% CI)
1 1.32 (1.05, 1.67) 1.96 (1.36, 2.80) 1 1.30 (1.04, 1.62) 1.34 (0.91, 1.98)
Bold = P < 0.05. CI, confidence interval; OR, odds ratio; QOL, quality of life.
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The strongest finding in the present results is the
association between QOL and early alcohol use (14
years). Poor QOL was associated with the early age of
onset of alcohol use and also with AUDs. As the
amount of alcohol being consumed at 14 years of age is
modest, it is likely that low levels of life satisfaction and
happiness precede the onset and level of alcohol use.
This may be reflective of parental [32,33] and strong
peer [34–36] influences. A recent study has illustrated
the importance of child/adolescent functioning and
family and peer environments on the early age of onset
of alcohol use and later problems [70].
These findings indicate that a poor QOL at an early
age predicts alcohol use at an early age. They also
suggest that early age of onset of alcohol use per se may
not be a risk factor for later problems. Early age of onset
of alcohol use may simply represent a manifestation of
higher risk behaviour. Poor QOL in childhood appears
to be a marker for later risky behaviours and problems.
Although there is substantial literature on the influence
of the early years on later life outcomes, literature on
the QOL of children as a predictor of subsequent out-
comes is limited [71]. However, as children at least as
young as eight can adequately assess their QOL
[66,72], research is possible to ascertain whether a
lower level of QOL predicts a number of subsequent
health outcomes.
To assess whether the reverse causal sequence pro-
vided an alternative explanation, we examined what was
found to be a modest and somewhat inconsistent asso-
ciation between alcohol use and QOL at 21 years.
Respondents who consumed alcohol reported dimin-
ished QOL compared with those who had remained
abstinent.While a lower QOL strongly predicts the use
of alcohol at a younger age, younger age of AUDs only
weakly and inconsistently predicts QOL in young
adulthood. Thus, binge drinking (alcohol abuse) is
more prevalent in young adults than is alcohol depend-
ence. At a younger age, many of the AUDs will involve
repeated episodes of short-term alcohol abuse rather
than alcohol dependence, with less evident impact on
medium-term QOL outcomes.
These findings support the importance of addressing
ways of reducing, and even preventing, the use of
alcohol in these age groups [10,12,73]. Interventions
should address the low QOL experienced by some
young people and also support ways of maintaining a
‘good QOL’ experienced by others. One approach may
Table 2. Quality of life at 14 years predicting age of onset of alcohol use disorders by 21 years (DSM-IV)
Unadjusted for socio-demographic variablesa
Age of onset alcohol
use—21 years
Satisfaction—14 years Happiness—14 years
Very satisfied
(n = 475)
OR (95% CI)
Satisfied
(n = 1074)
OR (95% CI)
Dissatisfied
(n = 94)
OR (95% CI)
Very happy
(n = 414)
Happy
(n = 999)
OR (95% CI)
Unhappy
(n = 231)
OR (95% CI)
Never used 1 1 1 1 1 1
18 years or more 1 1.02 (0.74, 1.40) 1.18 (0.61, 2.27) 1 0.93 (0.67, 1.30) 1.16 (0.73, 1.85)
16–17 years 1 1.88 (1.19, 2.96) 3.16 (1.54, 6.52) 1 1.24 (0.79, 1.94) 2.00 (1.14, 3.51)
15 years or less 1 1.94 (1.02, 3.69) 3.55 (1.34, 9.37) 1 1.04 (0.54, 1.92) 2.96 (1.46, 6.02)
Adjusted for socio-demographic variablesa
Age of onset alcohol
use—21 years
Satisfaction—14 years Happiness—14 years
Very satisfied
(n = 475)
OR (95% CI)
Satisfied
(n = 1074)
OR (95% CI)
Dissatisfied
(n = 94)
OR (95% CI)
Very happy
(n = 414)
Happy
(n = 999)
OR (95% CI)
Unhappy
(n = 231)
OR (95% CI)
Never used 1 1 1 1 1 1
18 years or more 1 1.03 (0.79, 1.36) 1.22 (0.69, 2.17) 1 1.04 (0.77, 1.40) 1.35 (0.89, 2.04)
16–17 years 1 2.05 (1.38, 3.06) 3.44 (1.72, 6.85) 1 1.36 (0.91, 2.03) 2.41 (1.44, 4.01)
15 years or less 1 1.86 (1.09, 3.19) 2.94 (1.28, 6.79) 1 1.08 (0.63, 1.85) 2.89 (1.56, 5.35)
Bold = P < 0.05. aAdjusted for the following socio-demographic variables: gender, employment status, government benefits,
currently attending educational institution, highest education, living arrangements, has boy/girlfriend. CI, confidence interval;
DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; OR, odds ratio.
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be campaigns and brief interventions that go beyond
reducing the harm associated with drinking per se, but
also consider the personal motivations for drinking and
particularly adolescent and young adult perceptions of
belonging and peer group credibility [44,46]. These
interventions will need to address the lower QOL that
some adolescents experience and alternative strategies
for improving this QOL. Alternative strategies may be
encouraging social activities that are not based upon
alcohol consumption.
Strengths and limitations
There is a concern with the extent to which our cohort
reflects population characteristics. In this study,
respondents’ first age of use and the prevalence of
alcohol use in young adulthood were consistent with
the 2010 Australian National Drug Strategy Household
Survey.The increase in prevalence between adolescence
(14-year follow up) and young adulthood (21-year
follow up) among respondents is also consistent with
Australian patterns of use between these age groups.
Among young Australian adults (16–24 years), the
prevalence of AUD, also using DSM-IV criteria, is
11.1% [13].
Increasingly, there is some consensus that subjective
QOL has three common dimensions: hedonic (meas-
ured as happiness), evaluation (measured as satisfac-
tion) and eudemonic (a sense of purpose) [23,74]. In
this study, only the first two indicators of QOL, happi-
ness and satisfaction, were examined. Although omit-
ting a eudemonic measure is a weakness of this study,
happiness and satisfaction measures have considerable
face validity and their use is consistent with the existent
research on alcohol use and subjective QOL among
youth [40,61,62].
Likert scales [30,75], including 10-point scales, have
been recommended to measure subjective QOL (e.g.
Organisation for Economic Co-operation and Develop-
ment and National Research Council [23,74]). This
type of measurement enables more precision in individ-
ual assessments at a given time and in measuring
response shifts; in this study, however, happiness and
satisfaction were used as a three-point scale, consistent
with the work of Campbell and colleagues [15].
Loss to follow up is a recurring problem with cohort
studies. In this study, children lost to follow up were
likely to be from families with low income at birth, to
have mothers who smoked tobacco throughout their
pregnancy and to have parents with low educational
attainment [76]. Najman et al. [64] have previously
examined participant dropout by 21 years and found
that that participants with higher Child Behavior
Checklist total problem scores at age 5 years and higher
anxiety/depression scores on the Youth Self Report at
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age 14 years were more likely to be lost to follow up
by 21 years (P < 0.05). However, the results from sen-
sitivity analyses based on these factors, including
inverse probability weighting, did not differ from the
unweighted analyses, suggesting that selection bias does
not substantially affect study results.
Conclusion
Lower QOL in the adolescent period (14 years of age)
is a strong predictor of onset of alcohol use. It is also a
strong predictor of the age when adolescents first
experience an AUD. Poor QOL assessments at an early
age may be a risk factor for commencing alcohol con-
sumption at an early age. Responses to young adult
alcohol consumption need to go beyond reducing the
harm per se from alcohol but also address adolescent
and young adult motivations for drinking in the first
place.
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ABSTRACT
Aims To examine whether child and adolescent psychopathology predicts subsequent tobacco use at 14 and
21 years of age. Design Prospective birth cohort study. Setting Data are taken from the Mater Misericordiae
Hospital and University of Queensland Study of Pregnancy and its outcomes (MUSP), a prospective longitudinal study
which recruited women at their first antenatal visit in Brisbane, Australia. Participants A 5-, 14- and 21-year
follow-up of children whose mother’s were recruited into the MUSP birth cohort study at their first antenatal visit.
Measurements Psychopathology exposure was measured using the Achenbach’s Child Behaviour Checklist (CBCL)
at 5 years, the Youth Self Report (YSR) at 14 years and the Young Adult Self Report (YASR) at 21 years. Outcome
measures were the children’s tobacco smoking status at the 14 and 21 years’ follow-up and the Composite Interna-
tional Diagnostic Interview (CIDI) based DSM-IV nicotine dependence at 21 years’ follow-up. Findings Externalizing
symptoms had the strongest association with subsequent tobacco use. Children who met the criteria for CBCL aggres-
sion at 5 years were more likely to be tobacco smokers at the 14-year follow-up. YSR externalizing behaviours at the
14-year follow-up predicted tobacco smoking, but not DSM-IV nicotine dependence at the 21-year follow-up. Inter-
nalizing behaviour (anxiety/depression) was associated with a reduced rate of smoking at the 14- and 21-year
follow-ups, but externalizing behaviour and attention problems at 14 and 21 years were associated separately and
cumulatively with nicotine dependence at the 21-year follow-up. Conclusion Childhood and adolescent psychopa-
thology predict tobacco smoking, but some forms of psychopathology predict increased (aggression/delinquency;
attention problems) and other forms decreased (anxiety/depression) smoking. There may be some benefits in targeting
children with early onset aggressive/delinquent behaviour problems with tobacco smoking prevention initiatives.
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INTRODUCTION
There is consistent evidence for an association between
tobacco smoking and mental illness [1–5], particularly
depression [6–12] and anxiety [1,2]. Smoking is associ-
ated with higher rates of anxiety and affective disorders,
with current smokers reporting greater psychological dis-
tress and mental illness diagnoses than non-smokers [2].
There is also a possibility that the association between
psychopathology and tobacco smoking may change as
the proportion of smokers in the population declines.
With fewer than 20% of the Australian population now
smokers [13,14], it may be that the remaining tobacco
smokers are more likely to have symptoms of psycholo-
gical distress.
The temporal sequence between tobacco smoking and
psychopathology in adolescents and young adults contin-
ues to be a matter of dispute [15–17]. Three causal path-
ways are possible. Tobacco smoking might precipitate
a mental illness; mental illness might lead to tobacco
smoking; or the associationmight be due to other factors;
that is, confounders which lead to both tobacco smoking
bs_bs_banner
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and mental illness. There is evidence supporting the
plausibility of each of the three alternative temporal
pathways.
A number of studies have suggested that tobacco
smoking precedes depression [18–23]. For example, Wu
& Anthony [24] found that tobacco smoking was associ-
ated with a subsequent increase in the risk of depression
in a prospective population-based study of 1731 youth.
Other studies have found that depression precedes
tobacco smoking [17,25–29]. For example, Fergusson
et al. [30] found that depression at 16 years was
associated with daily tobacco smoking and nicotine
dependence at 21 years.
There may be common pathways to tobacco smoking
and mental illness [3,4], or it may be bidirectional [5].
A range of possible confounders have been identified
[20,22,24,26,27,31–34]. Key social and demographic
variables which have been shown to predict both tobacco
smoking and mental illness are poverty [6] and marital
breakdown [7]. While hostility and aggression-type
behaviours have also been implicated [22,24,35], they
can also be conceptualized as evidence of psychopathol-
ogy as reflected in suchmeasures as the Achenbach Child
Behaviour Checklist (CBCL) [8] and the impulse control
disorders in the Composite International Diagnostic
Interview (CIDI) [9].
The present study aims to extend previous research
intended to determine the temporal sequence between
tobacco smoking and mental illness. It uses data from
a prospective birth cohort to examine whether early
life internalizing (anxiety and depression), externalizing
(aggressive/delinquent) and attention problems predict
tobacco smoking. The study also includes a number
of variables which might confound the relationship
between tobacco smoking and mental illness.
METHODS
Participants
Data for this study are taken from Mater Misericordiae
Hospital and University of Queensland Study of Preg-
nancy and its outcomes (MUSP). Between 1981 and
1983, interviewers approached 8556 women at their
first antenatal visit at the Mater Misericordiae Hospital
in Brisbane, Australia to participate in the study, 8458
(98.9%) of whom agreed. The cohort consists of 7223
live singleton babies who were not adopted. This repre-
sents 87% of all women who attended the antenatal
clinic during the study period [10]. Data are restricted to
the offspring for whom information was available at the
21-year follow-up. Some participants lost to follow-up
may subsequently return to the study. Figure 1 details the
follow-up cohort.
Mothers were followed-up when the children were
3–5 days old, 6 months old, and then 5, 14 and 21 years
Baseline 
1981-1983 
n = 7223 
live single births to 6703 mothers 
n = 52885 years 
1986-1988 
 n = 518414 years 
1995-1997 
LTFU: 
1425 could not be located 
1377 would not provide a response 
601 refused - withdrawn 
17 deceased  
21 years 
2001-2004 
n = 3803 
53% of the original child cohort 
LTFU: 
1344 could not be located 
300 would not provide a response 
383 refused - withdrawn 
12 deceased  
Loss To Follow-up (LTFU): 
1449 could not be located 
260 would not provide a response 
226 refused - withdrawn 
Figure 1 Overview of recruitment,
follow-up monitoring and data collection
within the cohort study
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later. Their offspring self-completed questionnaires at the
14- and 21-year follow-ups. At the 21-year follow-up the
average age of participating offspring was 20.4 years
(standard deviation = 0.8), 51.0% were female, 24.6%
had tertiary education, 54.6% had completed high
school and 20.8% had had some primary or secondary
school education [10]. Response rates weremaximized by
using a range of strategies. These included obtaining six
family/friend contact numbers from participants and
searching the electoral (voting) roll for details of any
change of address. In Australia voting is compulsory, and
all people over 18 years are required to register. Survey
administration occurred both over the telephone and
face to face.
Ethics clearances for each phase of data collection
were obtained from either or both the Mater Miseri-
cordiae Hospital and University of Queensland human
research ethics committees.
Instruments
Measurement of outcomes
Information on tobacco smoking was obtained from the
offspring at both the 14- and 21-year follow-ups. At these
times the children were asked ‘which of the following
best describes your smoking status now’, with response
options as follows: ‘I have never smoked’, ‘I used to
smoke’, ‘now smoke occasionally’ and ‘I now smoke
regularly’. These data were recoded into ‘smoking’ and
‘not smoking’ at both 14 and 21 years’ follow-up. ‘Not
smoking’ consists of never smokers and former smokers.
At the 21-year follow-up the Composite International
Diagnostic Interview (CIDI-Auto) was used to assess nico-
tine dependence according to DSM-IV diagnostic criteria
[11,12,15]. The CIDI-Auto is a structured diagnostic
interview that can produce DSM-IV and ICD-10 diag-
noses. The DSM-IV diagnosis of nicotine dependence was
used as a measure of outcome. The CIDI-Auto is a fully
computerized version of the standard CIDI, which can be
administered either by an interviewer or completed by the
respondent. The CIDI-Auto has good inter-rater reliabil-
ity, test–retest reliability and acceptable validity [9].
Measurements of exposure
‘Internalizing’, ‘externalizing’ and ‘attention problems’
measures of psychopathology were obtained using the
CBCL [36] and Youth Self Report (YSR) [8]. Both in-
struments consist of standardized checklists for child
and adolescent behaviour problems and competencies
[8,13,36]. The internalizingmeasures used include inter-
nalizing at 5 years and anxious/depressed symptoms at
14 and 21 years. The externalizing measure includes
aggression at 5 years and externalizing at 14 and 21
years. The attention problems measure used includes
social/attention/thought problems (of which five of the
10 are measures of attention) at 5 years and attention
problems at 14 and 21 years [37–39].
Amodified (short form) of the CBCL was completed by
mothers at 5 years. It included 33 of the 113 items from
the original scale. Items selected assessed the most com-
monly occurring behaviours in 5-year-olds. Mothers
rated items as occurring ‘often’, ‘sometimes’ or ‘never’,
rather than on a three-point scale ranging from 0 ‘not
true’ to 2 ‘very true’ to 3 ‘often true’, as described in the
original scale. Factor analyses and reliability estimates of
subscales produced results consistent with Achenbach’s
data [37,40]. In addition, a sample of 76 parents whose
6-year-old children were at school also completed the
long form of the CBCL. There were very strong corre-
lations (externalizing r = 0.94, internalizing r = 0.89)
between the short and full forms of the CBCL [14].
At the 14-year follow-up the YSR was self-completed
by the offspring. The YSR has been shown to be reliable
and provides arguably valid indicators of problem behav-
iour [8,16,36]. In this study the complete A–D scale
(Cronbach’s a = 0.84) and T–P scale (Cronbach’s
a = 0.94) were used and respondents were given the
modified options of ‘often’, ‘sometimes’, ‘rarely’ and
‘never’ at the 14-year follow-up.
Measurements of potential confounders
Child and maternal characteristics potentially relating to
child and adolescent mental health and tobacco smoking
were included as confounders in the analysis. Potential
child confounding and mediating factors included were:
gender (measured as either male or female), ‘other’ psy-
chopathology (internalizing, externalizing, attention
problems) and poverty [6,17,18]. The poverty measure
was created by averaging income data collected up to the
5-year follow-up and consists of three levels: ‘consistent
poverty’, ‘mid-income’ and ‘consistent mid- to high-
income’. Mothers were asked about their total gross
annual household income (including spouse’s income,
child endowment, etc.) during pregnancy (average 1/4 18
weeks’ gestation), when the child was aged 6 months,
5 years and 14 years. There were seven discrete income
categories as response options (listed in weekly and
annual amounts). At each phase family income was clas-
sified into two categories, with the 25th percentile being
the cut-off for low income. A composite variable was
created by adding the number of times the family had
experienced poverty.
Potential maternal confounding factors includedwere
smoking [19–21], anxiety and depression [22] and
partner changes [7]. Measures of these were taken from
the mothers’ data at the 5- and 14-year follow-ups. At
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each time-period mothers’ responses to whether they
smoked were coded into ‘smoking’ or ‘not smoking’.
Maternal anxiety and depression were measured using
the Delusions–Symptoms–States–Inventory (DSSI)
[23,25]. In this study the Cronbach’s a coefficient at
5-year follow-up was 0.835 for anxiety and 0.856 for
depression; and at 14-year follow-up the Cronbach’s a
coefficient was 0.845 for anxiety and 0.877 for depres-
sion. Categorical variables for anxiety and depression
were then created with ‘nil’, ‘some symptoms’ and ‘many
symptoms’. Maternal marital status changes were
obtained at two points in time, at the 5- and 14-year
follow-ups. At both data collection time-points, new vari-
ables were also created of ‘nil partner change’, ‘one’ and
‘two plus partner changes’.
Statistical analyses
Analysis is restricted to children who could be located at
all three time-periods and for whom there were data on
tobacco smoking status at 14 and 21 years of age. Unad-
justed results are presented along with adjustment for
(i) psychopathology exposures (i.e. internalizing, exter-
nalizing, attention problems) and (ii) selected child and
maternal characteristics, as described above. The 90th
percentile served as the cut-off for psychopathology
exposure, a cut-off mentioned by Achenbach for research
purposes [26].
The a priori hypothesis was that there is an associa-
tion between prior psychopathology and tobacco
smoking. Analysis of predictors of smoking at age 14was
carried out using a modified Poisson regression approach
[27] to obtain estimates of relative risk associated with a
behaviour problem at age 5 and 14 years, after adjusting
for other behaviour problems at the same time, and then
adjusting for potential confounding variables. Repeated-
measures Poisson models, using generalized estimating
equations (GEE), were used to obtain relative risks
for behaviour at ages 5, 14 and 21 and smoking at 21.
Finally, the Poisson model was used to analyse nicotine
dependence at age 21, with a similar process for adjust-
ments for other behaviour and covariates.
RESULTS
Table 1 presents child behaviour psychopathology at 5
and 14 years and the relative risk of tobacco smoking at
the 14-year follow-up. Children who met the criteria for
externalizing at the 5- and 14-year follow-ups were more
likely to be smokers at the 14-year follow-up. The very
strong association between externalizing behaviour at 14
years and smoking at 14 years emphasizes the degree
to which it is proximate externalizing behaviour that
is important in the onset of smoking. This association
remained after adjustment for the other psychopathology
and potential confounders. Curiously, internalizing
behaviours at 5 years were associated with a reduced rate
of smoking at 14 years after adjustment for other psy-
chopathology and potential confounders. There was a
weaker association between attention problems at the
14-year follow-up and smoking at that same age.
Table 2 provides details of the association between
psychopathology over the early life course and tobacco
smoking at the 21-year follow-up. Internalizing behav-
iour (anxiety/depression) at the 14-year follow-up
predicts subsequent smoking independently, with those
anxious/depressed at the 14-year follow-up least likely to
become smokers. By contrast, externalizing behaviour at
the 5- and 21-year follow-ups was associated with an
increased rate of smoking behaviour at the 21-year
follow-up. Attention problems at the 14-year follow-up
also predicted subsequent smoking, but the association is
best characterized as statistically significant but weak.
Table 1 Psychopathology at 5 [Achenbach’s Child Behaviour Checklist (CBCL)] and 14 [Youth Self Report (YSR)] years and tobacco
smoking at 14 years’ follow-up.
Type of
psychopathology
Psychopathology
Unadjusted RR
(95% CI)
Adjusteda RR
(95% CI)
Adjustedb RR
(95% CI)
Age of
resp
Non-cases Cases
Number % Smokers Number % Smokers
Internalizing 5 3392 10.7 432 9.7 0.91 (0.67, 1.23) 0.70 (0.50, 0.99) 0.70 (0.50, 0.96)
14 3498 9.3 327 24.8 2.67 (2.16, 3.32) 1.19 (0.94, 1.51) 1.09 (0.86, 1.37)
Externalizing 5 3426 9.9 399 16.5 1.67 (1.31, 2.13) 1.74 (1.32, 2.29) 1.54 (1.17, 2.02)
14 3444 7.1 381 42.0 5.90 (4.99, 6.99) 4.85 (3.92, 5.98) 4.06 (3.28, 5.04)
Attention problems 5 3360 10.2 465 13.1 1.28 (0.99, 1.65) 1.16 (0.85, 1.58) 1.09 (0.80, 1.49)
14 3496 8.7 329 30.7 3.53 (2.91, 4.29) 1.43 (1.12, 1.82) 1.44 (1.14, 1.81)
aAdjusted for other psychopathology (internalizing, aggression and attention problems) at the same time. bAdjusted for other psychopathology
(internalizing, aggression and attention problems) at the same time, gender, poverty, maternal smoking, depression, anxiety and marital change at 14
years. Relative risk (RR): 95% confidence interval (CI). Bold type indicates a significant result.
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Overall, while there were some early life predictors of
smoking, none were very strong and the association with
internalizing behaviour was an inverse association, while
the externalizing and attention problems association
were in the positive direction.
Table 3 examines the extent to which psychopathol-
ogy is associated with nicotine dependence at the 21-year
follow-up. Internalizing behaviour does not predict, nor
does it appear to be associated with, the diagnosis of ever
having experienced a nicotine disorder. Externalizing
behaviour is associated with a diagnosis of nicotine dis-
order, but only if the externalizing behaviour is measured
at the 21-year follow-up. This is a strong association.
Finally, attention problems at 14 and 21 years both
predict the diagnosis of nicotine disorder by the 21-year
follow-up. These are strong associations.
DISCUSSION
In this study, three early life course predictors of subse-
quent tobacco smoking and nicotine dependence, inter-
nalizing (anxiety/depression), externalizing (aggression/
delinquency) and attention problems have been
examined. A number of possible covariates have also
been accounted for in the analyses. We have found that
some psychopathology behaviours predict later onset of
Table 2 Psychopathology at 5 [Achenbach’s Child Behaviour Checklist (CBCL)], 14 [Youth Self Report (YSR)] and 21 [Young Adult
Self Report (YASR)] years and tobacco smoking at 21 years’ follow-up.
Type of
psychopathology
Psychopathology Tobacco smoking at 21 years
Age of
resp
Non-cases Cases
Unadjusted RR
(95% CI)
Adjusteda RR
(95% CI)
Adjustedb RR
(95% CI)Number % Smokers Number % Smokers
Internalizing 5 2425 34.1 301 35.6 1.02 (0.87, 1.20) 0.93 (0.78, 1.10) 0.91 (0.77, 1.08)
14 2468 33.5 258 41.5 1.19 (1.02, 1.40) 0.81 (0.68, 0.97) 0.77 (0.65, 0.92)
21 2478 33.5 248 41.9 1.20 (1.02, 1.42) 0.97 (0.81, 1.16) 0.97 (0.82, 1.15)
Externalizing 5 2444 33.2 282 43.6 1.19 (1.03, 1.37) 1.20 (1.03, 1.40) 1.19 (1.02, 1.38)
14 2489 32.3 237 55.3 1.48 (1.29, 1.69) 1.29 (1.10, 1.51) 1.15 (0.99, 1.34)
21 2495 31.7 231 62.3 1.77 (1.57, 2.01) 1.70 (1.48, 1.95) 1.61 (1.40, 1.85)
Attention
problems
5 2416 33.8 310 38.1 1.06 (0.91, 1.24) 0.99 (0.83, 1.17) 0.97 (0.82,1.14)
14 2503 32.4 223 55.1 1.61 (1.41, 1.84) 1.20 (1.01, 1.41) 1.17 (1.00, 1.38)
21 2428 32.7 298 46.4 1.31 (1.15, 1.51) 1.11 (0.95, 1.29) 11.16 (0.99, 1.35)
aAdjusted for other psychopathology (internalizing, aggression and attention problems) at the same time. bAdjusted for other psychopathology (inter-
nalizing, aggression and attention problems) at the same time, family poverty, maternal smoking, maternal depression and anxiety and marital changes
by 14 years. Relative risk (RR): 95% confidence interval (CI). Bold type indicates a significant result.
Table 3 Psychopathology at 5 [Achenbach’s Child Behaviour Checklist (CBCL)], 14 [Youth Self Report (YSR)] and 21 [Young Adult
Self Report (YASR)] years and nicotine disorder [Composite International Diagnostic Interview (CIDI)] at 21 years’ follow-up.
Type of
psychopathology
Psychopathology Nicotine disorder by 21 years
Age of
resp
Non-Cases Cases
Unadjusted RR
(95% CI)
Adjusteda RR
(95% CI)
Adjustedb RR
(95% CI)Number % Smokers Number % Smokers
Internalizing 5 1516 11.0 176 7.4 0.67 (0.39, 1.16) 0.65 (0.37, 1.15) 0.65 (0.37, 1.14)
14 1550 10.5 142 11.3 1.07 (0.66, 1.74) 0.83 (0.47, 1.46) 0.77 (0.44, 1.34)
21 1556 10.2 136 15.4 1.52 (1.00, 2.31) 0.92 (0.60, 1.40) 0.83 (0.53, 1.29)
Externalizing 5 1518 10.3 174 12.6 1.22 (0.81, 1.86) 1.51 (0.96, 2.38) 1.54 (0.98, 2.42)
14 1596 10.5 96 12.5 1.19 (0.69, 2.07) 0.89 (0.49, 1.64) 0.89 (0.48, 1.64)
21 1565 9.1 127 28.3 3.10 (2.26, 4.26) 2.47 (1.70, 3.60) 2.39 (1.61, 3.57)
Attention
problems
5 1513 10.8 179 8.4 0.77 (0.47, 1.28) 0.74 (0.41, 1.31) 0.71 (0.40, 1.24)
14 1580 9.9 112 20.5 2.08 (1.40, 3.08) 2.27 (1.43, 3.62) 2.18 (1.36, 3.51)
21 1514 9.2 178 22.5 2.45 (1.79, 3.36) 1.83 (1.26, 2.66) 1.94 (1.33, 2.85)
aAdjusted for other psychopathology (internalizing, aggression and attention problems) at the same time. bAdjusted for other psychopathology (inter-
nalizing, aggression and attention problems) at the same time, family poverty, maternal smoking, maternal depression and anxiety and marital changes
by 14 years. Relative risk (RR): 95% confidence interval (CI). Bold type indicates a significant result.
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tobacco smoking and nicotine dependence in adolescence
and young adults, suggesting that some dimensions of
mental health predict subsequent tobacco smoking and
nicotine dependence.
‘Internalizing’ behaviours are linked to social deficits,
expressed as interacting in a submissive and inhibited
way, poor interaction with peers, social isolation and
low self-concept [28,29].Whereas others have concluded
that depression is associated positively with tobacco
smoking [24,31–34,41], this study found that internal-
izing (anxiety/depression) behaviours were associated
with a reduced likelihood of the subsequent uptake of
tobacco smoking in children and adolescents, but only
after adjustment for other measures of psychopathology.
‘Externalizing’ behaviours are linked with social
aggression, disruptive behaviour, a perceived lack of con-
straint [42] and risky behaviours [35,43]. Consistent
with other studies, our study found that that externaliz-
ing behaviour predicts tobacco smoking [37,43–45].
Moolchan et al. [43] also found that higher CBCL exter-
nalizing behaviour scores are associated with the later
onset of smoking initiation and may also increase
tobacco dependence severity. Leff et al. [45], in a sample of
‘youths at risk’, found that externalizing behavioural
symptoms were associated with age of tobacco initiation.
Ferdinand et al. [44], in a prospective follow-up study of
10–14-year-olds (n = 787) from the Dutch general popu-
lation, found that higher YSR delinquent behaviour
scores predicted later tobacco smoking.
‘Attention’ problems is a ‘mixed syndrome’ of social
problems, attention problems and thought problems
related to both externalizing and internalizing symptoms
[47,48]. After adjustment for covariates, attention prob-
lems were associated with tobacco smoking, but it was
more apparent with nicotine dependence both in adoles-
cence and in young adulthood.
The strongest associations were for externalizing,
attention problems and nicotine dependence at the
21-year follow-up. This cumulative effect may be bidirec-
tional [5]. Nicotine dependence and psychopathology
may reinforce each other, worsening both conditions.
The co-occurrences of externalizing and nicotine depen-
dence and of attention problems and nicotine depen-
dence at the 21-year follow-up suggests that common
underlying core psychopathological processes are
involved [38,49]. This is biologically plausible. External-
izing disorders have been found to co-occur with alcohol
and other drugs misuse [39,40], and attention problems
are a mixed syndrome. Research is required on how and
why this may occur [50] and its implications for preven-
tion in at-risk children and adolescents.
This study has several strengths. First, the data are
from a longitudinal study that recruited participants pro-
spectively during the antenatal period. This has enabled
key aspects of participant lives to be measured prior to
the onset of smoking behaviour. Secondly, standard
measures were used, such as the CIDI-Auto to measure
nicotine dependence.
In this study we have used GEE. GEE has several
benefits for longitudinal research. First, it accounts for
missing observations, so that all participants are always
nominally included in the analysis [51]. A further chal-
lenge in longitudinal studies is accounting for ‘time’, in
particular the difficulty of including the timing of indica-
tor events in relation to changes in diagnostic status [52].
There are several potential limitations to the study.
CBCL responses at 5-year follow-up were provided by the
participant’s mothers and are based on their perceptions
of their child’s behaviours. However, the CBCL as admin-
istered to mothers and significant others in a child’s life
is considered to be a reliable measure of childhood psy-
chopathology [47]. Although this study used a modified
CBCL at 5-year follow-up, this measure was found to have
good reliability and internal consistency. Data were not
collected on paternal smoking.
Loss to follow-up is a consistent problem with cohort
studies. At the 21-year follow-up, 53% of the original
birth cohort participated.While attrition is high at the 5-,
14- and 21-year follow-ups, a great deal is known about
the characteristics of those lost to the study. Complete
data are available from recruitment and from after the
child’s birth [53]. In this study, children lost to follow-up
were more likely to be from families with low income at
birth, to have mothers who smoked tobacco throughout
their pregnancy and to have parents with low educa-
tional attainment [20]. Najman et al. [10] has previously
examined participant dropout by 21 years, and found
that participants with higher CBCL total problem scores
at age 5 years and higher anxiety/depression scores on
the YSR at age 14 years were more likely to be lost to
follow-up by 21 years (P < 0.05). However, the results
from sensitivity analyses based on these factors, includ-
ing inverse probability weighting, did not differ from the
unweighted analyses, suggesting that selection bias does
not affect study results substantially [10]. As participants
lost to follow-up may have worse health profiles, esti-
mates of the strength of the relationships found are likely
to be conservative [53].
In this study, tobacco smoking prevalence at the
14-year follow-up (1995–97) was 11.68% in the last
week. At the 21-year follow-up (2001–04) some 36.24%
of the cohort reported having ever smoked tobacco. Data
from the Cancer Council Victoria, which is the most
detailed and consistently available [51], can contextual-
ize this finding. The prevalence of tobacco smoking in
the last week among 14-year-olds in 1996 was 20–24%.
Our study found a much lower rate of tobacco use by
14-year-olds. It is possible that some respondents may
1674 Jane A. Fischer et al.
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have completed their questionnaires in a context where
they may have been concerned that their mother may
have seen some of their answers. It seems plausible that
we have an underestimate of the percentage of smokers
at 14 years of age. The prevalence of having ever smoked
tobacco among 18–24-year-olds in 2001 was 29%, and
in 2004 was 27% [51].
Using a prospective longitudinal analysis of an off-
spring cohort, our findings suggest that some measures
of psychological distress (specifically aggression and
delinquency) and attention problems predict tobacco
smoking. As we found no evidence that anxiety/
depression predict subsequent smoking behaviour, this
suggests that it is smoking which may lead to anxiety/
depression. Manifestation of anxiety and depression
symptoms in tobacco smokers may be an outcome of
smoking. Clearly, childhood and adolescent mental
health and tobacco smoking are intimately intertwined.
Primary prevention efforts targeting the risk of tobacco
smoking among children and adolescents with behav-
ioural problemsmay have some benefits to further reduce
the uptake of smoking.
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CHAPTER SEVEN: CANNABIS USE 
The formal citation for this investigation is: 
FISCHER, J.A., CLAVARINO, A.M., PLOTNIKOVA, M. & NAJMAN, J.M. 2015. Cannabis 
 use and quality of life of adolescents and young adults: findings from an  Australian 
 birth cohort. Journal of Psychoactive Drugs, 47 (2), 107-116.  
 
Box 1: Summary of Chapter Seven: Cannabis Use 
Study 
Purpose 
To describe and to examine the association between quality of life (QOL) 
and cannabis use, between adolescence (14 years of age) and young 
adulthood (21 years of age), in an Australian birth cohort.   
Main 
Variables  
• QOL (happiness and satisfaction) at the 14 and 21 year follow-ups 
• Cannabis: age of onset, frequency at the 14 and 21 year follow-ups 
• Demographic characteristics and depression at the 21 years follow-up. 
Key 
Findings 
• Poor QOL was associated with earlier age of cannabis use 
• Cannabis use was associated with reduced QOL at both the 14 and 21 
year follow-ups.  
Additional 
Information 
Tables 
Table 1 Respondent demographic, cannabis use and quality of life 
characteristics 
Table 2 Associations between demographic characteristics and cannabis 
use and quality of life at the 21 year follow-up (MN Logit) 
(N=3,754) 
Table 3 Quality of life at 14 years and cannabis use commencement by 21 
years follow-up (MN Logit) (N=3,754) 
Table 4 Age of onset cannabis use predicting quality of life at 21 years 
adjusted for pre-existing demographic characteristics and quality 
of life at 14 years (MN Logit with adjustments) (N=3,754) 
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CHAPTER EIGHT: MEDICATIONS  
The current citation for this investigation is: 
 FISCHER, J.A., CLAVARINO, A.M., PLOTNIKOVA, M. & NAJMAN, J.M. Draft. 
Medication use and quality of life of adolescents and young adults: findings from an 
Australian birth cohort.  
 
 
Box 1: Summary of Chapter Eight: Medications 
Study 
Purpose 
To describe & examine the association between QOL (14 & 21 year follow-
ups) & specific over-the-counter & prescribed medications at 21 year follow-
up. 
Main 
Variables 
• QOL (happiness and satisfaction) at 14 & 21 year follow-ups 
• Medications: specific medical and non-medical medications, frequency 
at 21 years follow-up 
•  Children demographic characteristics at 21 year follow-up. 
Key  
Findings 
• Diminished QOL precedes both the medical and non-medical use of 
medications 
• Any medication use (either for medical or non-medical purposes) is 
associated with diminished QOL, especially for non-medical purposes.  
Additional 
Information 
Tables 
Table 1 Medication type and associated respondent characteristics at 21 
years follow-up 
Table 2 QOL (satisfaction & happiness) at 14 years predicting medication 
use at 21 years follow-up 
Table 3 QOL (satisfaction & happiness) and specific type of medication 
use at 21 years follow-up 
Table 4 QOL (satisfaction & happiness) at 21 years predicting medication 
use at 21 years adjusted for happiness & satisfaction at the 14 year 
follow-up 
Table 5 Adjusted QOL (satisfaction & happiness) predicting any 
medication use at 21 year follow-up 
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ABSTRACT 
Aim:  Taking medication to feel better is common behaviour.  However, non-medical use of 
medications is high.  The extent to which prescribed and non-prescribed medication use is 
associated with quality of life (QOL) in young adulthood is unclear. There is a need to know 
whether those with a lower QOL are more likely to be involved in the medical and non-
medical use of medications and whether use is associated with subsequent QOL. 
 
Method:  A prospective longitudinal investigation of QOL associated with medical and non-
medical medication use.  Data is taken from the Mater Misericordiae Hospital and University 
of Queensland Study of Pregnancy and its outcomes (MUSP).  Data from children 
respondents at the 14 and 21 year follow-ups were examined.  At these time points children 
were asked about their QOL, as indicated by happiness and satisfaction, and at the 21 year 
follow-up they were asked about their medical and non-medical use of Ritalin and Dexedrine, 
pain killers, Ventolin, steroids, sedatives and tranquillisers.  Covariates were socio-
demographic characteristics, alcohol, tobacco and cannabis use at the 21 years follow-up.  
 
Results:  Some 62.8% of respondents had used medications as medically indicated only, and 
a further 17.3% had used medications for non-medical purposes.  Diminished QOL at 14 
years predicted any medical and non-medical use of medication at 21 years.  At 21 years a 
lower QOL was associated with any medication use, with lower QOL most profound amongst 
non-medical medication users.  In particular, dissatisfaction was associated with the non-
medical use of: Ritalin or Dexedrine (OR: 4.84, 95%CI: 2.56,27.67), painkillers (OR: 2.2, 
95%CI: 1.56,3.15), Ventolin (OR: 3.01, 95%CI: 1.80,5.03), steroids (OR: 4.40, 95%CI: 
1.32,14.6), sedatives (OR: 4.91, 95%CI: 2.95,8.17) and tranquillisers (OR: 6.41, 95%CI: 
3.10,13.28). 
 
Conclusions:  Poor QOL precedes and is associated with both the medical and non-medical 
use of medications, especially with the use of medications in non-medical ways. Poor QOL is 
also characteristic of users of all medications at the 21-year follow-up. While it is unlikely 
that medication use diminishes the respondents QOL, neither does it appear to materially 
enhance QOL.  
 
Key words: quality of life, medical and non-medical medication use, adolescents, young 
adults, Ritalin, Dexedrine, pain killers, Ventolin, steroids, sedatives, tranquillisers. 
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INTRODUCTION 
Medications are often used with the specific intent of improving the quality of life (QOL) of 
the user (Fischer & Rehm, 2007 ).  Medications are, generally, used to reduce pain, improve 
mobility and enhance daily functioning.  Of late there has been growing concern regarding 
the non-medical use of medications, especially by young adults 18-22 years (Dingle et al., 
2010; Young et al., 2012; Kelly et al., 2013) and the potential  of medications for harm 
(Cooper, 2013; Holloway et al., 2014; Maxwell, 2011; Nicholas et al., 2011).  Despite the 
potential risks, young people may perceive non-medical use of medications as rational 
behaviour intended to improve their QOL.  Whether this objective is achieved is uncertain.  
To date no studies have been conducted on the QOL associated with medication (medical and 
non-medical) use in a population sample.  There is a need to better understand temporal 
patterns in medication use (Young et al., 2012). In particular the QOL of young adult 
medication users and whether young adults with a lower QOL are more likely to use a 
specific type or a wide range of medications, and whether such medication use is associated 
with a better QOL.  
 
According to the 2013 National Drug Strategy Household Survey, 77.9% of Australians aged 
14 years and older have recently used over-the-counter painkillers/analgesics and 50.9% 
prescription painkillers/analgesics for medical purposes (Australian Institute of Health and 
Welfare (AIWH), 2014).  A further 11.4% have ever used medications for non-medical 
purposes and 4.7% in the past year have used medications for non-medical purposes (AIHW, 
2014).  
 
Arguably, taking medications for medical and/or non-medical purposes is normal behaviour.  
Drug use is ordinary (Parker et al., 1998; Parker et al., 2002; Schnuer, 2013), unremarkable 
(Measham & Shiner, 2009) and undertaken by people who make apparently rational 
decisions (Moore & Fraser, 2006).  People use drugs because they enjoy or otherwise benefit 
from some of the effects of use (Hammersley, 2005).  Central to this approach is examining 
use from the perspective of the user (Moore, 2008; O'Malley & Valverde, 2004; Pennay & 
Moore, 2010; Valentine & Fraser, 2008), with lay knowledge at least as important as 
epidemiological data (Hunt et al., 2007).  
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In this study QOL is conceptualised as a judgement encapsulating subjective assessments of 
the positive (happiness and satisfaction) and negative (mental health) aspects of a person’s 
life, that is, their life as a whole, moderated by a range of objective factors, at a given point in 
time (Andrews & Withey, 1976; Campbell et al., 1976; Headey & Wearing, 1992; Ventegodt 
& Merrick, 2003; Verdugo et al., 2005).  Happiness is a measure of short term affect, of how 
much people enjoy their lives (Campbell et al., 1976; Organisation for Economic Co-
operation and Development (OECD), 2013; Radcliff, 2013).  Satisfaction is an assessment of 
broader aspirations, achievements and perceived reality in comparison to peers (Constanza et 
al., 2006; Proctor et al., 2009) and to societal norms (Bowling, 2005; OECD, 2013).  
Investigating QOL in this sense provides a holistic approach to understanding what life is like 
above and beyond the potential benefits and harms associated with medication use. 
 
To date the study into the QOL of adolescents and young adults and medications has largely 
been related to specific health conditions including asthma, diabetes and cancer. Work in this 
area has generally examined the effectiveness and efficacy of medications and interventions 
on the health-related QOL of participants.  By their nature, these studies investigate QOL in 
treatment populations.  In contrast no studies were found which examined QOL associated 
with the use of medications, for medical or non-medical purposes, in community-based 
adolescents and young adults. 
 
The medical use of medications is defined as prescribed use, following prescription by a 
qualified physician or in accordance with stated instructions.  In contrast there is no definitive 
description of medication ‘misuse’, making defining caseness difficult (Larance et al., 2011; 
Nielsen & Bruno, 2011).  Therefore in this study non-medical medication use is defined as 
the use of medications for purposes, or by persons without a prescription, in order to induce 
or improve mood, enhance a drug experience, or for performance enhancement or cosmetic 
purposes (AIWH, 2011).  There is face validity to this definition, which can be considered to 
also include non-adherence to stated instructions (World Health Organization 2004), sharing 
or borrowing (Goldsworthy et al., 2008), or use for intoxicating purposes (Compton & 
Volkow, 2006). Medications may be used not as prescribed, to alleviate real or perceived 
pain (Fischer & Rehm, 2007; Zullig & Divin, 2012).  
 
As with adults generic pain may be indicative of poor QOL (Skevington, 1998).  Medication 
use in this manner by young people may be a means of self-treatment of physical pain 
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(McCabe et al., 2005).  In this case the use of the term ‘misuse’ is semantic.  Several studies 
of life satisfaction and young adults have found that young adults may take extra medications 
for health conditions and ailments without consulting a doctor or other health professional 
(Bogart et al., 2007; Chen et al., 2004; Zullig et al., 2005).  
 
Study Objectives 
This study investigates the QOL of adolescents and young adults who use medications for 
medical and non-medical purpose, with a specific focus on those users who live and function 
in the broader population.  The objectives of this study is to describe the QOL associated with 
the medical and non-medical use of medications and whether poor QOL in adolescence is 
associated with the use of medication for either medical or non-medical medication use in 
young adulthood.  
 
METHODS 
Respondents 
Respondents were the children of women who were recruited at their first antenatal visit at 
the Mater Misericordiae Hospital in Brisbane, Australia.  Between 1981 and 1984 
interviewers approached 8,556 women to participate in the Mater Misericordiae Hospital and 
University of Queensland Study of Pregnancy (MUSP), of which 8458 (98.9%) agreed.  The 
cohort consists of 7,223 women who delivered a live singleton baby who was not adopted 
out. This represents 87% of all women who attended the antenatal clinic during the study 
period (Najman et al., 2008).  Children have been followed-up when they were 3–5 days old, 
6 months old, 5, 14 and 21 years later, with children self-completing questionnaires at the 14 
and 21 year follow-ups.  The sample in this study consists of children cohort respondents who 
completed questionnaires at both the 14 and 21 year follow-ups (N=3,753).  Ethical 
clearances were obtained from the Mater Misericordiae Hospital and The University of 
Queensland Human Research Ethics Committees at all data study stages. 
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Measures 
Medications:  At the 21 years follow-up respondents were asked “during the last 12 months 
how often have you used the following for non-medical purposes”?  For each medication 
(Ritalin and Dexedrine, painkillers like Panadol and codeine, Ventolin, steroids, sedatives 
like sleeping pills, barbiturates or downers, tranquillisers like valium, rohypnol or mogodon) 
possible response options were: used only for medical purposes, have never used at all, not 
used during the past year, a few times during the year, a few times a month, a few times a 
week.  Nearly twenty per cent (19.9%) had not used any medications, 62.8% had used a 
medication for medical purposes only, 13.0% had used one or more without medical intent, 
and 4.3% had used for both medical and non-medical intent.  For analyses purposes the latter 
two categories were merged.  The following three categories were therefore created: no use 
(never used medications), medical use only (use for medical purposes only) and non-medical 
use (use for medical and non-medical purposes).  
 
Quality of life:  Satisfaction and happiness were used in this study as indicators of QOL and 
were assessed at both the 14 and 21 year follow-ups.  Satisfaction was measured by asking 
respondents: “how satisfied are you with your life as a whole these days?  What would you 
say you are…?” (very satisfied, satisfied, dissatisfied).  Similarly happiness was measured by 
asking respondents: “how would you say you feel these days? would you say you are …” 
(very happy, fairly happy, unhappy).   
 
Demographic characteristics:  These were reported at the 21 year follow-up and comprised: 
gender (male, female), main job last week (wage-salary earner, business, unpaid, no job), 
government benefits in last 12 months (yes/no), highest level of education completed (year 
ten, secondary, post-secondary), current education (none, university, other), living 
arrangements (with parents, rent, other) and boy/girlfriend (yes, no). 
 
Alcohol, tobacco and cannabis use:  The following drug use variables from the 14 and 21 
year follow-ups were also included in analyses: current smoker (yes, no), frequency of 
alcohol consumption (never, rarely/sometimes, frequently) and use of cannabis in the past 
month (never, sometimes, frequently).  
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Statistical Analysis 
Analyses are restricted to children who were located and had responded to the happiness, 
satisfaction questions at the 14 and 21 year follow-ups and the medication questions at the 21 
year follow-ups.  Analyses entailed examining QOL (as indicated by satisfaction and 
happiness) associated with specific types of medication use (i.e. Ritalin and Dexedrine, 
painkillers, Ventolin, steroids, sedatives and tranquillisers) and of any medication use.  
Analyses were undertaken using multinomial logistic regression (Schalock, 2004; Urzua et 
al., 2013; Verdugo et al., 2005).  Data analyses are undertaken with STATA (StataCorp, 
2009). 
 
RESULTS 
Respondent Characteristics 
At the 21 year follow-up 52.6% of respondents were female (male:47.4%), Three-quarters of 
respondents (74.7%) were wage/salary earners (business: 1.9%, unpaid: 2.1%, no job: 
21.4%), 52.7% had completed secondary school (post-secondary: 26.2%, year 10 or lower: 
21.2%), most (49.8%) lived with their parents (rented: 31.2%, other: 9.0%) and had a boy or 
girl friend (54.6%).  About a third of respondents (35.7%) had received government benefits 
in the past 12 months and/or were currently in education (university: 20.7%, other: 14.4%) 
(Table not shown). 
 
Many respondents had used medications alcohol, tobacco and cannabis at the 21 years 
follow-up.  Eight in ten (80.1%) respondents had used any of medications listed (medical 
only: 62.8%, non-medical: 17.3%).  Most respondents had consumed alcohol (frequently: 
32.8%, sometimes: 49.3%, never/rarely: 17.9%), half were either former or current tobacco 
smokers (12.3% and 37.7%, respectively) and had used cannabis in the past month 
(sometimes: 37.5%, frequently: 12.4%) (Table not shown). 
 
Most respondents at the 21 years follow-up gauged that they were satisfied (61.4%, very 
satisfied: 26.6%, dissatisfied: 11.9%) and happy (50.2%, very happy: 31.5%, unhappy: 8.3%) 
(Table not shown). 
 
The use of any of the medications examined was significantly associated with gender and 
with highest education obtained (Table 1).  In particular the non-medical use of Ritalin and 
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Dexedrine, painkillers, Ventolin and tranquillisers was significantly associated with having 
completed year 10 or lower.  None of the medications examined were associated with 
employment, receiving government benefits, although there was a significant association 
between sedatives for non-medical purposes and being in receipt of government benefits. 
 
[insert Table 1 about here] 
 
QOL and Specific Medication Use 
Table 2 examines QOL at 14 years and subsequent medication use at 21 years.  A lower 
QOL, particularly dissatisfaction at 14 years, was significantly associated with the non-
medical use of the following medications at 21 years: Ritalin or Dexedrine (OR: 2.26, 
95%CI:1.01-5.06), painkillers (OR: 2.40, 95%CI: 1.32-4.37), Ventolin (OR: 2.82 , 95%CI: 
1.44-5.53), steroids (OR: 4.09, 95%CI: 1.09-15.44) and sedatives (OR: 2.18, 95%CI: 1.11-
4.27).  Dissatisfaction at 14 years also seemed to predict the medical use of Ventolin at 21 
years (OR: 1.56, 95%CI: 1.05-2.32) whereas unhappiness at 14 years seemed to predict the 
subsequent medical use of sedatives (OR: 95%, CI: 1.05-2.64) and tranquillisers (OR: 1.83, 
95%CI: 1.00-3.33) at 21 years. 
 
[insert Table 2 about here] 
 
The association at 21 years between QOL and the use of specific medications was then 
considered (Table 3).  At 21 years there is a strong and consistent association between lower 
QOL and the medical and non-medical use of all medications examined, especially for 
sedatives and tranquillisers.  For example, respondents who had used sedatives at 21 years for 
medical purposes were three times more likely to be dissatisfied and three and half times 
more likely to be unhappy than respondents who had not used sedatives; and respondents 
who had used sedatives for non-medical purposes were four times more likely to be 
dissatisfied than those who had not used sedatives.   
 
[insert Table 3 about here] 
 
To determine whether the association between QOL and specific medications were possibly 
attributable to QOL prior to medication use, we then adjusted for QOL (satisfaction and 
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happiness) at 14 years (Table 4).  A strong and persistent association was evident, particularly 
for the non-medical medication use of sedatives, tranquillisers and steroids. 
 
[insert Table 4 about here] 
 
QOL and Any Medication Use 
Table 5 examines the QOL of those who use medications at 21 year follow-up, with 
adjustment for QOL at 14 years (adj 1) and covariates (adj 2).  QOL of life at 21 predicts 
medication use, particularly non-medical medication use (unadj).  The results were then 
adjusted for QOL at 14 years and socio-demographic characteristics at 21 years (gender, 
occupation, benefits, education, tobacco smoking, alcohol and cannabis use at 21 years 
follow-up).  The relationship was only slightly attenuated – young adults who were 
dissatisfied were still more likely to use any medication for medical or non-medical purposes.  
In particular young adults who were dissatisfied were two and half times and if unhappy 
twice as likely to use any medication for non-medical purposes.  
 
[insert Table 5 about here] 
 
DISCUSSION 
The purpose of this study was to examine the association between QOL and the medical and 
non-medical use of specific and of any medications by adolescents and young adults.  We 
believe that this is the first study to examine in a prospective cohort of children QOL 
associated with medication use.  This study found that lower QOL was associated with any 
use of medications and especially the use of medications for non-medical purposes.   
 
Lower QOL at 14 years seemed to predict any medication use in young adulthood.  This 
suggests that the medical and also the non-medical use of medications may be a manifestation 
of self-medication generally.  Poor QOL in childhood appears to initiate later risky 
behaviours and problems (Fischer et al., 2014).  However, of greater concern is the finding 
that, despite use of a wide variety of medications, the QOL of users remains very low.  While 
medications may alleviate symptoms it is clear that the QOL of users who use these 
medications remains low.  One interpretation of these findings is that young persons with a 
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low QOL at 14 years have a poor QOL trajectory.  They use medications to improve their 
mood but with apparent limited success. 
 
This study suggests that the QOL associated with the quality use of any medications in this 
population should be a concern.  Until recently young adults have largely been excluded from 
national strategies on the quality use of medicines (QUM) (e.g. Australian National 
Pharmaceutical Misuse Strategy 2013).  Arguably current statements on the QUM can be 
considered historical, however they are still what we use.  In Australia, the National Strategy 
on the Quality use of Medicines recognises the primacy of consumers in reducing the 
potential harm from medication misuse (Commonwealth of Australia, 2002); yet young 
adults are not identified as a group at risk.  Similarly a review of medication safety in the 
community (Easton et al., 2009) also omitted medication safety amongst adolescents and 
young adults.  The findings in this study point to the need to better understand the individual 
and societal contexts in which young adults are motivated to take medications for medical 
and for non-medical purposes.  
 
There is a need to better manage adolescent and young adult expectations (Wright et al., 
2006) and to develop safer norms of what medications can and cannot do to enhance their 
QOL.  Young adult assessments of how satisfied they are with their life have been found to 
be associated with health promoting behaviours (Zullig et al., 2005; Grant et al., 2009).  One 
possibility is to develop interventions on based on young adults’ wellbeing and self-care.  For 
example a British study that involved trialling a universal intervention found it was 
associated with reduced prescription drug misuse among adolescents and young adults (Spoth 
et al., 2008).  In this way using medications to reduce pain or to feel better is undertaken in 
ways in which the potential for ‘misuse’ may be limited or prevented. 
 
Limitations 
Several limitations to this study are recognised.  Increasingly there is some consensus that 
subjective QOL has three common dimensions: hedonic (measured as happiness), evaluation 
(measured as satisfaction) and eudemonic (a sense of purpose) (National Research Council 
2013; OECD 2013).  In this study only the first two indicators of QOL, happiness and 
satisfaction, were examined.  Although omitting a eudemonic measure is a weakness of this 
study, happiness and satisfaction measures have considerable face validity and their use is 
consistent with the existent research on alcohol use and subjective QOL amongst youth 
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(Bogart et al., 2007; Mason & Spoth, 2011; Swain et al., 2012).  Likert scales (Constanza et 
al., 2006; Diener, Inglehart, & Tay, 2013), including single-item ten point scales have been 
recommended to measure subjective QOL (e.g. (National Research Council, 2013; OECD, 
2013).  This type of measurement enables more precise individual assessments.  In this study 
however happiness and satisfaction were used as a 3-point scale, consistent with the work of 
Campbell and colleagues (1976).  
 
Detailed medication dosage was not recorded in this study.  Such data would have provided 
more precise findings on the dose-response relationship between QOL and medical and non-
medical use of medications.  It remains uncertain how closely QOL and medical and non-
medical use of medications correlate; and whether QOL assessments are the consequence of 
large quantities of medications infrequently taken or small amounts taken regularly. 
 
Loss to follow-up is a consistent problem with cohort studies.  In this study children lost to 
follow-up were likely to be from families with low income at birth, to have mothers who 
smoked tobacco throughout their pregnancy and to have parents with low educational 
attainment (Mamun et al., 2006).  Najman and colleagues (2008) has previously examined 
participant drop out by 21 years, and found that that participants with higher CBCL total 
problem scores at age 5 years and higher anxiety/depression scores on the YSR at age 14 
years, were more likely to be lost to follow-up by 21 years (p <0.05).  However, the results 
from sensitivity analyses based on these factors, including inverse probability weighting, did 
not differ from the unweighted analyses, suggesting that selection bias does not substantially 
affect study results. 
 
Conclusion 
Young adults with a poor QOL are significantly more likely to use medications and are at risk 
of extra-medical use of medications.  Medication use seems to be associated with a loser 
QOL in young adulthood.  National strategies addressing the quality use of medicines need to 
address the use of medications by adolescents and young adults, so that the normal use of 
medication entails minimising harm associated with that use.  Distressed persons are using a 
wide variety of medications to reduce their distress, but there is little reason to believe that 
this medication use is leading to the desired outcome.  
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TABLES 
Table 1: Medication type and associated respondent characteristics at 21 years follow-up 
Medication Type 
Respondent Characteristic 
% 
Gender Main job Highest Education Government Benefit 
Male Female Wage-salary earner No job Other > Year 10 
Completed 
secondary 
Post 
secondary Yes No 
Ritalin or 
Dexedrine 
Never used 90.8 94.3 92.9 91.7 93.9 88.6 93.6 93.9 91.1 93 
Medical use only 3.9 2.5 3.3 3.1 0.7 5.2 2.5 3 3.2 3.2 
Non-medical use 5.3 3.1 3.8 5.2 5.4 6.2 3.9 3.2 4.9 3.8 
Test Statistic χ2 = 17.454 p < .001 χ2 = 6.540 p = 0.162 χ2 = 24.657 p < .001 χ2 = 2.595 p = 0.273 
Painkillers 
Never used 26.9 16.7 22.1 19.3 20.4 22.6 20.9 21.8 19.8 22.1 
Medical use only 55.6 67.9 61.7 63.3 63.9 57.3 64.5 61.1 62.6 62.1 
Non-medical use 17.5 15.5 16.2 17.3 15.6 20.2 14.6 17.1 17.7 15.8 
Test Statistic χ2 =  70.255 p < .001 χ2 = 3.097 p = 0.542 χ2 = 16.722 p = 0.002 χ2 = 3.831 p = 0.147 
Ventolin 
Never used 74.4 67.9 71.4 69.6 67.3 65.8 72.8 71.4 68.5 72.1 
Medical use only 20 26.4 23.1 24.2 26.5 26.3 22 23.9 25.1 22.5 
Non-medical use 5.6 5.8 5.5 6.2 6.1 8 5.2 4.7 6.3 5.4 
Test Statistic χ2 =  21.782 p < 0.001 χ2 = 2.149 p = 0.708 χ2 = 17.987 p = 0.001 χ2 = 5.162 p = 0.076 
Steroids 
Never used 94.4 92.8 93.6 93.6 92.5 91.6 93.7 94.9 93.6 93.6 
Medical use only 3.4 5.3 4.3 4.3 5.4 5.6 4.2 3.9 4.2 4.5 
Non-medical use 2.2 1.9 2 2 2 2.8 2.1 1.2 2.2 1.9 
Test Statistic χ2 =  7.890 p = 0.019 χ2 =.414 p = 0.981 χ2 = 9.153 p = 0.057 χ2 =.454 p = 0.797 
Sedatives 
Never used 88.2 83.7 86.8 83.2 82.9 83.4 86.6 83.6 82.9 87.4 
Medical use only 6 9.4 7.3 9.1 8.2 8.5 7.7 7.5 8.8 7.4 
Non-medical use 5.7 6.9 5.8 7.7 8.9 8.1 5.7 6.2 8.4 5.3 
Test Statistic χ2 =  18.107 p < .001 χ2 = 8.616 p = 0.071 χ2 = 6.288 p = 0.179 χ2 = 16.905 p < 0.001 
Tranquillisers 
Never used 91 91.6 92 89.7 88.4 87.1 92.3 92.6 90.2 92 
Medical use only 3.5 4.4 3.7 4.4 4.8 5 3.7 3.7 4 3.9 
Non-medical use 5.5 4 4.3 5.8 6.8 7.9 4.1 3.7 5.8 4.1 
Test Statistic χ2 =  5.861 p = 0.053 χ2 = 5.979 p = 0.201 χ2 = 24.651 p < .001 χ2 = 5.668 p = 0.059 
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Table 2: QOL (satisfaction/happiness) at 14 years predicting medication use at 21 years follow-up 
Medication Use 
At 21 years Follow-up 
QOL at 14 Years Follow-up 
95%CI 
Satisfaction Happiness 
Very 
satisfied Satisfied Dissatisfied 
Very 
Happy Happy Unhappy 
Ritalin or  
Dexedrine 
Not used 1 1 1 1 1 1 
Medical use only 1 0.93  (0.57,1.50) 
0.80  
(0.28,2.34) 1 
0.68 
(0.41,1.13) 
1.03 
(0.53,2.01) 
Non-medical use 1 1.38  (0.83,2.30) 
2.26  
(1.01,5.06) 1 
1.09 
(0.65,1.84) 
1.56 
(0.81,3.02) 
Pain killers 
Not used 1 1 1 1 1 1 
Medical use only 1 1.11 (0.90,1.37) 
1.58  
(0.97,2.57) 1 
1.00 
(0.79,1.25) 
0.95 
(0.69,1.32) 
Non-medical use 1 1.37  (1.02,1.84) 
2.40  
(1.32,4.37) 1 
1.09 
(0.80,1.49) 
1.35 
(0.88,2.06) 
Ventolin 
Not used 1 1 1 1 1 1 
Medical use only 1 1.01  (0.82,1.25) 
1.56 
(1.05,2.32) 1 
0.86 
(0.69,1.08) 
1.23 
(0.91,1.65) 
Non-medical use 1 1.20  (0.78,1.86) 
2.82  
(1.44,5.53) 1 
0.74 
(0.48,1.14) 
1.54 
(0.90,2.64) 
Steroids 
Not used 1 1 1 1 1 1 
Medical use only 1 1.16  (0.74,1.80) 
1.83 
(0.87,3.85) 1 
0.77 
(0.49,1.22) 
1.69 
(0.09,2.92) 
Non-medical use 1 2.25  (0.86,5.89) 
4.09  
(1.09,15.44) 1 
0.86 
(0.37,2.00) 
2.12 
(0.81,5.56) 
Sedatives 
Not used 1 1 1 1 1 1 
Medical use only 1 1.25  (0.89,1.75) 
1.72  
(0.95,3.11) 1 
1.20 
(0.83,1.72) 
1.67 
(1.05,2.64) 
Non-medical use 1 1.30  (0.86,1.96) 
2.18 
(1.11,4.27) 1 
0.93 
(0.61,1.41) 
1.48 
(0.87,2.51) 
Tranquillisers 
Not used 1 1 1 1 1 1 
Medical use only 1 1.26  (0.78,2.02) 
1.95 
(0.89,4.29) 1 
0.98 
(0.60,1.61) 
1.83 
(1.00,3.33) 
Non-medical use 1 1.31  (0.82,2.10) 
1.95  
(0.89,4.49) 1 
0.99 
(0.61,1.61) 
1.67 
(0.92,3.05) 
Bold is significant 
142 
 
Table 3: QOL (satisfaction/happiness) and specific type of medication use at the 21 years follow-up 
Medication Use at 21 Years Follow-up QOL at 21 Years Follow-up 
95%CI 
Satisfaction Happiness 
Very 
satisfied Satisfied Dissatisfied 
Very 
Happy Happy Unhappy 
Ritalin or 
Dexedrine 
Not used 1 1 1 1 1 1 
Medical use only 1 0.95  (0.62,1.46) 
1.65  
(0.93,2.90) 1 
0.98 
(0.65,1.48) 
1.82 
(1.00,3.33) 
Non-medical use 1 2.39  (1.46,3.93) 
4.35  
(2.45,7.71) 1 
1.80 
(1.20,2.70) 
2.65 
(1.48,4.71) 
Painkillers Not used 1 1 1 1 1 1 
Medical use only 1 1.13  (0.94,1.36) 
1.49  
(1.10,2.00) 1 
1.21 
(1.02,1.44) 
1.42 
(1.02,1.98) 
Non-medical use 1 1.33  (1.04,1.71) 
2.02  
(1.39,2.93) 1 
1.35 
(1.07,1.70) 
1.90 
(1.26,2.86) 
Ventolin Not used 1 1 1 1 1 1 
Medical use only 1 1.21  (1.01,1.45) 
1.55  
(1.19,2.01) 1 
1.20 
(1.00,1.41) 
1.61 
(1.21,2.15) 
Non-medical use 1 1.32  (0.93,1.90) 
2.64  
(1.70,4.11) 1 
1.48 
(1.06,2.07) 
2.56 
(1.57,4.16) 
Steroids Not used 1 1 1 1 1 1 
Medical use only 1 1.41  (1.94,2.12) 
2.15  
(1.28,3.60) 1 
1.00 
(0.70,1.42) 
2.04 
(1.23,3.38) 
Non-medical use 1 1.74  (0.92,3.30) 
3.16  
(1.48,6.74) 1 
1.81 
(1.01,3.23) 
2.44 
(1.06,5.64) 
Sedatives Not used 1 1 1 1 1 1 
Medical use only 1 1.49  (1.09,2.04) 
3.07  
(2.08,4.53) 1 
1.38 
(1.03,1.84) 
3.48 
(2.34,5.18) 
Non-medical use 1 1.50  (1.04,2.14) 
4.04  
(1.04,2.14) 1 
1.47 
(1.06,2.04) 
1.47 
(1.06.2.04) 
Tranquillisers Not used 1 1 1 1 1 1 
Medical use only 1 1.47  (0.95,2.28) 
2.96  
(1.74,5.02) 1 
1.19 
(0.80,1.77) 
3.43 
(2.06,5.71) 
Non-medical use 1 1.63  (1.06,2.52) 
4.77  
(2.94,7.73) 1 
1.84 
(1.23,2.74) 
5.10 
(3.10,8.37) 
Bold is significant 
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Table 4: QOL (satisfaction & happiness) at 21 years predicting medication use at 21 years adjusted 
for happiness & satisfaction at the 14 year follow-up 
Adjusted Medication Use at 21 
Years Follow-up  
QOL at 21 Years Follow-up 
Satisfaction Happiness 
Very 
Satisfied 
Satisfied Dissatisfied Very 
Happy 
Happy Unhappy 
Ritalin or  
Dexedrine 
Not used 1 1 1 1 1 1 
Medical use only 1 0.98 (0.47,2.04) 
1.90 
(0.73,4.96) 1 
0.99 
(0.51,1.93) 
1.87 
(0.68,5.12) 
Non-medical use 1 3.68 (1.23,10.97) 
4.84 
(2.56,27.67) 1 
2.22 
(1.04,4.74) 
3.77 
(1.36,10.43) 
Pain killers Not used 1 1 1 1 1 1 
Medical use only 1 1.101 (0.85,1.19) 
1.40 
(1.06,1.84) 1 
1.16 
(0.86,1.58) 
1.38 
(0.75,2.52) 
Non-medical use 1 1.29 (1.02,1.64) 
2.21 
(1.56,3.15) 1 
1.35 
(0.88,2.07) 
1.82 
(0.84,3.92) 
Ventolin Not used 1 1 1 1 1 1 
Medical use only 1 1.26  (1.02,1.54) 
1.73  
(1.29,2.31) 1 
1.3 0 
(0.93,1.80) 
1.67 
(0.95,2.94) 
Non-medical use 1 1.14  (0.74,1.76) 
3.01 
(1.80,5.03) 1 
1.53 
(0.76,3.08) 
2.76 
(1.00,7.61) 
Steroids Not used 1 1 1 1 1 1 
Medical use only 1 1.22 (0.71,2.09) 
2.08  
(1.05,4.13) 1 
0.92 
(0.54,1.58) 
1.54 
 (0.67,3.56) 
Non-medical use 1 1.45  (0.48,4.37) 
4.40 
(1.32,14.63) 1 
1.83 
(0.59,5.74) 
3.97 
(0.93,16.93) 
Sedatives Not used 1 1 1 1 1 1 
Medical use only 1 1.19  (0.85,1.65) 
2.66  
(1.76,4.03) 1 
1.24 
(0.81,1.89) 
2.77 
 (1.49,5.14) 
Non-medical use 1 1.59  (1.01,2.48) 
4.91  
(2.95,8.17) 1 
1.72 
(0.98,3.04) 
5.66 
(2.77,11.56) 
Tranquillisers Not used 1 1 1 1 1 1 
Medical use only 1 1.35  (0.76,2.39) 
2.70 
(1.33,5.47) 1 
1.01 
(0.55,1.83) 
2.52 
(1.10,5.74) 
Non-medical use 1 1.93  (1.00,3.76) 
6.41 
(3.10,13.28) 1 
2.41 
(1.17,4.98) 
6.24 
(2.56,15.19) 
Bold is significant 
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Table 5: Adjusted QOL (satisfaction and happiness) predicting any medication use at 21 year follow-up 
Any Medication Use 
at 21 year follow-up 
QOL at 21 Years Follow-up 
Unadjusted Adjustment1 Adjustment2 
Satisfaction Very Satisfied Satisfied Dissatisfied 
Very 
Satisfied Satisfied Dissatisfied 
Very 
Satisfied Satisfied Dissatisfied 
Not used 1 1 1 1 1 1 1 1 1 
Medical use only 1 1.14  (0.95, 1.37) 
1.47  
(1.08, 1.99) 1 
1.03 
(0.90,1.17 
1.32  
(1.06,1.65) 1 
1.11 
(0.92, 1.35) 
1.48 
(1.08, 2.04) 
Non-medical use 1 1.49  (1.16, 1.91) 
2.41  
(1.66, 3.50) 1 
1.45 
(1.21,1.74) 
2.55 
(1.95, 3.35) 1 
1.30 
(1.01, 1.67) 
1.81  
(1.23, 2.66) 
Happiness Very Happy Happy Unhappy 
Very 
Happy Happy Unhappy 
Very 
Happy Happy Unhappy 
Not used 1 1 1 1 1 1 1 1 1 
Medical use only 1 1.15  (0.96, 1.37) 
1.46  
(1.02, 2.08) 1 
1.12 
(0.82,1.53) 
1.37 
(0.73.2.57) 1 
1.15  
(0.96, 1.37) 
1.46  
(0.98, 2.04) 
Non-medical use 1 1.31  (1.04, 1.66) 
2.62  
(1.73, 3.95) 1 
1.22 
(0.88,2.02) 
2.47 
(1.19,5.24) 1 
1.15 
 (0.91, 1.46) 
2.00  
(1.31, 3.05) 
Bold is significant 
1 QOL (happiness and satisfaction) at 14 years follow-up 
2Adjusted for respondents’ gender, occupation, whether on benefits, education, tobacco smoking, alcohol use and cannabis use 
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CHAPTER NINE: OPIOIDS 
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Box 1: Summary of Chapter Nine: Opioids 
Study 
Purpose 
To describe the quality of life (QOL) of people who inject drugs (PWID) and 
to compare with populations with chronic conditions. 
Main 
Variables 
• QOL (WHOQOL-BREF), transformed domain scores (out of 100 each) 
• PWID demographic characteristics and injecting patterns. 
Key 
Finding 
PWID reported reduced QOL compared to populations with chronic 
conditions. 
Additional 
Information 
Tables 
Table 1 Last drug injected, sample and NSP attendee data compared 
Table 2 PWID demographic characteristics, injecting patterns, hepatitis C 
and drug treatment by WHOQOL-BREF domains 
Table 3 WHOQOL-BREF domain scores of PWID sample compared to 
other samples 
Table 4 Compared populations on WHOQOL-BREF mean domain scores 
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Abstract
Purpose To assess the quality of life (QOL) of persons
who inject drugs.
Methods Some 483 current injecting drug users visiting a
large NSP over a 2-week period in October 2009 were
interviewed using a structured questionnaire. QOL was
measured using the WHOQOL-BREF. Data were collected
on age, gender, injecting patterns, current drug treatment
status and hepatitis C status. Participant QOL profiles were
compared to published domain scores for a range of other
population groups.
Results People who inject drugs (PWID) experience a
very poor QOL irrespective of socio-demographic charac-
teristics, injecting patterns, hepatitis C sero-status and drug
treatment status. Sample participants (PWID) experience a
QOL below that experienced by many population groups in
the community affected by disabling chronic illnesses.
Conclusions Injecting drug use is associated with a poor
QOL. Some PWID may be self-medicating for chronic
non-malignant pain, and it is likely that these people had a
low QOL prior to the decision to inject. Despite this caveat,
it remains likely that injecting drug use does little to
enhance the QOL of the user.
Keywords People who inject drugs  Quality of life 
Needle and syringe programme
Introduction
Little is known about the quality of life (QOL) of people
who inject drugs (PWID) [1, 2]. There are negative ste-
reotypes associated with injecting drug use [3–5], and
these may reflect a critical view of persons who self-
medicate in order to attain a positive mood. Recent esti-
mate is that 11–21 million persons globally injected drugs
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[6] and 35.5 % of Australia’s 75,000 PWIDs accessing
sterile injecting equipment from needle and syringe pro-
grammes (NSPs) [7]. There is a prevalent stereotype that
PWID is intended for pleasure and to enhance a drug
users’ QOL. There is a need to test the accuracy of these
stereotypes.
Injecting drug use is a major international public-health
problem [6, 8, 9] and for individuals is associated with
depression [10–12] and comorbidity [13]. However, there
is a dearth of research into the QOL of PWID. In a case–
control study conducted in Ireland, methadone mainte-
nance clients experienced lower health-related QOL than
harm reduction programme clients (N = 72) [14]. In a
comparison of rural and regional PWID (N = 260)
recruited in New South Wales, Australia, few associations
between QOL and injecting or drug use patterns were
found [15]. In a city sample, the QOL of PWID was poor
[13]. More recently, the Personal Wellbeing Index (PWI)
was administered to PWID (N = 881) visiting NSPs across
Australia which found a dose–response relationship
between well-being and injecting drug use, with higher
levels of injecting associated with lower well-being [16].
Substance use, generally, and injecting drug use in
particular are perceived to be activities specifically inten-
ded to enhance the user’s QOL. While many of the avail-
able stereotypes would emphasize the close temporal
association between IDU and the positive mood which
follows, the reality is that obtaining pleasure from the use
of drugs may become a secondary consideration from those
who are dependent. This study aims to examine the factors
that are associated with the QOL of PWID and to rank the
QOL of PWID in the broader context of the QOL
experienced by persons with a range of other chronic dis-
abling conditions.
Methods and procedures
Participants
Participants were a self-selected sample of 483 current
PWID accessing a major inner-city NSP in Brisbane,
Australia, over a 2-week period in October 2009. The
sample was similar to all attendees visiting the NSP during
that time (Table 1). The mean age of our sample was
33.75 years (range 15–66 years) and for the NSP
33.83 years (range 16–70 years). For both groups, the last
drug most commonly injected was heroin, followed by
prescription opiates and amphetamines.
Procedures
NSP staff invited all attendees to self-complete a short
survey documenting the prevalence of risk behaviours [17,
18], QOL and mental health. They were also asked to
supply a capillary blood sample for HCV antibody testing.
Participants were reimbursed $30 for their time.
Measures
Demographic and injecting characteristics
Data were collected on age and gender, years injected, last
drug injected (heroin, amphetamines, prescription opioids),
Table 1 Last drug injected, sample and NSP attendee data compared
Sample Biala Oct 12–24, 2009 Sample Biala Oct 12–24, 2009 Sample Biala Oct 12–24, 2009
Male Male Female Female Total Total
n % n % n % n % n % n %
Heroin 129 34.8 522 31.6 40 36.0 207 45.7 169 35.0 729 34.6
Amphetamine 103 27.8 548 33.2 26 23.4 141 31.1 130 26.9 689 32.7
Prescription opiates 68 18.3 278 16.8 19 17.1 55 12.4 87 18.0 333 15.8
Buprenorphine 24 6.5 53 3.2 8 7.2 15 3.3 32 6.6 68 3.2
More than 1 16 4.3 6 5.4 22 4.6
Methadone 12 3.2 62 3.5 4 3.6 6 1.3 16 3.3 68 3.2
Cocaine 5 1.3 19 1.2 2 1.8 3 1.1 7 1.4 22 1.0
Steroids 3 0.8 96 5.8 0 0 5 2 3 0.6 101 4.8
Bupnaloxone 3 0.8 17 1 1 0.9 9 2 4 0.8 26 1.2
Other 2 0.5 28 1.7 0 0 9 2 2 0.4 37 1.8
Missing data 6 1.6 29 1.8 5 4.5 3 0.7 11 2.3 32 1.5
Total 371 100 1,652 99.8 111 100 453 101.6 483 100.0 2,105 99.8
Due to rounding, totals may not equal 100 %
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Table 2 PWID demographic characteristics, injecting patterns, hepatitis C and drug treatment by WHOQOL-BREF domains
Characteristic WHOQOL-BREF domains
Physical Psychological
n mean SD Test statistic n mean SD Test statistic
Age
\25 66 50.70 12.26 F = 0.325
(3, 49.96)
p = 0.807
74 60.92 13.89 F = 3.502
(3, 827.68)
p = 0.015
25–34 164 49.11 12.27 171 54.56 15.73
35–44 134 49.76 12.06 142 54.52 15.36
45? 50 48.86 13.77 61 55.94 16.09
Gender
Male 314 49.24 12.55 F = 0.702
(1, 107.48)
p = 0.403
346 55.64 15.64 F = 0.039
(1, 9.36)
p = 0.844
Female 99 50.43 11.80 101 55.98 15.09
Years injected
0–4 45 48.97 11.56 F = 0.795
(4, 120.51)
p = 0.529
48 56.34 14.96 F = 2.088
(4, 504.91)
p = 0.081
5–9 60 51.49 11.62 67 60.26 15.55
10–14 98 50.44 12.18 102 55.84 14.61
15–19 94 48.56 12.81 102 53.39 16.95
20? 103 48.72 12.67 115 54.96 15.29
Last drug injected
Heroin 41 50.03 12.89 F = 0.0298
(2, 46.16)
p = 0.742
156 54.86 15.50 F = 0.934
(2, 220.47)
p = 0.394
Amphetamine 113 49.75 12.31 121 57.37 16.44
Prescription opiates 111 48.84 11.95 124 55.58 14.05
Frequency of injecting
Not in last month 41 47.47 11.77 F = 0.547
(4, 84.48)
p = 0.701
44 53.41 14.42 F = 0.551
(4, 133.35)
p = 0.698
Less than weekly 59 50.24 14.24 64 54.75 16.11
[weekly, not daily 77 50.56 11.63 87 57.38 14.57
Once a day 95 49.85 12.98 104 55.77 15.69
[once a day 138 48.96 11.80 145 55.75 15.81
Hepatitis antibodies status
Negative 235 49.82 11.78 F = 0.268
(1, 41.06)
p = 0.605
257 56.15 14.70 F = 0.95
(1, 94.94)
p = 0.530
Positive 179 49.18 13.11 191 55.21 16.54
Hepatitis self-report status
Negative 149 49.16 12.42 F = 0.061
(1, 9.59)
p = 0.806
161 55.62 15.01 F = 0.400
(1, 97.53)
p = 0.527
Positive 180 49.50 12.70 191 54.59 16.10
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Table 2 continued
Characteristic WHOQOL-BREF domains
Physical Psychological
n mean SD Test statistic n mean SD Test statistic
Current drug treatment
None 259 49.46 12.14 F = 0.023
(2, 3.51)
p = 0.978
284 55.82 15.14 F = 0.745
(2, 179.17)
p = 0.475
Pharmacotherapy 104 49.35 13.53 112 54.09 16.84
Non-pharmacotherapy 42 49.83 11.43 43 57.07 14.28
Characteristic WHOQOL-BREF Domains
Social relationships Environment
n mean SD Test statistic n mean SD Test statistic
Age
\25 77 54.98 25.23 F = 0.754
(3, 473.98)
p = 0.520
77 57.10 16.97 F = 1.155
(3, 361.91)
p = 0.327
25–34 181 55.76 24.62 177 52.88 17.74
35–44 146 52.85 24.90 146 53.17 17.94
45? 60 50.83 26.61 57 54.66 17.94
Gender
Male 358 53.59 24.89 F = 0.585
(1, 368.19)
p = 0.445
352 55.17 17.61 F = 2.649
(1, 827.99)
p = 0.104
Female 105 55.71 25.75 105 53.37 25.75
Years injected
0–4 48 52.78 25.69 F = 0.696
(4, 444.44)
p = 0.595
49 53.44 15.72 F = 1.664
(4, 517.59)
p = 0.157
5–9 71 58.22 25.30 66 58.67 18.15
10–14 105 53.57 24.43 105 54.79 16.31
15–19 106 52.67 25.63 105 52.32 18.61
20? 115 52.46 25.51 113 52.49 18.35
Last drug injected
Heroin 160 53.54 24.49 F = 0.308
(2.192.09)
p = 0.735
160 53.87 17.60 F = 0.122
(2, 38.17)
p = 0.885
Amphetamine 125 55.27 26.15 126 52.83 18.64
Prescription opiates 132 52.90 24.43 126 53.45 16.73
Frequency of injecting
Not in last month 46 51.27 24.47 F = 0.679
(4, 426.85)
p = 0.607
47 51.86 15.73 F = 1.078
(4, 339.17)
p = 0.367
Less than weekly 65 57.44 26.85 66 57.20 21.90
[weekly, not daily 91 53.21 23.20 91 53.50 16.70
Once a day 107 52.65 25.56 106 52.06 16.46
[once a day 151 55.57 25.22 143 54.61 17.79
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injecting frequency (not in last month, less than weekly,
more than weekly, not daily, once a day, more than once a
day) and current drug treatment (none, pharmacotherapy,
non-pharmacotherapy). Non-pharmacotherapy treatment is
any non-drug treatment, such as psychotherapy and 12
steps programmes.
Hepatitis C
Self-reported hepatitis C (positive, negative, unknown) was
obtained along with antibody sero-status.
QOL
Participants self-completed the WHOQOL-BREF [19]. This
internationally validated instrument consists of 26 items, of
which 24 items measure four potentially independent QOL
domains—physical health (six facets), psychological (six
facets), social relationships (three facets) and environment
(eight facets). The two remaining WHOQOL-BREF items
rate overall subjective QOL and satisfaction with health.
Consistent with WHOQOL recommendations, domain
scores were transformed to a score out of 100, with higher
scores indicating a better QOL [20–22].
Comparative data
Eight studies were found reporting WHOQOL-BREF
transformed scores. These reported the QOL for the general
Australian population [23] and samples involving a range
of health conditions and prisoners [24–30]. Details of these
studies are provided in the ‘Appendix’.
Statistical methods
To examine associations between PWID characteristics
and WHOQOL-BREF domain scores, analyses of variance
were performed using PASW V19 [31]. To compare the
mean WHOQOL-BREF domain scores of our participants
with results reported in other studies, tests for differences
in means were performed using MedCalc version 12.1.3.
Results
The majority of participants were male (75.8 %) and aged
between 25 and 34 years (37.9 %) and 35–44 years
(31.7 %). Duration of injecting drug use ranged from\1 to
46 years (mean = 15 years, SD 8.62 years). The last drug
most frequently injected was heroin (34.4 %), followed by
prescription opiates (27.5 %) and amphetamines (27.1 %).
Participants most commonly injected at least daily
(31.9 %). Although 36.0 % of participants self-reported
their hepatitis C status as negative, 56.9 % of participants
actually tested antibody negative. This discrepancy may be
due to many participants not knowing their actual hepatitis
C status (21.9 %), or no longer having the virus but
remaining antibody positive. Over a third of participants
Table 2 continued
Characteristic WHOQOL-BREF Domains
Social relationships Environment
n mean SD Test statistic n mean SD Test statistic
Hepatitis antibodies status
Negative 266 54.39 25.51 F = 0.095
(1, 59.56)
p = 0.758
263 54.08 17.13 F = 0.058
(1, 18.12)
p = 0.810
Positive 198 53.66 24.49 194 53.67 18.51
Hepatitis self-report status
Negative 168 55.26 24.97 F = 0.150
(1, 92.18)
p = 0.699
166 54.57 17.88 F = 0.302
(1, 93.16)
p = 0.583
Positive 198 54.25 24.69 191 53.55 17.28
Current drug treatment
None 289 53.35 25.43 F = 0.245
(2, 153.13)
p = 0.783
289 53.60 18.26 F = 0.476
(2, 149.33)
p = 0.622
Pharmacotherapy 119 55.18 25.56 115 53.02 17.15
Non-pharmacotherapy 45 53.15 20.05 42 56.10 15.31
Qual Life Res (2013) 22:2113–2121 2117
123
Table 3 WHOQOL-BREF domain scores of PWID sample compared to other samples
Population WHOQOL-BREF domain
Physical Psychological
N Mean SD Test statistic (95% CI) N Mean SD Test statistic (95% CI)
PWID 418 49.6 12.3 Test mean 452 55.8 15.5 Test mean
Aus pop norms 396 80.0 17.1 t = 35.38
p \ 0.0001
(78.3; 81.7)
396 72.6 14.2 t = 23.54
p \ 0.0001
(71.2; 74.0)
CHDa 111 71.8 16.4 t = 14.26
p \ 0.0001
(68.7; 74.9)
111 70.8 13.7 t = 11.54
p \ 0.0001
(68.2; 73.4)
CNMPb 100 41.9 19.7 t = 3.91
p = 0.0002
(38.0; 45.8)
100 52.3 21.0 t = 1.67
p = 0.0987
(48.1; 56.5)
Neuroc 402 48.5 19.0 t = 1.16
p = 0.2464
(46.6; 50.4)
402 52.1 18.6 t = 3.99
p = 0.0001
(50.3; 53.9)
Prisoners 388 79.2 14.5 t = 40.21
p \ 0.0001
(77.8; 80.7)
388 70.9 13.5 t = 22.03
p \ 0.0001
(69.6; 72.3)
SCId 270 63.0 19.0 t = 11.59
p \ 0.0001
(60.7; 65.3)
270 66.0 18.0 t = 9.31
p \ 0.0001
(63.8; 68.2)
Stroke 74 60.5 21.2 t = 4.42
p \ 0.0001
(55.6; 65.4)
74 59.8 21.5 t = 1.60
p = 0.1138
(54.8; 64.8)
Population WHOQOL-BREF domain
Social relationships Environment
N Mean SD Test statistic (95% CI) N Mean SD Test statistic (95% CI)
PWID 469 54.1 25.1 Test mean 462 54.0 17.8 Test mean
Aus Pop Norms 396 72.2 18.5 t = 19.47
p \ 0.0001
(70.4; 74.0)
396 74.8 13.7 t = 30.21
p \ 0.0001
(73.5; 76.2)
CHDa 111 73.8 16.9 t = 12.28
p \ 0.0001
(70.6; 77.0)
na na na na
CNMPb 100 60.3 23.3 t = 2.66
p = 0.0091
(55.7; 64.9)
100 63.6 18.7 t = 5.13
p \ 0.0001
(59.9; 67.3)
Neuroc 402 55.9 21.3 t = 1.69
p = 0.0910
(53.8; 58.0)
402 67.1 15.6 t = 16.84
p \ 0.0001
(65.6; 68.6)
Prisoners 388 74.2 18.7 t = 21.17
p \ 0.0001
(72.3; 76.1)
388 69.9 13.8 t = 22.27
p \ 0.0001
(68.2; 71.0)
SCId 270 62.0 22.0 t = 5.90
p \ 0.0001
(59.4; 64.6)
270 70.0 15.0 t = 17.53
p \ 0.0001
(68.2; 71.8)
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(35.0 %) were currently in some form of drug treatment
(Table not shown).
Some 45.5 % participants judged their QOL as ‘good/
very good’, 36.2 % as ‘neither good nor poor’ and a further
17.8 % as ‘poor/very poor’. Two participants (0.4 %) did
not answer this question. Overall 43.2 % of participants
were ‘satisfied/very satisfied’ with their health, 33.5 % as
‘neither satisfied/dissatisfied’ and a further 16.4 % as
‘dissatisfied/very dissatisfied’. A further 33 participants
(6.8 %) did not answer this question (Table not shown).
There were effectively no statistically significant asso-
ciations between participant demographic characteristics
(i.e. age, gender), injecting patterns, hepatitis C status and
treatment status in the four WHOQOL-BREF domains
(Table 2). This was unexpected. Indeed, it was particularly
surprising that occasional injectors were no different in the
QOL to daily injectors in their WHOQOL-BREF scores
and that no differences were found regarding hepatitis C
self-reports and antibody status.
The QOL experienced by our study population was
significantly poorer compared to the Australian sample
norms on all WHOQOL-BREF domains (Table 3). The
QOL experienced by our sample was also significantly
poorer on all domains when compared to samples con-
sisting of persons with chronic heart disease, prisoners and
persons with spinal cord injuries. Our study sample also
experienced significantly poorer QOL on most domains
compared to persons with pain, neurological illnesses and
stroke. Our study sample experienced a similar QOL on the
psychological domain with persons with pain and stroke,
and physical and social relationships domains to those
persons with neurological illnesses.
Discussion
The purpose of this study was to describe the QOL expe-
rienced by a convenience sample of PWID visiting a NSP.
We found that PWID experience a poor QOL irrespective
of their socio-demographic characteristics, injecting pat-
terns, hepatitis C sero-status and drug treatment status.
QOL was lower than reported by an Australian general
population sample. The second major finding that the QOL
of PWID is lower than the QOL experienced by those with
a range of serious and chronic illnesses is important. While
there is high community acceptability for supporting those
with CHD or a stroke, for example, there may be a reluc-
tance to accept the debilitating and negative health status of
PWID.
QOL is affect laden and self-reports will partly reflect
the respondents mental state [32]. It may be that depression
may be a confounding factor in the association between
injecting drug use and the QOL experienced by PWID [14].
Pain has also been found to negatively influence various
health domains in clinical and community populations of
PWID [33] and may also be a confounder. However, the
association between depression, pain and injecting remains
to be determined.
Study limitations
Ours is a selective sample of PWID NSP clients. Most
sterile injecting equipment in Australia is purchased
through community pharmacists [7], and it remains
uncertain whether the location of sterile injecting provision
is associated with different PWID populations. Our sample
was, however, similar to the total PWID population who
accessed the NSP during the study period. In this study,
data were not collected on other types of drug use, which
may also influence QOL, such as alcohol [34, 35]. Further
we were unable to determine whether those with a low
QOL chose to inject drugs, or whether injecting drug use
reduced the QOL of those using, or whether both these
causal pathways are involved.
In conclusion, NSP clients generally experience a very
poor QOL, even when compared to the QOL experienced
by other populations with chronic conditions. Our findings
suggest that injecting status is indicative of a very poor
Table 3 continued
Population WHOQOL-BREF domain
Social relationships Environment
N Mean SD Test statistic (95% CI) N Mean SD Test statistic (95% CI)
Stroke 74 62.1 25.4 t = 2.71
p = 0.0084
(56.2; 68.0)
74 67.9 19.1 t = 14.48
p \ 0.0001
(66.0; 69.8)
Statistically significant values are in bold
Australian population norms [23], chronic heart diseasea [27], chronic non-malignant painb [30], neurological illnessesc [28], spinal cord injuryd
[26], stroke [25], prisoners [24]
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QOL. Some PWID may be self-medicating for emotional
distress or pain. However, these associations require further
investigations. These findings suggest that PWID may
benefit from efforts to address their low QOL. Our findings
are also relevant to a concern with population stereotypes
concerning the ‘pleasure’ that PWID obtain from their
behaviour. Arguably, the findings suggest that there is a
need for a much more sympathetic understanding of people
in the community who inject drugs.
Appendix
See Table 4.
Table 4 Compared populations on WHOQOL-BREF mean domain scores
References Population Method Sample
Population Abbreviation Location Size Characteristics
Our sample (2012) People who inject
drugs
PWID Cross-sectional
Convenience
Self-selected
Brisbane,
Queensland,
Australia
483 Regular and current injecting drug
users visiting a needle and
syringe programme
Murphy et al. [23] Population norms Aus pop
norms
Cross-sectional
stratified
Random sample
In and out of
Treatment
Melbourne, Victoria,
Australia
996 WHOQOL-BREF Validation
Study
Random sample of community
members weighted by socio-
economic status (n = 396),
public hospital outpatients
(n = 334) and public hospital
inpatients (n = 266)
Rose et al. [27] Chronic heart
disease
CHD Cross-sectional
Convenience
In treatment
Berlin, Germany 111 Different degrees of congenital
heart defects recruited in the
context of their regular,
outpatient appointment
Aigner et al. [30] Chronic non-
malignant pain
CNMP Cross-sectional
Convenience
In treatment
Vienna, Germany 100 WHOQOL-BREF - Germany
Validation Study
Outpatients diagnosed with
somatoform pain disorder
attending a behavioural medicine
clinic
McCabe et al. [28] Neurological
illnesses
Neuro Cross-sectional
Convenience
In treatment
Victoria, Australia 423 Motor neurone disease (n = 123),
Huntington’s disease (n = 48),
Parkinson’s disease (n = 143)
and multiple sclerosis (n = 112)
Skevington and
McCrate [24]
Prisoners Prisoners Cross-sectional
Convenience
United Kingdom 388 27 disease groups or health
conditions or health people
recruited at 38 UK sites
(N = 4,628) of which prisoners
were one group
Barker et al. [26] Spinal cord injury SCI Cross-sectional
Random
Brisbane,
Queensland,
Australia
270 SCI obtained during the past
60 years. Potential participants
drawn from archival records
Edwards and
O’Connell [25]
Stroke Stroke Cross-sectional
Convenience
Self-selected
Rural Victoria,
Australia
74 SIS 2.0 Validation Study
Stroke survivors living in the
community who responded to a
newspaper advertisement or via
the Stroke Association of
Victoria
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CHAPTER TEN: DISCUSSION AND CONCLUSIONS 
10.1  INTRODUCTION 
The core of this thesis comprises five papers that have been published and a sixth paper that 
is in submission.  This chapter provides an overview to the thesis results, the main findings 
are reported and the implications of these findings are discussed.  The strengths and 
limitations of the thesis are acknowledged.  Finally unanswered questions and future research 
questions are considered. 
 
10.2 OVERVIEW OF THESIS RESULTS 
This thesis commenced by considering the harms associated with drug use.  It was found that 
most people who take drugs do not experience significant harm, such as hospital admission, 
dependence or death and that it is young people in particular who use drugs.  The thesis went 
on to consider motivations for drug use.  There was an interest in the extent to which drug use 
can be pleasurable.  Seeking and obtaining pleasure from drug use seems to be underpinned 
by both the chemical nature of the substance and also individual and social aspects of drug 
use (Zinberg, 1984; Zinberg et al., 1975).  Whilst pleasure in itself seems a plausible 
rationale, arguably it is a limited explanation of drug use.   
 
QOL, however, provides an important and broader perspective than either pleasure or harm 
alone. As a concept QOL can encompass the potential harms and benefits associated with 
drug use.  QOL was defined here as the subjective assessment of the positive (happiness and 
satisfaction) and negative (anxiety and depression) aspects of life.  The extant literature on 
QOL and drug use was subsequently examined.  From this review it was clear that QOL 
assessments are innately personal and involves an assessment of multiple life domains that 
are themselves dynamic.  Describing QOL helps us understand drug use from the point of 
view of the user.  Evaluating QOL also enables an examination of the ways in which the 
effects of drug use may change over time.  
 
There were several limitations to the current evidence, especially in relation to the QOL of 
adolescent and young adult drug users.  Few studies have actually examined the QOL of 
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young users not recruited from school settings, limiting the generalisability of these studies.  
Secondly no studies have reported the QOL of adolescents and young adults prior to the onset 
of substance use.  The existing evidence is unable to resolve the question of whether a poor 
QOL may precede substance use, or whether substance use may enhance (or diminish) QOL. 
 
The purpose of this thesis, therefore, was to add to the evidence base by describing, 
comparing and examining the impact of drug use on QOL.  Understanding the aetiology and 
dynamics of drug use amongst adolescents and young adults requires an understanding of 
what life was like prior to commencement of use and further, whether for the user, 
motivations for taking drugs were subsequently achieved.  This entailed investigating the 
following questions: 
 
1. What is the QOL of drug users? 
2. Does the QOL of drug users vary by drug type and frequency of use? 
3. What could be the temporal sequence between drug use and QOL? 
4. Does drug use enhance or diminish users’ QOL? 
 
To address these questions the thesis comprised a series of investigations into the QOL of 
alcohol, tobacco, cannabis, prescribed and over-the-counter medications and opioid users. 
Four of these studies, in the form of published, and a draft paper investigated the potential 
temporal sequence between QOL and substance use in a community based population of 
adolescent and young adult drug users.  Secondary data analyses were conducted using data 
from the Mater Misericordiae Hospital and University of Queensland Study of Pregnancy and 
its outcomes (MUSP), a prospective longitudinal study which recruited pregnant women at 
their first antenatal visit in Brisbane, Australia.  In these investigations data from the 5, 14 
and 21 year post-birth follow-ups were used.  The exposures of interest were frequency of 
tobacco, alcohol, cannabis and medications use.  The outcome measure was QOL, as 
indicated by happiness and satisfaction, anxiety and depression at 21 years.  The fifth study 
examined the QOL of people who inject drugs, using data collected as part of the National 
Fingerprick Survey.  In this later study cross-sectional data were examined and involved 
mainly participants using opioids. 
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10.3 MAIN FINDINGS 
10.3.1 WHAT IS THE QOL OF DRUG USERS? 
The first finding of this thesis is that drug users disproportionately report a lower QOL 
compared with people who do not use drugs.  Both alcohol consumption and cannabis use 
were associated with lower levels of QOL.  Similarly, any medication use (either for medical 
or non-medical purposes) was also associated with diminished QOL, but this was particularly 
so for respondents who had used medications in a non-medical way.  Arguably, if 
psychopathology (operationalised here as internalizing, externalizing and attention problems) 
is used as an indicator of QOL then tobacco smokers also reported a lower QOL compared 
with persons who had never smoked.  
 
This study is consistent with a number of recent studies that have reported that drug use was 
associated with diminished QOL (Topolski et al., 2001; Vaez & LaFlamme, 2003), reduced 
subjective well-being (Batki et al., 2009; Katja et al., 2002; Lanier, 2001; Phillips-Howard et 
al., 2010), or dissatisfaction (Farhart et al., 2011; Kuntsche et al., 2005; Murphy et al., 2005; 
Sumnall et al., 2010; Zullig et al., 2001).  Compared with most of these studies, the findings 
from this thesis arguably provide stronger evidence for the QOL of young adult drug users.  
This is because the studies into alcohol, tobacco, cannabis and medications comprised 
population based samples of young adults rather than relying on selected populations of 
school, college or university students.  
 
This thesis also found that people who inject drugs (PWID) reported very poor QOL in 
comparison with the Australian population and populations with chronic conditions (Dietze et 
al., 2010; Fischer et al., 2013).  This was irrespective of their socio-demographic 
characteristics, injecting patterns, hepatitis C sero-status and drug treatment status (Conroy et 
al., 2008; Dietze et al., 2010; Fischer et al., 2013).  Injecting represents a serious step along 
the drug use continuum and may impact on many more aspects of life, including social and 
familial connections and relationships (Armstrong et al., 2013; Dietze et al., 2010) than other 
chronic conditions (Fischer et al., 2013).  QOL assessments by PWID may also partly be a 
consequence of stigma.  For example, even amongst PWID, a person’s belief that they are 
hepatitis C positive is associated with lower QOL assessments than PWID who are unaware 
that they are hepatitis C positive (Dalgard et al., 2004).  
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10.3.2 DOES QOL VARY BY DRUG TYPE & FREQUENCY OF USE? 
QOL assessments are influenced by a combination of frequency of drug use and other factors.  
This thesis found that increased frequency of drug use has a negative effect on respondent 
assessments of QOL.  Here the greatest differences in QOL assessments were between 
regular users and those who were abstinent.  For example, respondents who consumed 
alcohol or used cannabis reported a lower QOL compared with those who remained abstinent.  
This was also the case for both the medical and non-medical use of medications, when 
compared with young adults who had not used medications.  These findings are consistent 
with the existing literature. 
 
A dose-response relationship between frequency of use and QOL assessments has been found 
in studies of adolescent and young adult drug users.  Several studies have found a possible 
dose-response relationship between QOL and drug use, with QOL or its indicators, negatively 
correlated with increased frequency of drug use (Clifford & Edmundson, 1991; Farhart et al., 
2011; Phillips-Howard et al., 2010; Sumnall et al., 2010; Topolski et al., 2001).  In particular 
this has been found in studies examining the more commonly used alcohol use (e.g. Foster et 
al., 1999; Vaez & LaFlamme, 2003) and cannabis (e.g. Green et al., 2004). 
 
The findings reported in this thesis differ somewhat from available research into QOL and the 
use of medications.  Medications are commonly used with the specific intent of improving 
the QOL of the user (Fischer & Rehm, 2007; Johnston, 2009; Zullig & Divin, 2012).  In 
contrast we have found that lower QOL is associated with both the medical and non-medical 
use of medications.  Several studies of life satisfaction in young adults have found that young 
adults may engage in extra-medication use for health conditions and ailments that have not 
been presented to a medical professional (Bogart et al., 2007; Chen et al., 2004; Zullig et al., 
2005).  Potentially while medications may alleviate symptoms it is clear that the QOL of 
those who use these medications is low, possibly reflecting the underlying condition that has 
led to the medicines use and lower still for young adults who used medications in a non-
medical way.  This suggests that self-medication of prescribed or over-the-counter 
medication maybe an early indicator of poor QOL. 
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10.3.3 WHAT IS THE POTENTIAL TEMPORAL ASSOCIATION BETWEEN QOL 
AND DRUG USE? 
A third objective of the thesis was to examine the temporal association between QOL and 
drug use.  Our results indicate that poor QOL precedes commencement of drug use.  This 
finding of a temporal association between QOL and drug use is novel, as no other study that 
we are aware of has examined the QOL of drug users prior to the commencement of 
substance use.  This finding was consistent across the studies into QOL associated with 
alcohol, cannabis and medications use.  Specifically, poor QOL was associated with the early 
age of onset of alcohol use and also with AUDs.  As the amount of alcohol being consumed 
at 14 years of age is modest, it is likely that low levels of life satisfaction and happiness 
precede the onset and level of alcohol use.  Poor QOL was also apparent in cannabis users 
prior to the commencement of use.  Lower QOL also predicted both the medical and non-
medical use of medications. 
 
Poor QOL was also implicated in the study of psychopathology and tobacco smoking. 
Children who met the criteria for aggression using the Child Behaviour Checklist at 5 years 
were more likely to be tobacco smokers at the 14-year follow-up.  Further, externalising 
behaviours, based on the Youth Self Report (YSR) at the 14-year follow-up, predicted 
tobacco smoking at the 21-year follow-up. 
 
The issue of dependence seems to be more complex. In this study the development of 
dependence varied between drug types.  Poor QOL at 14 years was a strong predictor of 
earlier age of onset of an alcohol use disorder (AUD).  However, when age of onset of AUD 
was used to predict subsequent QOL the association was weak and inconsistent.  YSR 
externalizing behaviours at the 14-year follow-up predicted tobacco smoking, but not DSM-
IV nicotine dependence at the 21-year follow-up, whereas attention problems at 14 and 21 
years were associated separately and cumulatively with nicotine dependence at the 21-year 
follow-up. 
 
Research focusing on the importance of the early years to adolescent and young adult 
development suggests that the early onset of alcohol consumption (e.g. Grant & Dawson, 
1997; Loring, 2014), tobacco smoking (e.g. Morissette et al., 2007; Page & Danielson, 2011) 
and cannabis use (e.g. Fergusson & Boden, 2008) are markers of later risky behaviours and 
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socio-economic problems.  In this study QOL assessments were shown to be an important 
factor in the age at which substance use first commenced – respondents who used substances 
at an early age reported the poorest QOL both at 14 and 21 years.  Poor QOL in childhood 
may be the first self-reported indicator of potential problems and difficulties in young 
adulthood. 
 
10.3.4 DOES DRUG USE ENHANCE OR DIMINISH QOL? 
The final main finding of this thesis is that drug is associated with a very low QOL, 
especially for persons who have a poorer QOL prior to commencement of use.  Specifically, 
this thesis found that alcohol consumption was associated with an apparent decline in the 
QOL for users when compared with those who had remained abstinent.  Cannabis use at 14 
years was associated with reduced QOL at the 21 year follow-up.  Poor QOL at 14 years also 
preceded the use of any medications at the 21-year follow-up.  While drug use may alleviate 
immediate symptoms it is clear that the QOL of users is not enhanced and is possibly reduced 
as a consequence of the use of any drugs. 
 
Through examining a longitudinal cohort this thesis has been able to investigate QOL prior to 
commencement of drug use.  In this regard, this thesis is novel in its finding of a lower QOL 
preceding drug use, and that drug use further diminishes the QOL of the user.  However, the 
latter is consistent with the broader body of literature on QOL outcomes after changes in 
substance use patterns.  For drug users with a broad range of problems treatment is necessary, 
but not sufficient, for improved QOL (e.g. de Maeyer et al., 2010; Laudet, 2011).  Similarly 
users of alcohol (e.g. Connor et al., 2006; Donovan et al., 2005) and tobacco (e.g. Wang et 
al., 2014; Piper et al., 2012) who reduce or cease their use also report enhanced QOL. 
Amongst cannabis users apparently there is there is a dose-response relationship with 
increased frequency of cannabis use associated with reduced life satisfaction, an indicator of 
QOL (Green et al., 2004; Swain et al. 2012; van Laar et al. 2007; Barnwell et al., 2006; 
Gruber et al. 2003).  
 
10.4 THESIS STRENGTHS AND LIMITATIONS 
10.4.1  STRENGTHS  
This thesis has drawn upon a number of existing data sets to address the issue of the QOL of 
substance users.  This has allowed us to examine the topic cross-sectionally and also 
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longitudinally.  The availability of a large birth cohort (which provided the majority of the 
data presented) allowed the examination of temporal associations between QOL assessments 
and substance use.  The size of the dataset has also generated relatively precise effect 
estimates.   
 
10.4.2 LIMITATIONS 
The limitations of this study have been discussed in detail in each of the publications 
comprising this thesis; however, it is important to bear these in mind when interpreting the 
findings of the thesis as a whole.  As with most population-based cohort studies attrition over 
time becomes an important issue.  As noted in Chapter 4, loss to follow-up is a consistent 
problem with cohort studies.  Missing data due to attrition or item non-response may result in 
biased findings, loss of statistical power or both.  However, data missing not at random and 
where the probability of missing data is linked to the outcome of interest represents the 
greatest problem.  Those missing from MUSP are disproportionately young, economically 
disadvantaged, and with higher rates of mental health disorders, alcohol, tobacco and 
substance use (Najman et al., 2014).  A range of techniques have been used to adjust or 
correct for this bias associated with differential loss to follow-up (including inverse 
probability weighting, multiple imputation).  It has been repeatedly found that after 
adjustment for loss to follow up the results remain unaffected (Najman et al., 2014). 
 
A second limitation is that substance use has been assessed using self-reports.  It may be that 
adolescents and young adults are reluctant to divulge their substance use, or over or under-
state the amount that they use (Hennekens & Buring 1987; Schaeffer, 2000).  However there 
is consistent evidence to suggest otherwise (Darke 1998; Johnson et al., 1999).  Nevertheless, 
if this effect existed it is more likely to lead to an underestimation of the true associations 
between QOL and substance use.   
 
In this thesis drugs were examined individually.  This is generally an artificial situation.  In 
reality, multiple drug use is common.  However, as succinctly put by Gossop “matters 
become complicated when multiple substances are considered” (Gossop, 2013).  To address 
this limitation, the most common drugs used by young adults, that is alcohol and tobacco, 
were treated as covariates in the studies.  
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10.5 IMPLICATIONS  
This thesis has found that beyond the immediate pleasures of intoxication there are few if any 
benefits from drug use.  Whilst drug use may be normalised behaviour amongst young adults, 
it does not necessarily follow that a decline in QOL amongst young users should also be 
considered a ‘normal’ or an acceptable outcome from use – whether this be the use of 
alcohol, tobacco, cannabis or indeed medications. In contrast to the normalisation hypothesis, 
drug use does not seem to facilitate a ‘good life’ for adolescents and young adults.  The 
implications of these results are examined by asking a further four questions. 
 
Is diminished QOL a direct or indirect consequence of substance use? 
The main issue here is whether or not the association between QOL and subsequent drug use 
could be considered to be causal.  The nine criteria proposed by Bradford Hill (1965) provide 
a useful framework for making such a judgement (Table 1).   
 
There is some evidence to suggest that the associations identified here between poorer QOL 
and the use of drugs may be causal.  There does appear to be a temporal association, and 
there is evidence of some moderately strong associations. The findings of this thesis are also 
consistent with the extant literature on the QOL of drug users.  However, the evidence 
provided needs to be interpreted with some caution.  It is possible, given the timing of data 
collection points (nine years between the 5 and 14 year follow-ups and seven years between 
the 14 and 21 year follow-ups) that other factors may also have contributed to these findings.  
This thesis was unable to establish the precise dose-response relationship between substance 
use and QOL.  Biological plausibility was not specifically addressed in this thesis.  A 
symptom of dependence amongst frequent drug users is withdrawal, which involves the user 
experiencing the opposite effects to the drug that they experience when intoxicated 
(American Psychiatric Association, 2013).  Even amongst drug users who are not dependent, 
there are anecdotal reports of ‘hangovers’ and ‘comedowns’ from drug use in the day and 
days following intoxication.  Together these findings are suggestive of a causal relationship, 
but more research is required.  Therefore the determination of the causal relationship between 
QOL and drug use remains to be resolved.  
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Table 1: Criteria for causation and application to the findings of this thesis 
Criteria for 
Causation 
Application to the findings of this thesis 
Strength of the 
Association 
The majority of the OR presented in the papers forming this thesis indicate 
moderate associations (>/= to 2) (Holt & Peveler, 2006).  Using this criterion 
there is moderate evidence for causality. 
Dose-response There is some evidence for a dose-response relationship. However in the 
papers in this thesis it was primarily between drug using and abstinent 
respondents, rather than between increasing amounts of a particular substance.  
Consistency The association between poorer QOL and substance use is consistent across 
all substances examined. 
Specificity Given the range of psychological, social and behavioural factors associated 
with QOL and substance use this criteria was not met. 
Temporal 
Relationship 
The temporal association between poor QOL prior to drug use was consistent 
across alcohol consumption, tobacco smoking, cannabis use and the medical 
and non-medical use of medications. 
Biological 
plausibility 
The properties of substances positively affect chemical properties in the brain. 
When drug dependent persons experience withdrawal the opposite effects of 
the drug are experienced by the person. 
Experimental 
evidence 
The available evidence comes from cross-sectional and prospective studies.  
We are not aware of any relevant experimental studies. 
Reversibility  This would require intervention studies. Studies of dependent drug users have 
shown treatment is necessary but not sufficient in itself to improve clients’ 
QOL.   
Coherence of the 
evidence 
The findings from the studies presented here are consistent with the existing 
body of available literature suggesting a level of coherence of the evidence 
presented.   
 
 
Is it possible that people who use substances have a declining QOL irrespective of 
using? 
 In this study QOL was examined in an ostensibly healthy population of adolescents and 
young adults yet use was associated with prior poorer QOL.  It may be that regardless of use 
QOL would remain poor amongst these young adults.  A further finding of this thesis was 
that the use of any of the examined drug types was associated with a poorer QOL.  For 
example consuming alcohol or cannabis may enhance the mood of the user at the time of use 
(Baker-Dennis & Pryor, 2014; Inaba & Cohen, 2007; Julien, 2001; Rang et al., 2011).  
However, the effects of the substance do not appear to extend into generally feelings of 
happiness even in the short to mid-term.  For some adolescents and young adults intoxication 
seems to be only a momentarily reprieve from a generally poor QOL.  
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In health research QOL is commonly used as a marker of treatment success. Could a 
low QOL be used as a marker of people who are likely to use substances, that is, a 
marker for early intervention? 
From the results presented here there is some evidence to suggest that QOL may act as a 
marker of increased vulnerability to or risk of substance use, however the complexity of this 
issue and of the behaviours and circumstances that lead to initiation,  does not lend itself to 
the identification of single explanatory factors (Sloboda et al., 2012).  Psychopathology or 
mental health disorders are well recognised risk factors for substance use (Degenhardt & Hall 
2001; Krueger & Markon, 2006; Teesson et al., 2003).  What is useful about QOL 
assessments is that they are generally based upon subjective judgements of a range of life 
domains including environmental, social, physical and mental health domains (The 
WHOQOL-BREF Group 1995; O’Connor 2004; Organisation of Economic Co-operation and 
Development, 2013; National Research Council, 2013; Goldin et al., 2014) many of which 
are associated with drug use (Zubaran & Foresti, 2009; Assari & Jafari, 2010; De Maeyer, et 
al., 2010; Laudet, 2011; Tiffany, et al., 2012; Feelemyer, et al., 2013).  As such the 
assessment of QOL may prove to be a useful addition to a comprehensive approach to 
identifying vulnerable individuals.  Further research is needed to explore this. 
 
Should there be public health campaigns which use these findings to dissuade some 
from using, particularly those who are using to enhance mood and QOL? 
There are a range of approaches to intervening to prevent substance use and misuse.  These 
include universal approaches that target the entire population, selective interventions 
targeting specific sub-groups at risk of substance use and individually targeted interventions 
(Hamilton & Rumbold, 2004; Ministerial Council on Drug Strategy, 2011).  Our findings, 
from the population of healthy, young Australians show that drug use does not appear to 
improve QOL, that is QOL diminishes as a consequence of drug use and this is consistent 
with the literature.  Nevertheless adolescents and young adults persist with drug use.  There is 
considerable research that suggests a single prevention or harm reduction strategy used in 
isolation will not be effective in reducing drug use amongst adolescents and young adults 
(Cuijpers, 2003; Toumbourou, et al., 2007; Lubman, et al., 2007).  However, the adverse 
impact substance use has on QOL provides a potentially novel and useful adjunct to a broader 
approach to the development and evaluation of alcohol and other drug prevention and harm 
reduction strategies.   
 
165 
10.6 UNANSWERED QUESTIONS AND FUTURE RESEARCH 
DIRECTIONS 
The first unanswered question is that of the association between QOL and substance use.   
This thesis suggests that the association may be causal and if so this has implications for 
future targeting of interventions.  This then raises the second question, and that is the 
usefulness of QOL as a marker for early intervention.  Both of these questions require further 
research but the results presented here do provide a potential platform for the development of 
preventive programs that target those adolescents and young adults reporting poorer QOL.  
The findings reported here also raise fundamental questions for decision makers about the 
adequacy of our current understanding of the interactions between QOL and subsequent drug 
use.  While this study does provide some insights, our knowledge of the long term 
consequences is at present limited. 
 
10.7 THESIS CONCLUSION 
This thesis has addressed the question of why adolescents and young adults use drugs despite 
their potential for harm.  It has found that people with a poor QOL disproportionately use 
drugs.  Some people have reduced QOL because they frequently use drugs.  For others their 
use is associated with a pre-existing poor QOL.  Beyond intoxication, drugs do not enhance 
or in any way we have been able to determine, improve the QOL of the user.    
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